Document:

blackberry-subscriptiona

Certain identified information has been excluded from this exhibit because it is both (i)  not material and (ii) would likely cause competitive harm to the registrant if publicly  disclosed. Such excluded information has been marked with [Redacted].”                                SUBSCRIPTION AGREEMENT                                                                           August 31, 2020                                                 BlackBerry Limited  2200 University Avenue East  Waterloo, Ontario  Canada  N2K 0A7    Dear Sirs/Mesdames:          This agreement (the “Agreement”) is further to recent discussions regarding a transaction  pursuant to which (a) the undersigned, Hamblin Watsa Investment Counsel Ltd. (“HWIC”), in its  capacity as investment manager of Fairfax Financial Holdings Limited and various controlled  affiliates thereof and [redacted] in its capacity as investment manager of [redacted], as set out in  Schedule A  to this Agreement (collectively the “Purchasers” and each a “Purchaser”), will  subscribe for, and BlackBerry Limited (“BlackBerry”) will issue to each Purchaser, the principal  amount set out beside its name on Schedule A of 1.75% unsecured subordinated convertible  debentures of BlackBerry (the “Debentures”) on a private placement basis, for an aggregate  subscription price of U.S.$365,000,000 (the “Purchase Price”), and (b) the outstanding 3.75%  convertible unsecured debentures of BlackBerry issued on September 7, 2016 on a private  placement basis for an aggregate subscription price of U.S.$605,000,000  (the “Existing  Debentures”) will be redeemed (collectively, the “Transaction”). Any portion of the principal  amount of the Debentures outstanding will be convertible into common shares of BlackBerry (the  “Underlying Common Shares”) in accordance with the terms of the Indenture.          This Agreement sets out the terms and conditions upon which, for good and valuable  consideration, BlackBerry and each of the Purchasers (collectively, the “parties”) agree to  complete the Transaction. All rights and obligations of the Purchasers hereunder are several, and  not joint nor joint and several. BlackBerry acknowledges that one or more of the Purchasers is a  registered portfolio manager acting on behalf of one or more fully managed accounts managed  by it and, as such, would be deemed by Section 2.3(4) of National Instrument 45-106 – Prospectus  Exemptions (“NI 45-106”) to be purchasing the Debentures as principal.   1.     Purchase of the Debentures.          Each Purchaser hereby subscribes for and agrees, severally and not jointly, to purchase  from BlackBerry, and BlackBerry hereby agrees to issue or cause to be issued to each such  Purchaser on the Closing Date, that principal amount of Debentures as is set out beside its name  on Schedule A for aggregate consideration equal to such principal amount, on the terms and  conditions set forth in this Agreement.      36990-2073 30148883.13   

 

                                         - 2 -      2.     Mutual Conditions of Closing.          Each Purchaser’s obligation to purchase the applicable principal amount of Debentures  from BlackBerry and BlackBerry’s obligation to issue and sell the applicable principal amount of  Debentures to each Purchaser are subject to the fulfilment of each of the following conditions,  which conditions are for the mutual benefit of the Purchasers and BlackBerry and may be waived  only by the mutual consent of the Purchasers and BlackBerry:          (a)    concurrent with the issuance and purchase of the Debentures, all of the Existing                Debentures will have been redeemed and the indenture dated as of September                7, 2016 between BlackBerry, the guarantors named therein  and  BNY Trust                Company of Canada (as amended and supplemented, including pursuant to a                supplemental indenture among the same parties dated  on or about the date                hereof) shall have been terminated;          (b)    the Toronto Stock Exchange (“TSX”) shall have approved the issuance of the                Debentures and the listing of the Underlying Common Shares and the New York                Stock Exchange (“NYSE”) shall have approved the listing of the Underlying                Common Shares, in each case subject only to the satisfaction of customary listing                conditions, and without the requirement to seek the approval of the shareholders                of BlackBerry;          (c)    the Indenture has been entered into by the Indenture Trustee, BlackBerry and the                Guarantors;           (d)    there shall not be in effect any applicable domestic or foreign federal, national,                state, provincial or local law (statutory, common or otherwise), constitution, treaty,                convention, ordinance, code, rule, regulation, notice, order, injunction, judgment,                decree, ruling or other similar requirement enacted, made, issued, adopted,                promulgated or applied by a Governmental Authority (collectively, “laws”) that                makes the  consummation of the Transaction illegal or otherwise prohibits or                enjoins any party from consummating the Transaction, or that is made in                connection with the Transaction and imposes any material restrictions, limitations                or conditions on any of the parties; and          (e)    no Governmental Authority shall have commenced any action or proceeding to                enjoin the issuance and sale of the Debentures to the Purchasers pursuant to this                Agreement or to suspend or cease or stop trading of securities of BlackBerry, and                no Governmental Authority shall have given written notice to any party of its                intention to commence any such action or proceeding.   3.     Conditions of Closing for the Benefit of BlackBerry.          Each Purchaser acknowledges and agrees that BlackBerry’s obligation to issue and sell  the Debentures to the Purchasers is subject to the fulfilment of each of the following conditions,  which conditions are for the exclusive benefit of BlackBerry and may be waived, in whole or in  part, by BlackBerry in its sole discretion:          (a)    the representations, warranties and acknowledgements of each Purchaser set                forth in this Agreement shall be true and correct in all material respects as at the                Closing Date, with the same force and effect as if made as at the Closing Date      36990-2073 30148883.13   

 

                                         - 3 -                    (except for representations, warranties and acknowledgements made as of a                specified date, the accuracy of which shall be determined as of that specified date,                and except in each case, for those representations, warranties and                acknowledgements that are subject to a materiality qualification, which must be                true and correct in all respects); and          (b)    all covenants of each Purchaser under this Agreement to be performed prior to                the Closing shall have been duly performed in all material respects.   4.     Conditions of Closing for the Benefit of the Purchasers.          BlackBerry acknowledges and agrees that each Purchaser’s obligation to purchase the  Debentures from BlackBerry is subject to the fulfilment of each of the following conditions, which  conditions are for the exclusive benefit of the Purchasers and may be waived, in whole or in part,  by the Purchasers in their sole discretion:          (a)    the representations and warranties of BlackBerry set forth in this Agreement shall                be true and correct in all material respects as at the Closing Date, with the same                force and effect as if made by BlackBerry as at the Closing Date (except for                representations and warranties made as of a specified date, the accuracy of which                shall be determined as of that specified date, and except in each case, for those                representations and warranties that are subject to a materiality or Material                Adverse Effect qualification, which must be true and correct in all respects);          (b)    all covenants of BlackBerry to be performed under this Agreement shall have                been duly performed in all material respects;          (c)    from and including the date hereof up to and including the Closing Date, there                shall not have occurred a Material Adverse Effect;          (d)    each Purchaser shall have received a legal opinion addressed to the Purchasers                in form and substance satisfactory to the Purchasers and their counsel, acting                reasonably, dated the Closing Date, from counsel to BlackBerry (who may rely,                as to matters of fact, on certificates of public officials and officers of BlackBerry)                with respect to the following matters:                (i)    that BlackBerry is a corporation existing under the laws of Ontario and has                      the corporate power to enter into and perform its obligations under this                      Agreement, and has the corporate power and capacity to own or hold its                      properties and to conduct the businesses carried on by it;                (ii)   as to the authorized share capital of BlackBerry;                (iii)  that the execution and delivery of and performance by BlackBerry of this                      Agreement has been authorized by all necessary corporate action on the                      part of BlackBerry;                (iv)   that this Agreement has been duly executed and delivered by BlackBerry,                      and constitutes a legal, valid and binding agreement of BlackBerry                      enforceable against it in accordance with its terms, subject to customary                      qualifications;      36990-2073 30148883.13   

 

                                         - 4 -                   (v)    that neither the execution and delivery of this Agreement, the Indenture or                      the Debentures, nor the performance by BlackBerry of its obligations                      hereunder or thereunder, will conflict with or result in any breach of the                      constating documents or by-laws of BlackBerry;                (vi)   that the issuance of the Debentures has been authorized by all necessary                      corporate action on the part of BlackBerry, that the Debentures have been                      duly executed and delivered by BlackBerry and that subject to receipt of                      payment in full for them, the Debentures will be legal, valid and binding                      agreements of BlackBerry enforceable against it in accordance with their                      terms, subject to customary qualifications;                  (vii)  that the execution and delivery of and performance by BlackBerry of the                      Indenture has been authorized by all necessary corporate action on the                      part of BlackBerry;                (viii) that the Indenture has been duly executed and delivered by BlackBerry,                      and constitutes a legal, valid and binding agreement of BlackBerry                      enforceable against it in accordance with its terms, subject to customary                      qualifications;                (ix)   that the Underlying Common Shares have been validly authorized for                      issuance by BlackBerry and, upon the conversion of the Debentures in                      accordance with the terms and conditions of the Debentures, and when                      issued, will be validly issued and outstanding as fully paid Common Shares;                (x)    that the issuance and sale by BlackBerry of the Debentures to the                      Purchaser in accordance with this Agreement is exempt from the                      prospectus and registration requirements of applicable securities laws in                      Ontario and no documents are required to be filed by BlackBerry (other                      than customary private placement reports accompanied by requisite filing                      fees), proceedings taken or approvals, permits, consents or authorizations                      obtained under the applicable securities laws in Ontario to permit such                      issuance and sale;                (xi)   no filing, proceeding, approval, consent or authorization is required to be                      made, taken or obtained under the laws of Ontario to permit the issuance                      by BlackBerry of the Underlying Common Shares upon the conversion of                      the Debentures in accordance with the terms and conditions of the                      Debentures to the holders of the Debentures;                (xii)  the first trade of the Debentures in Ontario will not be a distribution or                      otherwise subject to the prospectus and registration requirements of                      applicable securities laws in Ontario if:                        (A)    BlackBerry is and has been a reporting issuer in a jurisdiction of                             Canada for the four months immediately preceding such first trade;                       (B)    at the time of the first trade, at least four months have elapsed from                             the date of distribution of the Debentures;        36990-2073 30148883.13   

 

                                         - 5 -                          (C)   the certificates representing the Debentures carry a legend, or an                            ownership statement issued under a direct registration system or                            other electronic book-entry system acceptable to the regulators                            bears a legend restriction notation, as required by Section 2.5(2)3(i)                            of National Instrument 45-102 - Resale of Securities (“NI 45-102”);                       (D)   the trade is not a “control distribution” as defined in NI 45-102;                       (E)    no unusual effort is made to prepare the market or to create a                             demand for the Debentures subject to such trade and no                             extraordinary commission or consideration is paid to a person or                             company in respect of the trade; and                       (F)    if the seller of the Debentures is an “insider” or “officer” of                             BlackBerry (as those terms are defined in applicable securities                             laws), the seller has no reasonable grounds to believe that                             BlackBerry is in default of any requirement of securities legislation;                             and                 (xiii) the first trade by a holder of Underlying Common Shares upon the                      conversion of the Debentures in accordance with the terms and conditions                      of the Debentures will not be a distribution or otherwise subject to the                      prospectus and registration requirements of applicable securities laws in                      Ontario, and no filing, proceeding, approval, consent or authorization will                      be required to be made, taken or obtained under the laws of Ontario to                      permit such trade or distribution, through investment dealers or brokers, if                      required, registered under the applicable legislation of Ontario who have                      complied with the relevant provisions of such legislation.   5.     Delivery and Payment.          The closing of the issuance of the Debentures (the “Closing”) will, subject to the  satisfaction or waiver of each of the conditions set forth in Sections 2, 3 and 4 of this Agreement,  to be completed remotely on September 1, 2020, or as soon thereafter as the other conditions of  Closing can be satisfied or have been waived (such date, the “Closing Date”), at 10:00 a.m.  (Toronto time) via electronic transmission of documents (such as by use of PDF) at the offices of  Torys LLP, 79 Wellington Street West, Toronto, Ontario, M5K 1N2; or at such other time and date  as may be agreed upon orally or in writing by the parties.   6.    Covenants   (1)   The Purchasers shall deliver or cause to be delivered to BlackBerry at or prior to Closing        by electronic means:          (a)    all documentation as may be required from the Purchasers by applicable                securities laws (including the rules and requirements of the TSX and NYSE, as                applicable) in connection with the purchase by the Purchasers of the Debentures;          (b)    wire transfers by or on behalf of the respective Purchasers in immediately                available United States funds to an account designated by BlackBerry in writing                at least one Business Day prior to Closing, in the aggregate amount of the      36990-2073 30148883.13   

 

                                         - 6 -                    subscription price for the Debentures being purchased by such Purchasers, such                wire transfers to be made by the Purchasers; and          (c)    a certificate of each Purchaser, signed on behalf of such Purchaser, without                personal liability, by a senior officer of such Purchaser, addressed to BlackBerry                and dated the Closing Date certifying that (i) the representations, warranties and                acknowledgements of such Purchaser set forth in this Agreement which are                qualified by materiality are true and correct in all respects as at the Closing Date,                with the same force and effect as if made by the Purchaser as at the Closing Date                (except to the extent that such representations, warranties and                acknowledgements expressly speak of an earlier date, in which event, such                representations, warranties and acknowledgements shall be true and correct as                of such earlier date), (ii) all other representations, warranties and                acknowledgements of such Purchaser set forth in this Agreement are true and                correct in all material respects as at the Closing Date, with the same force and                effect as if made by such Purchaser as at the Closing Date (except to the extent                that such representations, warranties and acknowledgements expressly speak of                an earlier date, in which event, such representations, warranties and                acknowledgements shall be true and correct in all material respects as of such                earlier date), and (iii) such Purchaser has performed in all material respects its                obligations under this Agreement required to be performed on or prior to the                Closing Date.   (2)    At or prior to Closing, BlackBerry shall:          (a)   deliver or cause to be delivered to the Purchasers:                (i)    one or more global certificates representing the Debentures registered in                      the name of “CDS & Co.” or “Cede & Co.”,  against satisfaction of the                      subscription price for the Debentures being purchased as contemplated in                      Section 6(1)(b) of this Agreement, with such Debentures to be issued in                      “book-entry only” form in accordance with instructions as to the respective                      Purchasers’ jurisdiction of residence as provided by the Purchasers;                 (ii)   a certificate of BlackBerry, signed on behalf of BlackBerry, without personal                      liability, by a senior officer of BlackBerry, addressed to each Purchaser and                      dated the Closing Date certifying that (i) the representations and warranties                      of BlackBerry set forth in this Agreement which are qualified by materiality                      or Material Adverse Effect are true and correct in all respects as at the                      Closing Date, with the same force and effect as if made by BlackBerry as                      at the Closing Date (except to the extent that such representations and                      warranties expressly speak of an earlier date, in which event, such                      representations and warranties shall be true and correct as of such earlier                      date), (ii) all other representations and warranties of BlackBerry set forth in                      this Agreement are true and correct in all material respects as at the                      Closing Date, with the same force and effect as if made by BlackBerry as                      at the Closing Date (except to the extent that such representations and                      warranties expressly speak of an earlier date, in which event, such                      representations and warranties shall be true and correct in all material                      respects as of such earlier date), (iii) BlackBerry has performed in all                      material respects its obligations under this Agreement required to be     36990-2073 30148883.13   

 

                                         - 7 -                          performed on or prior to the Closing Date, and (iv) since the date hereof,                      there has not occurred a Material Adverse Effect;                (iii)  certified copies of (i) the articles and by-laws of BlackBerry and each                      Guarantor, and (ii) all resolutions of the board of directors of BlackBerry                      approving the entering into and completion of the transactions                      contemplated by this Agreement;                 (iv)   a certificate of Computershare Investor Services Inc. confirming the issued                      and outstanding Common Shares;                (v)    evidence satisfactory to the Purchasers of the approval of the listing and                      posting for trading on the TSX and NYSE  of the Underlying Common                      Shares subject only to the satisfaction by BlackBerry of customary listing                      conditions, which conditions shall not include a requirement of shareholder                      approval prior to the issuance of the Debentures;                (vi)   the Guarantees executed by the Guarantors;                (vii)  the opinion contemplated in Section 4(d) of this Agreement; and         (b)    execute and deliver the Indenture; and         (c)    pay, or cause to be paid, to HWIC an amount equal to all the reasonable and               documented legal fees and expenses incurred by HWIC  in connection with this               Agreement and the Transaction, including all reasonable fees, disbursements and               taxes of McCarthy Tétrault LLP and Shearman & Sterling LLP.   (3)   BlackBerry shall use commercially reasonable efforts to obtain TSX approval of the listing        of the Debentures by February 15, 2021.    7.     Outside Date.          Each Purchaser and BlackBerry agree that if Closing has not occurred on or prior to   September  9, 2020 (the “Outside Date”), then any of the Purchasers or BlackBerry may   terminate this Agreement, except that the right to terminate this Agreement will not be available   to a party whose breach of this Agreement has been the cause of, or resulted in, the failure of   Closing to occur by such date. If this Agreement is properly terminated pursuant to the foregoing,   then there shall be no further liability of the parties hereunder. Nothing in this Section 7 will relieve   any party from liability for any breach of this Agreement.   8.     Mutual Covenant regarding Closing.          Subject to the terms and conditions of this Agreement, the Purchasers and BlackBerry  shall use their reasonable commercial efforts, on a cooperative basis, to take, or cause to be  taken, all actions and to do, or cause to be done, all things necessary, proper or advisable under  applicable laws to consummate the Transaction as soon as practicable, including:          (a)    BlackBerry using its reasonable commercial efforts to obtain and maintain all                approvals, clearances, consents, registrations, permits, authorizations, notices                and other confirmations required to be obtained from any domestic or foreign      36990-2073 30148883.13   

 

                                         - 8 -                    federal, provincial, state, municipal or other governmental department, court,                tribunal, commission or commissioner, bureau, minister or ministry, board or                agency, or other regulatory authority, including any securities regulatory authority,                the NYSE and the TSX (each, a “Governmental Authority”) or other third party                including any person or entity exercising governmental powers that are                necessary, proper or advisable to consummate the transactions contemplated by                this Agreement (the “Approvals”);          (b)    BlackBerry preparing and filing as promptly as practicable all necessary                documents, registrations, statements, petitions, filings and applications for the                Approvals; and          (c)    BlackBerry or the Purchasers, as the case may be, using reasonable commercial                efforts to oppose, lift or rescind any injunction or restraining or other order or                notice seeking to stop, or otherwise adversely affecting its ability to consummate,                the Transaction or imposing any material restrictions, limitations or conditions on                the parties or the Transaction.         The parties shall co-operate in the preparation of any application for the Approvals and  any other orders, clearances, consents, notices, rulings, exemptions, certificates, no-action letters  and approvals reasonably deemed by either the Purchasers or BlackBerry to be necessary to  discharge their respective obligations under this Agreement or otherwise advisable under  applicable laws in connection with the Transaction.         Subject to applicable laws, the parties shall cooperate with and keep each other fully  informed as to the status of and the processes and proceedings relating to obtaining the Approvals  and any other actions or activities pursuant to this Section 8, and shall promptly notify each other  of any material communication from any Governmental Authority in respect of the Transaction or  this Agreement, and shall not make any submissions, correspondence or filings, or participate in  any communications or meetings with any Governmental Authority in respect of any filings,  investigations or other inquiries or proceedings related to the Transaction or this Agreement  unless it consults with the other parties in advance and, to the extent not precluded by such  Governmental Authority, gives the other parties the opportunity to review drafts of, and provides  final copies of, any submissions, correspondence or filings, and to attend and participate in any  communications or meetings.    9.    Purchasers’ Acknowledgements.          Each Purchaser covenants to execute and deliver all documentation as may be required  to be executed and delivered by it pursuant to applicable securities laws in connection with the  Transaction. Each Purchaser acknowledges that:          (a)    BlackBerry is required to file a report of trade with all applicable securities                regulators containing personal information about each Purchaser. This report of                trade will include the full name, residential address and telephone number of each                Purchaser, the number and type of purchased securities, the Purchase Price, the                date of the Closing and the prospectus and registration exemption relied upon                under applicable securities laws to complete such purchase. In Ontario, this                information is collected indirectly by the Ontario Securities Commission under the                authority granted to it under, and for the purposes of the administration and                enforcement of, the securities legislation in Ontario. The Purchaser may contact     36990-2073 30148883.13   

 

                                         - 9 -                    the Inquiries Officer at 20 Queen Street West, 22nd Floor, Toronto, Ontario, M5H                3S8 or by telephone at (416) 593-8314 for more information regarding the indirect                collection of such information by the Ontario Securities Commission. BlackBerry                may also be required pursuant to applicable securities laws to file this Agreement                on the System for Electronic Document Analysis and Retrieval (“SEDAR”). By                completing this Agreement, the Purchaser authorizes the indirect collection of the                information described in this Section 9(a) by all applicable securities regulators                and consents to the disclosure of such information to the public through (i) the                filing of a report of trade with all applicable securities regulators and (ii) the filing                of this Agreement on SEDAR;          (b)    the Debentures and the Underlying Common Shares are subject to resale                restrictions under applicable Canadian and U.S. securities laws;          (c)    the certificates representing the Debentures and the Underlying Common Shares                (or alternatively the ownership statement or written notice provided to the                Purchaser if the Debentures and the Underlying Common Shares are issued                under a direct registration system or other electronic book-entry system) will bear                the restrictive legends as set forth in the Indenture;          (d)    the Debentures and the Underlying Common Shares have not been and will not                be registered under U.S. Securities Act, and may not be offered or sold in the                United States or to U.S. persons unless registered under the U.S. Securities Act                or an exemption from the registration requirements of the U.S. Securities Act is                available;           (e)    the Debentures are being offered and sold to the Purchaser on a “private                placement” basis;          (f)    it is not purchasing the Debentures as a result of any general solicitation or                general advertising, including advertisements, articles, notices or other                communications published in any newspaper, magazine or similar media or                broadcast over radio or television, or any seminar or meeting whose attendees                have been invited by general solicitation or general advertising;          (g)    no securities commission or similar regulatory authority has reviewed or passed                on the merits of the Debentures;          (h)    there is no government or other insurance covering the Debentures;          (i)    it has had access to such additional information, if any, concerning BlackBerry as                it has considered necessary in connection with its investment decision to acquire                the Debentures;          (j)    it has such knowledge and experience in financial and business matters as to be                capable of evaluating the merits and risks of its investment in the Debentures and                the Underlying Common Shares and is able to bear the economic risks of such                investment;          (k)    there are risks associated with the purchase of the Debentures; and      36990-2073 30148883.13   

 

                                         - 10 -             (l)    there are restrictions on a Purchaser’s ability to resell the Debentures and the                Underlying Common Shares, and it is the responsibility of the Purchaser to find                out what those restrictions are and to comply with them before selling the                Debentures or the Underlying Common Shares.   10.   Purchasers’ Representations and Warranties.          Each Purchaser hereby severally and not jointly makes the following representations and  warranties with respect to itself to BlackBerry, and acknowledges that BlackBerry is relying upon  such representations and warranties in connection with the issue and sale of the Debentures,  that:          (a)    Organization and Good Standing. As of the date hereof and as of the Closing                Date, it is a corporation, limited liability company or other entity duly incorporated,                established or organized and validly existing under the jurisdiction of its                organization.          (b)    Due Authorization. As of the date hereof and as of the Closing Date, (i) the                execution, delivery and performance by the Purchaser of this Agreement and the                consummation by the Purchaser of the transactions contemplated hereby are                within their respective corporate, trust or other governing powers and have been                duly authorized, and no other corporate, trust or other proceedings required by                the constating documents of the Purchaser are necessary to authorize the                execution, delivery and performance of this Agreement or the transactions                contemplated hereby; and (ii) this Agreement has been duly executed and                delivered by the Purchaser and when duly executed and delivered by each of the                other parties hereto, this Agreement will constitute a legal, valid and binding                agreement of the Purchaser enforceable against it in accordance with its terms,                except in each case as enforceability may be limited by applicable bankruptcy,                insolvency, reorganization, moratorium or similar laws affecting the enforcement                of creditors’ rights generally or by equitable principles relating to enforceability,                regardless of whether considered in a proceeding in equity or at law.          (c)    Governmental Authorization. As of the date hereof and as of the Closing Date,                the execution, delivery and performance by the Purchaser of this Agreement and                the consummation by the Purchaser of the transactions contemplated hereby,                require no action by or in respect of, or filing with or approval from, or consent or                authorization from, any Governmental Authority, other than (i) filings under                applicable securities laws; and (ii) any actions, filings or approvals the absence of                which would not reasonably be expected to materially impair the ability of it to                complete the Transaction on or prior to the Outside Date.          (d)    Non-Contravention. As of the date hereof and as of the Closing Date, the                execution, delivery and performance by the Purchaser of this Agreement and the                consummation by the Purchaser of the transactions contemplated hereby do not                and will not (i) contravene, conflict with, or result in any violation or breach of any                provision of (A) the articles of incorporation, by-laws or resolutions of the                shareholders or directors (or any committee thereof) of the Purchaser, or (B) in                the case where the Purchaser is not a corporation, its declaration of trust or other                constating document under which the Purchaser has been established or                organized, or any resolutions of the board, trustees or other body named in such     36990-2073 30148883.13   

 

                                         - 11 -                    constating document as performing a similar function as a board of a corporation                or as trustees of a trust, or of a committee thereof, (ii) assuming compliance with                the matters referred to in paragraph (c) above, contravene, conflict with or result                in a violation or breach of any provision of any applicable law, or (iii) require any                consent or other action by any person under, or constitute, with or without notice                or lapse of time or both, a breach of any material contract to which it is a party or                by which it or any of its properties or assets may be bound, with such exceptions,                in the case of each of clauses (ii) and (iii) above, as would not be reasonably                expected to adversely affect the ability of the Purchaser to consummate the                transactions contemplated hereby on or prior to the Outside Date.          (e)    Principal. The Purchaser is purchasing, or is deemed by Section 2.3(4) of NI 45-               106 to be purchasing, the Debentures as principal.          (f)    Offering Memorandum. It has not been provided with an offering memorandum                (as defined in any applicable Canadian securities laws) or any similar document                in connection with its subscription for the Debentures, and the decision to execute                this Agreement and to purchase the Debentures has not been based upon any                verbal or written representations as to fact or otherwise made by or on behalf of                BlackBerry, other than such written representations as are expressly contained in                this Agreement.          (g)    Investment Purposes. The Purchaser is purchasing the Debentures for                investment purposes only and not with a view to any resale, distribution or other                disposition of the Debentures or the Underlying Common Shares in violation of                applicable securities laws, and not in a transaction or series of transactions                involving a purchase and sale or a repurchase and resale in the course of or                incidental to a distribution.          (h)    Purchaser Status. Either (1) the Purchaser is not a person within the United                States or a “U.S. Person” (as such term is defined in Rule 902(k) of Regulation S                under the U.S. Securities Act), the Debentures were not offered to the Purchaser                in the United States and this Agreement has not been signed by the Purchaser in                the United States or (2) the Purchaser is a “qualified institutional buyer” within the                meaning of Rule 144A under the U.S. Securities Act.          (i)    No Joint Action. The Purchaser is acquiring the Debentures for its own account                and is not (a) acting together, within the meaning of the TSX Company Manual,                or (b) acting jointly or in concert, within the meaning of Canadian securities laws,                in each case, with any other person or entity in respect of its investment in                BlackBerry.   11.   Representations and Warranties of BlackBerry.         BlackBerry represents and warrants to each Purchaser, and acknowledges that each  Purchaser is relying upon such representations and warranties in purchasing the Debentures,  that:          (a)    Organization and Good Standing. As of the date hereof and as of the Closing                Date, each of BlackBerry and its subsidiaries has been duly created, incorporated,                amalgamated or organized and is validly existing and in good standing and up to      36990-2073 30148883.13   

 

                                         - 12 -                    date in all corporate filings under the laws of its respective jurisdictions of                organization, is duly qualified to do business in each jurisdiction in which its                respective ownership or lease of property or the conduct of its respective                businesses requires such qualification, and has all power and authority necessary                to own or hold its respective properties and to conduct the businesses currently                and customarily carried on by it, except where the failure to be so qualified or                have such power or authority would not, individually or in the aggregate, have or                reasonably be expected to have a Material Adverse Effect. As of the date hereof,                the subsidiaries listed on page 4 of BlackBerry’s Annual Report on Form 10-K                dated April 7, 2020 are the only subsidiaries of BlackBerry material to the                business, earnings, assets, condition (financial or otherwise), liabilities, results of                operations or business prospects of BlackBerry and its subsidiaries, taken as a                whole.          (b)    Capitalization. As of June 30, 2020, there were 555,573,072 Common Shares,                no Class A common shares and no preference shares issued and outstanding                and since June 30, 2020 to the date hereof, no Common Shares have been                issued or become issuable other than pursuant to BlackBerry’s equity incentive                plans or executive inducement equity awards. As of the date hereof and as of the                Closing Date, (i) BlackBerry’s authorized share capital consists of an unlimited                number of Common Shares, an unlimited number of Class A common shares and                an unlimited number of preference shares, issuable in series; (ii) all the                outstanding shares of capital stock or other equity interests of BlackBerry and of                each subsidiary of BlackBerry have been duly and validly authorized and issued                and are fully paid and non-assessable; (iii) all the outstanding shares of capital                stock or other equity interests of each subsidiary of BlackBerry (including each of                the subsidiaries of BlackBerry reflected in the BlackBerry Public Documents) are                owned directly or indirectly by BlackBerry, in each case, free and clear of any lien,                charge, encumbrance, security interest, restriction on voting or transfer (except                as may be set out in the constating documents of each subsidiary of BlackBerry                or liens, charges, or encumbrances, that have been publicly disclosed) or any                other claim of any third party, in each case, except (A) as publicly disclosed by                BlackBerry or (B) as would not result in a Material Adverse Effect; (iv) other than                the Existing Debentures, and other than the Debentures or in connection with the                Debentures there are no securities convertible into, or exchangeable or                exercisable for, or other rights to acquire from BlackBerry, Common Shares of                BlackBerry or other equity interests in BlackBerry, other than (A) as disclosed or                referred to the audited consolidated financial statements and the related notes                thereto of BlackBerry and its consolidated subsidiaries for the year ended                February 29, 2020 or the interim consolidated financial statements and the related                notes thereto of BlackBerry and its consolidated subsidiaries for the three months                ended May 31, 2020, (B) securities issued in the normal course after May 31,                2020 in connection with the issuance of securities by BlackBerry pursuant to its                equity incentive plans or executive inducement equity awards, and (C) as                contemplated by this Agreement; and (v) there are no contractual obligations of                BlackBerry or any subsidiary to repurchase, redeem or otherwise acquire any                outstanding securities or indebtedness of BlackBerry or any subsidiary, except in                the case of subsidiaries of BlackBerry, any such obligations entered into in the                ordinary course of business that would not individually or collectively result in a                Material Adverse Effect. For the purposes of this Agreement, a matter shall be      36990-2073 30148883.13   

 

                                         - 13 -                    considered to be “publicly disclosed” only to the extent it is disclosed in one of the                BlackBerry Public Documents filed on SEDAR prior to the date hereof.          (c)    Guarantors. Each    of the Guarantors are wholly-owned subsidiaries of                BlackBerry.          (d)    Due Authorization. As of the date hereof and as of the Closing Date, the                execution, delivery and performance by BlackBerry of this Agreement and the                consummation by BlackBerry of the transactions contemplated hereby are within                the corporate powers of BlackBerry and have been duly authorized, and no other                corporate proceedings on the part of BlackBerry are necessary to authorize the                execution, delivery and performance of this Agreement, or the transactions                contemplated hereby. This Agreement has been duly executed and delivered by                BlackBerry and when duly executed and delivered in accordance with its terms                by each of the parties thereto, this Agreement will constitute a legal, valid and                binding agreement of BlackBerry enforceable against BlackBerry in accordance                with its terms, except as enforceability may be limited by applicable bankruptcy,                insolvency, fraudulent transfer, reorganization, moratorium or similar laws                affecting the enforcement of creditors’ rights generally or by equitable principles                relating to enforceability, regardless of whether considered in a proceeding in                equity or at law.          (e)    Power and Authority. BlackBerry has all requisite power and authority: (i) to                enter into the Indenture; (ii) to carry out all the terms and provisions of the                Indenture; and (iii) to issue and deliver the Debentures in accordance with the                provisions of this Agreement and the Underlying Common Shares in accordance                with the provisions of the Indenture. The Guarantors each have all requisite power                and authority: (i) to enter into the Guarantees and (ii) to carry out all the terms and                provisions of the Guarantees.          (f)    Authorization. When executed and delivered, the Indenture and the Guarantees                will constitute legal, valid and binding obligations of BlackBerry and the                Guarantors, respectively, enforceable in accordance with its terms, except as                enforceability may be limited by applicable bankruptcy, insolvency,                reorganization, moratorium or similar laws affecting the enforcement of creditors’                rights generally or by equitable principles relating to enforceability, regardless of                whether considered in a proceeding in equity or at law.          (g)    Authorization of Debentures. The issuance of the Debentures by BlackBerry to                the Purchasers in accordance with the terms of this Agreement has been                authorized by all necessary action of BlackBerry, and upon payment therefor in                accordance with this Agreement, the Debentures will be validly issued and                outstanding.          (h)    Authorization of Underlying Common Shares. The issuance of the Underlying                Common Shares in accordance with the terms of the Indenture has been                authorized by all necessary action of BlackBerry, and upon the conversion, and                when issued will be validly issued and outstanding as fully paid and non-               assessable Common Shares.      36990-2073 30148883.13   

 

                                         - 14 -             (i)    BlackBerry Securities. As of the date hereof and as of the Closing Date: (i) no                order, ruling or decision granted by a securities commission, court of competent                jurisdiction or regulatory or administrative body or other Governmental Authority                having jurisdiction is in effect, pending or (to the best of BlackBerry’s knowledge)                threatened that restricts any trades in any securities of BlackBerry including any                cease trade orders; (ii) the currently issued and outstanding Common Shares are                listed and posted for trading on the TSX and the NYSE, the currently issued and                outstanding Existing Debentures are listed and posted for trading on the TSX, and                BlackBerry is in compliance in all material respects with all of the listing conditions                on such exchanges; and (iii) the Debentures to be sold pursuant to this Agreement                have been duly authorized for issuance and sale by all necessary action on the                part of BlackBerry and, when issued and delivered by BlackBerry against payment                of the consideration therefor pursuant to this Agreement will have been validly                issued and outstanding and will not have been issued in violation of or subject to                any pre-emptive rights or other contractual rights to purchase securities issued by                BlackBerry.          (j)    Governmental Authorization. As of the date hereof and as of the Closing Date,                the execution, delivery and performance by BlackBerry of this Agreement, the                Indenture and the Debentures or by the Guarantors of the Guarantees, and the                consummation by    BlackBerry and the Guarantors of the transactions                contemplated hereby and thereby require no action by or in respect of, or filing                with or approval from, or consent or authorization from any Governmental                Authority, other than (i) filings under applicable securities laws (including filings                with the TSX and the NYSE); and (ii) any actions or filings the absence of which                would not reasonably be expected to materially impair the ability of BlackBerry to                complete the Transaction on or prior to the Outside Date.          (k)    Non-Contravention. As of the date hereof and as of the Closing Date, the                execution, delivery and performance by BlackBerry of this Agreement, the                Indenture and the Debentures and by the Guarantors of the Guarantees and the                consummation by BlackBerry and the Guarantors of the transactions                contemplated hereby and thereby do not and will not (i) contravene, conflict with,                or result in any violation or breach of any provision of the articles of amalgamation,                by-laws or resolutions of the shareholders or directors (or any committee thereof)                of BlackBerry or any of its subsidiaries; (ii) assuming compliance with the matters                referred to in paragraph (j) above, contravene, conflict with or result in a violation                or breach of any provision of any applicable law; or (iii) require any consent or                other action by any person under, constitute a default, or an event that, with or                without notice or lapse of time or both, would constitute a default, under, or cause                or permit the termination, cancellation, acceleration or other change of any right                or obligation or the loss of any benefit to which BlackBerry or any of its                subsidiaries is entitled under any provision of any material contract to which                BlackBerry or any of its subsidiaries is a party or by which it or any of its properties                or assets may be bound, with such exceptions, in the case of each of clauses (ii)                and (iii) above, as would not individually or in the aggregate, reasonably be                expected to have a Material Adverse Effect or adversely affect the ability of                BlackBerry to consummate the transactions contemplated hereby on or prior to                the Outside Date.      36990-2073 30148883.13   

 

                                         - 15 -             (l)    Compliance with Laws. BlackBerry and its subsidiaries are and have been in                compliance with, and conduct their businesses in conformity with, all applicable                laws, except where the failure to be in compliance or conformity would not result                in a Material Adverse Effect. BlackBerry is a reporting issuer under the securities                laws of each of the provinces of Canada (collectively the “Canadian                Jurisdictions”) that recognizes the concept of reporting issuer, is in compliance                in all material respects with the applicable securities legislation of the Canadian                Jurisdictions, and the respective rules, regulations and written and published                policies thereunder, and is not on the list of defaulting reporting issuers                maintained by the applicable securities regulatory authority in each such                Canadian Jurisdiction that maintains such a list. BlackBerry is subject to Section                13 or 15(d) of the United States Securities Exchange Act of 1934, as amended                (the “Exchange Act”) and has filed all reports required under the Exchange Act                in the last twelve month period.           (m)    Financial Statements. The audited consolidated financial statements and the                related notes thereto of BlackBerry and its consolidated subsidiaries for the years                ended February 29, 2020 and February 28, 2019 and  the interim consolidated                financial statements and the related notes thereto of BlackBerry and its                consolidated subsidiaries for the three months ended May 31, 2020    (the                “Financial Statements”) comply in all material respects with the applicable                requirements of the Canadian securities laws and present fairly the financial                position of BlackBerry and its subsidiaries as of the dates indicated and the results                of their operations and the changes in their cash flows for the periods specified,                and have been prepared in conformity with United States generally accepted                accounting principles, in each case applied on a consistent basis throughout the                periods covered thereby (except (i) as otherwise indicated in such financial                statements and notes thereto, or, in the case of audited statements, in the related                report of BlackBerry independent auditors, as the case may be, or (ii) in the case                of unaudited interim statements, are subject to nominal period-end adjustments                and may omit notes which are not required by applicable laws in the unaudited                statements). None of BlackBerry or its subsidiaries has any liabilities, obligations,                indebtedness or commitments, whether accrued, absolute, contingent or                otherwise, which are not disclosed or referred to in the Financial Statements,                other than liabilities, obligations, or indebtedness or commitments (i) incurred in                the normal course of business, (ii) which have been publicly disclosed by                BlackBerry, or (iii) which would not or would not reasonably be expected to have                a Material Adverse Effect.          (n)    No Material Adverse Change. Between February 29, 2020 and the date hereof,                (i) there has not been any material change in the share capital or long-term debt                of BlackBerry, or any dividend or distribution of any kind declared, set aside for                payment, paid or made by BlackBerry on any class of shares, or, individually or                in the aggregate, a Material Adverse Effect; (ii) neither BlackBerry nor any of its                subsidiaries has entered into any transaction or agreement that is material to                BlackBerry and its subsidiaries taken as a whole or incurred any liability or                obligation, direct or contingent, that is material to BlackBerry and its subsidiaries                taken as a whole; and (iii) neither BlackBerry nor any of its subsidiaries has                sustained any material loss or interference with its business from fire, explosion,                flood or other calamity, whether or not covered by insurance, or from any labor                disturbance or dispute or any action, order or decree of any court or arbitrator or     36990-2073 30148883.13   

 

                                         - 16 -                    Governmental Authority, except in each of clauses (i) through (iii) above as                otherwise publicly disclosed by BlackBerry.          (o)    No Violation or Default. Other than as publicly disclosed by BlackBerry, neither                BlackBerry nor any of its subsidiaries is (i) in violation of its charter or by-laws or                similar organizational documents; (ii) in default of, and no event has occurred that,                with notice or lapse of time or both, would constitute such a default, in the due                performance or observance of any term, covenant or condition contained in any                indenture, mortgage, deed of trust, loan agreement or other agreement or                instrument to which BlackBerry or any of its subsidiaries is a party or by which                BlackBerry or any of its subsidiaries is bound or to which any of the property or                assets of BlackBerry or any of its subsidiaries is subject; or (iii) in violation of any                laws, except, in the case of clauses (ii) and (iii) above, for any such default or                violation that would not, individually or in the aggregate, have a Material Adverse                Effect.          (p)    Legal Proceedings. Except as publicly disclosed by BlackBerry, there are no                legal, governmental or regulatory investigations, actions, suits or proceedings                pending to which BlackBerry or any of its subsidiaries is or may be a party or to                which any property of BlackBerry or any of its subsidiaries is or may be the subject                that, individually or in the aggregate, if determined adversely to BlackBerry or any                of its subsidiaries, would or would reasonably be expected to have a Material                Adverse Effect, and no such investigations, actions, suits or proceedings are                threatened or, to the knowledge of BlackBerry, contemplated by any                Governmental Authority or threatened by others.          (q)    Reports. BlackBerry has, in accordance with applicable laws, filed with securities                regulatory authorities, the TSX and the NYSE, as applicable, true and complete                copies of all forms, reports, schedules, statements, material change reports,                circulars, press releases, disclosures relating to options and other stock based                incentive plans, prospectuses, other offering documents and all other documents                required to be filed by it with securities regulatory authorities, the TSX or the                NYSE  as applicable since February 28, 2019 (such forms, reports, schedules,                statements and other documents, including any financial statements or other                documents, including any schedules included therein, are referred to herein as                the “BlackBerry Public Documents”). The BlackBerry Public Documents (i) at                the time filed did not; (ii) as of the date hereof (taken as a whole after giving effect                to all filings made prior to the date hereof), do not; and (iii) as of the Closing Date                (taken as a whole after giving effect to all filings made prior to the Closing Date)                will not, contain any untrue statement of a material fact or omit to state a material                fact required to be stated therein or necessary in order to make the statements                made therein, in light of the circumstances under which they were made, not                misleading except to the extent that such statements have been modified or                superseded by a later-filed company filing. BlackBerry has not filed any                confidential material change report with any of the securities regulatory                authorities, the TSX, the NYSE or any other self-regulatory authority that remains                confidential.          (r)    Title to Real and Personal Property. Except as publicly disclosed by BlackBerry,                BlackBerry and its subsidiaries have good and marketable, in the case of real                property, and valid, in the case of personal property, title in fee simple to, or have     36990-2073 30148883.13   

 

                                         - 17 -                    valid rights to lease or otherwise use, all items of real and personal property that                are used or held by BlackBerry and its subsidiaries, in each case free and clear                of all liens, encumbrances, claims and defects and imperfections of title except                those that (i) do not materially interfere with the use made and proposed to be                made of such property by BlackBerry and its subsidiaries; (ii) would not or would                not reasonably be expected to have, individually or in the aggregate, a Material                Adverse Effect; or (iii) have been granted in connection with BlackBerry’s                outstanding credit agreements and other applicable debt obligations, in each case                as publicly disclosed by BlackBerry.          (s)    Licenses and Permits. Except as publicly disclosed by BlackBerry, BlackBerry                and its subsidiaries possess all licenses, certificates, permits and other                authorizations issued by, and have made all declarations and filings with, the                appropriate Governmental Authorities that are necessary for the ownership or                lease of their respective properties or the conduct of their respective businesses                except where the failure to possess or make the same would not, individually or                in the aggregate, have a Material Adverse Effect; and except as publicly disclosed                by BlackBerry or as would not have a Material Adverse Effect, neither BlackBerry                nor any of its subsidiaries has (to the best knowledge of BlackBerry) received any                written notice of any revocation or modification of any such license, certificate,                permit or authorization or has any reason to believe that any such license,                certificate, permit or authorization will not be renewed in the ordinary course.          (t)    Compliance with Environmental Laws. Except as publicly disclosed by                BlackBerry, BlackBerry and its subsidiaries (i) are in compliance with any and all                applicable laws relating to the protection of human health and safety, the                environment or hazardous or toxic substances or wastes, pollutants or                contaminants (collectively, “Environmental Laws”); (ii) have received and are in                compliance in all material respects with all permits, licenses or other approvals                required of them under applicable Environmental Laws to conduct their respective                businesses; and (iii) have not received written notice of any actual or potential                liability for the investigation or remediation of any disposal or release of hazardous                or toxic substances or wastes, pollutants or contaminants, except in any such                case for any such failure to comply with, or failure to receive required permits,                licenses or approvals, or liability as would not, individually or in the aggregate,                reasonably be expected to have a Material Adverse Effect.          (u)    Disclosure Controls. BlackBerry and its subsidiaries maintain an effective                system of “disclosure controls and procedures” (as defined in Rule 13a-15(e) of                the Exchange Act and National Instrument 52-109 - Certification of Disclosure in                Issuers’ Annual and Interim Filings (“NI 52-109”)) that are intended to provide                reasonable assurance that information required to be disclosed by BlackBerry in                its annual filings, interim filings or other reports filed or submitted under the                Exchange Act and Canadian securities laws is recorded, processed, summarized                and reported within the time periods specified in the United States Securities and                Exchange Commission’s and Canadian securities authorities’ rules and forms,                including controls and procedures designed to ensure that such information is                accumulated and communicated to BlackBerry’s management as appropriate to                allow timely decisions regarding required disclosure. BlackBerry and its                subsidiaries have carried out evaluations of the effectiveness of their disclosure      36990-2073 30148883.13   

 

                                         - 18 -                    controls and procedures as required by Rule 13a-15 of the Exchange Act and as                contemplated under NI 52-109.          (v)    Accounting Controls. BlackBerry and its subsidiaries maintain systems of                “internal control over financial reporting” (as defined in Rule 13a-15(f) of the                Exchange Act and NI 52-109) that comply with the requirements of the Exchange                Act and NI 52-109 and have been designed by, or under the supervision of, their                respective principal executive and principal financial officers, or persons                performing similar functions, to provide reasonable assurance regarding the                reliability of financial reporting and the preparation of financial statements for                external purposes in accordance with United States generally accepted                accounting principles, including internal accounting controls sufficient to provide                reasonable assurance (i) that transactions are executed in accordance with                management’s general or specific authorizations; (ii) that transactions are                recorded as necessary to permit preparation of financial statements in conformity                with Canadian generally accepted accounting principles and to maintain asset                accountability; (iii) that access to assets is permitted only in accordance with                management’s general or specific authorization; (iv) that the recorded                accountability for assets is compared with the existing assets at reasonable                intervals and appropriate action is taken with respect to any differences; and (v)                regarding prevention or timely detection of unauthorized acquisition, use or                disposition of BlackBerry’s assets that could have a material effect on                BlackBerry’s annual financial statements or interim financial statements. Since                the date of the most recent balance sheet of BlackBerry publicly disclosed by                BlackBerry, BlackBerry’s auditors and the Audit Committee of the board of                directors of BlackBerry have not been advised of: (A) any significant deficiencies                in the design or operation of internal controls over financial reporting which are                reasonably likely to adversely affect BlackBerry’s ability to record, process,                summarize and report financial information; and (B) any fraud, whether or not                material, that involves management or other employees who have a significant                role in BlackBerry’s internal control over financial reporting. Except as publicly                disclosed by BlackBerry, there are no material weaknesses in BlackBerry’s                internal controls.          (w)    Certain Payments. Neither BlackBerry nor any of its subsidiaries nor, to the best                knowledge of BlackBerry, any director, officer, agent, employee or other person                associated with or acting on behalf of BlackBerry or any of its subsidiaries has (i)                used any corporate funds for any unlawful contribution, gift, entertainment or other                unlawful expense relating to political activity; (ii) made any direct or indirect                unlawful payment to any foreign or domestic government official or employee from                corporate funds; (iii) violated or is in violation of any provision of the Foreign                Corrupt Practices Act of 1977 or the Corruption of Foreign Public Officials Act                (Canada) or any other anti-corruption laws applicable to BlackBerry or any of its                subsidiaries; (iv) made any bribe, rebate, payoff, influence payment, kickback or                other unlawful payment, except in each case as would not be material to                BlackBerry and its subsidiaries, taken as a whole; (v) directly or indirectly,                obtained or induced or attempted to so obtain or induce the procurement of this                Agreement or any contract, consent, approval, right, interest, privilege or other                obligation or benefit related to this Agreement or the Transaction or your other                dealings with any of the Purchasers or their Connected Persons through any                violation of law or regulation; or (vi) have not given or agreed to give and shall not     36990-2073 30148883.13   

 

                                         - 19 -                    give or agree to give to any person, either directly or indirectly, any placement                fee, introductory fee, arrangement fee, finder’s fee or any other fee,                compensation, monetary benefit or any other benefit, gift, commission,                gratification, bribe or kickback, whether described as a consultation fee or                otherwise, with the object of obtaining or inducing the procurement of the                Transaction or any contract, right, interest, privilege or other obligation or benefit                related to the Transaction, except for bona fide fees payable to arm’s length legal,                accounting or financial service providers. As used herein, “Connected Persons”                means, with respect to a Purchaser: (A) its affiliates; (B) the advisers, agents,                representatives and consultants of it and its affiliates; and (C) the directors,                officers, partners and employees of it, its affiliates and of its and their advisers,                agents, representatives and consultants.          (x)    Compliance with Money Laundering Laws. The operations of BlackBerry and                its subsidiaries are and have been conducted at all times in compliance with                applicable financial recordkeeping and reporting requirements of the Currency                and Foreign Transactions Reporting Act of 1970, as amended, the Proceeds of                Crime (Money Laundering) Act (Canada), the money laundering statutes of all                applicable jurisdictions, the rules and regulations thereunder and any related or                similar rules, regulations or guidelines, issued, administered or enforced by any                governmental agency to which BlackBerry and its subsidiaries are subject                (collectively, the “Money Laundering Laws”) and no action, suit or proceeding                by or before any Governmental Authority or body or any arbitrator involving                BlackBerry or any of its subsidiaries with respect to the Money Laundering Laws                is pending or, to the best knowledge of BlackBerry, threatened.          (y)    No Broker’s Fees. Neither BlackBerry nor any of its subsidiaries is a party to any                contract, agreement or understanding with any person that would give rise to a                valid claim against the Purchasers for a brokerage commission, finder’s fee or like                payment in connection with the issuance and sale of the Debentures.          (z)    Independent Accountants. Each of PricewaterhouseCoopers LLP, BlackBerry’s                current auditor, and Ernst & Young LLP, which has audited certain financial                statements of BlackBerry and its subsidiaries, is an independent registered public                accounting firm with respect to BlackBerry and its subsidiaries within the                applicable rules and regulations adopted by the Canadian securities regulators                and the Public Accounting Oversight Board (United States) and as required by                the Securities Act. There has not been any reportable event (within the meaning                of National Instrument 51-102 of the Canadian Securities Administrators) with                either of Ernst & Young LLP or PricewaterhouseCoopers LLP.          (aa)   Investment Company Act. BlackBerry is not and, after giving effect to the                offering and sale of the Debentures and the application of the proceeds thereof                as described herein, will not be required to be registered as an “investment                company” pursuant to the Investment Company Act of 1940, as amended, and                the rules and regulations of the United States Securities and Exchange                Commission thereunder.           (bb)   Taxes. Except as publicly disclosed by BlackBerry, BlackBerry and each                subsidiary has timely filed or caused to be filed all tax returns and reports required                to have been filed by it and has paid or caused to be paid all taxes required to     36990-2073 30148883.13   

 

                                         - 20 -                    have been paid by it, except (i) taxes that are being contested in good faith by                appropriate proceedings and for which BlackBerry or such subsidiary has set                aside on the Financial Statements a reasonable reserve, or (ii) taxes that                commenced being contested in good faith by appropriate proceedings during the                period after the most recent period covered in the Financial Statements and in                which case BlackBerry or such subsidiary has set aside on its books a reasonable                reserve for such taxes. In Canada and each of its provinces and territories, there                will be no stamp duty, stamp tax or similar indirect taxes upon issuance,                redemption or conversion of the Debentures.           (cc)   BlackBerry is not, and after giving effect to the offering and sale of the Debentures                and the application of the proceeds thereof as described herein will not be, an                “investment fund” as that term is used in paragraph (q) of the definition of                “accredited investor” in Section 1.1 of NI 45-106.          (dd)   Assuming the accuracy of the Purchasers’   representations and warranties                contained in Section 10, no registration under the U.S. Securities Act of 1933, as                amended, of the Debentures and no qualification of the Indenture under the Trust                Indenture Act of 1939, as amended, is required for the offer and sale of the                Debentures by BlackBerry to the Purchasers.   12.   Indemnification.          (a)    The representations, warranties and covenants of BlackBerry contained in this                Agreement are made by BlackBerry with the intent that they may be relied upon                by the Purchasers in entering into this Agreement, determining whether to                purchase the Debentures and consummating the transactions contemplated                hereby, and BlackBerry covenants and agrees to indemnify and save harmless                each Purchaser (and their respective affiliates and their respective shareholders,                officers, directors, employees and agents) from and against all (i) civil or                administrative penalties arising from violations or alleged violations of applicable                laws, (ii) losses, claims, damages, liabilities, costs and expenses, including all                amounts paid to settle actions (provided BlackBerry has previously consented to                such settlement) or satisfy judgements or awards, and (iii) reasonable legal fees                and expenses relating to the above, in each case caused by or arising directly or                indirectly by reason of any inaccuracy in or breach by BlackBerry of any                representation, warranty or covenant made by BlackBerry under this Agreement.          (b)    The representations, warranties and covenants of each Purchaser contained in                this Agreement are made by each Purchaser severally and not jointly with the                intent that they may be relied upon by BlackBerry in entering into this Agreement,                determining whether to issue the Debentures and consummating the transactions                contemplated hereby, and each Purchaser severally and not jointly covenants                and agrees to indemnify and save harmless BlackBerry (and its affiliates and their                respective shareholders, officers, directors, employees and agents) from and                against all (i) civil or administrative penalties arising from violations or alleged                violations of applicable laws, (ii) losses, claims, damages, liabilities, costs and                expenses, including all amounts paid to settle actions (provided the Purchaser                has previously consented to such settlement) or satisfy judgements or awards,                and (iii) reasonable legal fees and expenses relating to the above, in each case                caused by or arising directly or indirectly by reason of any inaccuracy in or breach     36990-2073 30148883.13   

 

                                         - 21 -                    by such Purchaser of any representation, warranty or covenant made by the                Purchaser under this Agreement.   13.   Survival of Representations, Warranties and Covenants.         The Purchasers and BlackBerry agree that the representations and warranties made by  each of them in this Agreement, including pursuant to Sections 10 and 11 of this Agreement, and  in any certificate delivered pursuant hereto, shall survive until the end of the second anniversary  of the Closing Date; provided, however, that the representations and warranties set forth in  Sections 10(a), 10(b), 10(d), 11(a), 11(b), 11(c), 11(d) and 11(f) shall survive indefinitely.         The Purchasers and BlackBerry agree that unless required to be performed on or prior to  the Closing Date or unless otherwise expressly set forth herein, the covenants made pursuant  hereto shall survive indefinitely. For greater certainty, the Purchasers and BlackBerry each  acknowledge and agree that in the event of a breach or threatened breach of its covenants  hereunder, the harm suffered would not be compensable by monetary damages alone and,  accordingly, in addition to other available legal or equitable remedies, each non-breaching party  shall be entitled to apply for an injunction or specific performance with respect to such breach or  threatened breach, without proof of actual damages (and without the requirement of posting a  bond, undertaking or other security), and each of the Purchasers and BlackBerry agree not to  plead sufficiency of damages as a defence in such circumstances.   14.   Governing Law.         The Purchasers and BlackBerry agree that this Agreement shall be governed by and  interpreted and enforced in accordance with the laws of the Province of Ontario and the federal  laws of Canada applicable therein. Each of the Purchasers and BlackBerry irrevocably attorns  and submits to the non-exclusive jurisdiction of the Ontario courts situated in the City of Toronto,  and waives objection to the venue of any proceeding in such court or that such court provides an  inconvenient forum.   15.   Notices.         Any notice, direction or other communication given pursuant to this Agreement (each a  “Notice”) must be in writing, sent by personal delivery, courier, or email and addressed:          if to a Purchaser:   See Schedule A for notice information for each Purchaser           if to BlackBerry:    BlackBerry Limited                              2200 University Avenue East                              Waterloo, Ontario                              Canada  N2K 0A7                                                             Attention:   Randall Cook                              Email:       randall.cook@blackberry.com                                    36990-2073 30148883.13   

 

                                         - 22 -             with a copy to:      Torys LLP                              Suite 3000, 79 Wellington Street W.                              Toronto, Ontario M5K 1N2                               Attention:   Glen Johnson                              Email:       grjohnson@torys.com                              Fax:         416.865.7380            Any Notice, if personally delivered or couriered, shall be deemed to have been validly and  effectively given and received on the date of such delivery to the recipient, if delivered before 5:00  p.m. on a Business Day in the place of delivery, or the Business Day in the place of delivery, if  not delivered on a Business Day or if sent after 5:00 p.m., and if sent by email, shall be deemed  to have been validly and effectively been given and received on the Business Day next following  the day it was transmitted. Any party may at any time change its address for service from time to  time by giving notice to the other parties in accordance with this Section 15.   16.    Assignment.          The Purchasers and BlackBerry agree that none of the Purchasers or BlackBerry may  assign or transfer this Agreement or any of the rights or obligations under it without the prior  written consent of the other parties. Notwithstanding the foregoing, any of the Purchasers shall  be entitled to assign its rights under this Agreement without the consent of BlackBerry to any  affiliates of such Purchaser that agree to be bound by all of the covenants of such Purchaser  contained herein and comply with the provisions of this Agreement and deliver to BlackBerry a  duly executed undertaking to such effect in form and substance satisfactory to BlackBerry, acting  reasonably, and provided that any such assignment shall not relieve such Purchaser of any of its  obligations hereunder and shall not provide subscription rights to such affiliates that are greater  in aggregate than those held by such Purchaser.   17.    Announcements.          Other than the press releases with respect to the Transaction issued by BlackBerry in  connection with the execution of the Consent Agreements and to be issued by BlackBerry  concurrent with the notice of redemption of the Existing Debentures, the Purchasers and  BlackBerry agree that during the period up to and including the Closing Date, no press release,  public statement or announcement or other public disclosure (a “Public Statement”) with respect  to this Agreement or the Transaction may be made except with the prior written consent and joint  approval of BlackBerry and the Purchasers or if required by law or a Governmental Authority, and  that where the Public Statement is required by law or a Governmental Authority, the person  required to make the Public Statement will use reasonable commercial efforts to obtain the  approval of the others as to the form, nature and extent of the disclosure.   18.    Entire Agreement.          The Purchasers and BlackBerry agree that this Agreement and the Consent Agreements,  contain, for good and valuable consideration, the entire agreement of the Purchasers and  BlackBerry relating to the subject matter hereof and there are no representations, covenants or  other agreements relating to the subject matter hereof except as stated or referred to herein. This      36990-2073 30148883.13   

 

                                         - 23 -      Agreement may not be amended or modified in any respect except by written instrument executed  by each of the Purchasers and BlackBerry.   19.   Expenses.         Subject to the provisions of Section 6(2)(c), the Purchasers and BlackBerry agree that all  costs and expenses (including the fees and disbursements of legal counsel and other professional  advisors) incurred in connection with this Agreement and the transactions contemplated herein  shall be paid by the party incurring such expenses.   20.   Enurement.         The Purchasers and BlackBerry agree that this Agreement is binding upon and enures to  the benefit of each of the Purchasers and BlackBerry and their respective successors and  assigns.   21.   Severability.         The Purchasers and BlackBerry agree that if any provision of this Agreement is  determined by a court of competent jurisdiction to be invalid, illegal or unenforceable in any  respect, such determination shall not impair or affect the validity, legality or enforceability of the  remaining provisions hereof, and each provision is hereby declared to be separate, severable and  distinct.   22.   Interpretation.         The Purchasers and BlackBerry agree that in this Agreement:          (a)    “including” means including without limitation;          (b)    words importing the singular number only shall include the plural and vice versa                and words importing any gender shall include all genders;          (c)    if a word or phrase is defined, its other grammatical forms have a corresponding                meaning;          (d)    the division of this Agreement into Sections and other subdivisions and the                insertion of headings are for convenient reference only and do not affect the                Agreement’s interpretation;          (e)    all amounts in this Agreement referred to by “$” or “U.S.$” mean United States                currency;          (f)    “Business Day” means any day other than a Saturday, Sunday or any day on                which banks are generally not open for business in the City of Toronto. In the                event that any action is required or permitted to be taken under this Agreement                on or by a date that is not a Business Day, such action may be taken on or by the                Business Day immediately following such date;          (g)    “Closing” and “Closing Date” have the meanings ascribed to those terms in                Section 5 hereof;      36990-2073 30148883.13   

 

                                         - 24 -             (h)    “Common Shares” means the common shares in the capital of BlackBerry;          (i)    “Consent Agreements”   means, collectively, the consent agreements entered                into between (i) BlackBerry and HWIC dated July 21, 2020; and (ii) BlackBerry                and [redacted] dated July 21, 2020;          (j)    “Guarantors”  means each of   BlackBerry Corporation, Cylance Inc., Good                Technology Software Inc., QNX Software Systems Limited and any other Person                (as defined in the Indenture) who from time to time guarantees the obligations of                BlackBerry under Specified Senior Indebtedness (as defined in the Indenture);          (k)    “Guarantees”  means the guarantees contemplated by the Indenture to be                executed and delivered by the Guarantors in substantially the form contemplated                by the Indenture;          (l)    “Indenture”  means the convertible debenture indenture providing for the                creation, issuance and governance of and in connection with the Debentures,                substantially in the form attached as Schedule B;          (m)    “Indenture Trustee” means BNY Trust Company of Canada, the trustee under                the Indenture;          (n)    “Material Adverse Effect”  means any fact, circumstance, change, event,                occurrence or effect that, individually or in the aggregate is, or would reasonably                be expected to be, materially adverse to the business, assets, condition (financial                or otherwise), liabilities or results of operations of BlackBerry and its subsidiaries                taken as a whole, provided that, none of the following will constitute or be taken                into account in determining whether a “Material Adverse Effect” has occurred or                could occur: (i) any change in United States generally accepted accounting                principles; (ii) any adoption, proposal, implementation or change in applicable law                or any interpretation thereof by any Governmental Authorities; (iii) any change in                global, national or regional political conditions (including the outbreak of war or                acts of terrorism) or in general economic, business, regulatory, political or market                conditions or in national or global financial or capital markets; (iv) any pandemic,                earthquake, hurricane, tornado or other natural disaster; and (v) any action taken                by the BlackBerry or any of its subsidiaries which is required pursuant to the                Agreement; provided, however, that with respect to clauses (i), (ii), (iii) and (iv) of                this definition, such matter does not have a materially disproportionate effect on                BlackBerry and its subsidiaries, taken as a whole, relative to other comparable                companies and entities operating in the industries in which BlackBerry and/or its                subsidiaries operate;          (o)    for purposes of this Agreement, it shall in each case be a question of fact as to                whether two persons are dealing “at arm’s length” in connection with securities                of BlackBerry, and without limitation: (i) a person will not be considered to be                dealing not at arm’s length with another person solely because it is under common                ownership with such person; (ii) persons who are affiliates of each other will be                presumed not to deal at arm’s length; (iii) persons who are acting jointly or in                concert with one another in connection with securities of BlackBerry are not                dealing at arm’s length; (iv) where one or more persons is controlling in fact the                actions of another person in connection with securities of BlackBerry, then such     36990-2073 30148883.13   

 

                                         - 25 -                    persons are not dealing at arm’s length; and (v) where two or more persons are,                directly or indirectly, acting under the common direction of a single person in                connection with securities of BlackBerry, then such persons are not dealing at                arm’s length;          (p)    the term “person” is to be broadly interpreted and includes an individual, a natural                person, a firm, a corporation, a partnership, a trust, an unincorporated                organization, the government of a country or any political subdivision thereof, or                any agency or department of any such government, and the executors,                administrators or other legal representatives of an individual in such capacity;          (q)    a person is deemed to be an “affiliate” of another person if one is a subsidiary of                the other, or if both are subsidiaries of the same person, or if each of them is                controlled by the same person;          (r)    a person is deemed to be a “subsidiary” of another person if it is controlled                directly or indirectly by that person, and includes a subsidiary of that subsidiary;                and          (s)    “control” means control in any manner that results in control in fact, whether                directly through the ownership of securities or indirectly through a trust, an                agreement or arrangement or otherwise.   23.    Further Assurances.          Each of the parties upon the request of the other, whether before or after Closing, shall  do, execute, acknowledge and deliver or cause to be done, executed, acknowledged and  delivered all such further acts, deeds, documents, assignments, transfers, conveyances, powers  of attorney and assurances as may reasonably be necessary or desirable to complete the  transactions contemplated herein.   24.    Time of Essence.          The Purchasers and BlackBerry agree that time is of the essence in this Agreement.    25.    Counterparts.          The Purchasers and BlackBerry agree that this Agreement may be executed in any  number of counterparts, each of which shall be deemed to be an original and all of which taken  together shall be deemed to constitute one and the same instrument. Counterparts may be  executed either in original or electronic form and the parties may rely on delivery by electronic  delivery of an executed copy of this Agreement.   26.    Acceptance.          If the foregoing accurately reflects your understanding of our agreement, please sign in  the space provided below and return it to us by no later than 3:00 p.m. on August 31, 2020, failing  which it shall immediately become null and void.                                   [Signature pages follow]      36990-2073 30148883.13   

 

                                                                                   HAMBLIN WATSA INVESTMENT                      COUNSEL LTD.                                                                              by:   /s/ Peter Clarke                            Name: Peter Clarke                            Title:    Chief Risk Officer                    [Signature page to Subscription Agreement] 

 

                                                                                   [REDACTED                                                                              by:   /s/ [redacted]                            Name: [redacted]                            Title: Authorized Signatory                                     [Signature page to Subscription Agreement] 

 

                                                Agreed as of this 31st day of August, 2020   BLACKBERRY LIMITED                          by:    /s/ Steve Rai        Name: Steve Rai         Title:  Chief Financial Officer                                                                                               [Signature page to Subscription Agreement] 

 

                                        SCHEDULE A                                      PURCHASERS                                                 Name of Purchaser           Address for notice purposes                Principal amount                                                                          of Debentures to                                                                          be purchased at                                                                          Closing    Hamblin Watsa               Suite 802                                  U.S.$330,000,000   Investment Counsel Ltd.,    95 Wellington Street West   in its capacity as          Toronto Ontario M5J 2N7   investment manager of   Fairfax Financial Holdings  Attention: General Counsel   Limited and certain         Email: generalcounsel@fairfax.ca   controlled affiliates   thereof    [redacted]                  [redacted]                                 U.S.$35,000,000                                       36990-2073 30148883.13   

 

                                        SCHEDULE B                                  FORM OF INDENTURE      36990-2073 30148883.13   

 

                                         - 31 -                                   SUBSCRIPTION AGREEMENT                                                                           August 31, 2020                                                 BlackBerry Limited  2200 University Avenue East  Waterloo, Ontario  Canada  N2K 0A7    Dear Sirs/Mesdames:          This agreement (the “Agreement”) is further to recent discussions regarding a transaction  pursuant to which (a) the undersigned, Hamblin Watsa Investment Counsel Ltd. (“HWIC”), in its  capacity as investment manager of Fairfax Financial Holdings Limited and various controlled  affiliates thereof and [redacted] in its capacity as investment manager of [redacted], as set out in  Schedule A  to this Agreement (collectively the “Purchasers” and each a “Purchaser”), will  subscribe for, and BlackBerry Limited (“BlackBerry”) will issue to each Purchaser, the principal  amount set out beside its name on Schedule A of 1.75% unsecured subordinated convertible  debentures of BlackBerry (the “Debentures”) on a private placement basis, for an aggregate  subscription price of U.S.$365,000,000 (the “Purchase Price”), and (b) the outstanding 3.75%  convertible unsecured debentures of BlackBerry issued on September 7, 2016 on a private  placement basis for an aggregate subscription price of U.S.$605,000,000  (the “Existing  Debentures”) will be redeemed (collectively, the “Transaction”). Any portion of the principal  amount of the Debentures outstanding will be convertible into common shares of BlackBerry (the  “Underlying Common Shares”) in accordance with the terms of the Indenture.          This Agreement sets out the terms and conditions upon which, for good and valuable  consideration, BlackBerry and each of the Purchasers (collectively, the “parties”) agree to  complete the Transaction. All rights and obligations of the Purchasers hereunder are several, and  not joint nor joint and several. BlackBerry acknowledges that one or more of the Purchasers is a  registered portfolio manager acting on behalf of one or more fully managed accounts managed  by it and, as such, would be deemed by Section 2.3(4) of National Instrument 45-106 – Prospectus  Exemptions (“NI 45-106”) to be purchasing the Debentures as principal.   27.    Purchase of the Debentures.          Each Purchaser hereby subscribes for and agrees, severally and not jointly, to purchase  from BlackBerry, and BlackBerry hereby agrees to issue or cause to be issued to each such  Purchaser on the Closing Date, that principal amount of Debentures as is set out beside its name  on Schedule A for aggregate consideration equal to such principal amount, on the terms and  conditions set forth in this Agreement.   28.    Mutual Conditions of Closing.          Each Purchaser’s obligation to purchase the applicable principal amount of Debentures  from BlackBerry and BlackBerry’s obligation to issue and sell the applicable principal amount of  Debentures to each Purchaser are subject to the fulfilment of each of the following conditions,  which conditions are for the mutual benefit of the Purchasers and BlackBerry and may be waived  only by the mutual consent of the Purchasers and BlackBerry:      36990-2073 30148883.13   

 

                                         - 32 -             (a)    concurrent with the issuance and purchase of the Debentures, all of the Existing                Debentures will have been redeemed and the indenture dated as of September                7, 2016 between BlackBerry, the guarantors named therein  and  BNY Trust                Company of Canada (as amended and supplemented, including pursuant to a                supplemental indenture among the same parties dated  on or about the date                hereof) shall have been terminated;          (b)    the Toronto Stock Exchange (“TSX”) shall have approved the issuance of the                Debentures and the listing of the Underlying Common Shares and the New York                Stock Exchange (“NYSE”) shall have approved the listing of the Underlying                Common Shares, in each case subject only to the satisfaction of customary listing                conditions, and without the requirement to seek the approval of the shareholders                of BlackBerry;          (c)    the Indenture has been entered into by the Indenture Trustee, BlackBerry and the                Guarantors;           (d)    there shall not be in effect any applicable domestic or foreign federal, national,                state, provincial or local law (statutory, common or otherwise), constitution, treaty,                convention, ordinance, code, rule, regulation, notice, order, injunction, judgment,                decree, ruling or other similar requirement enacted, made, issued, adopted,                promulgated or applied by a Governmental Authority (collectively, “laws”) that                makes the consummation of the Transaction illegal or otherwise prohibits or                enjoins any party from consummating the Transaction, or that is made in                connection with the Transaction and imposes any material restrictions, limitations                or conditions on any of the parties; and          (e)    no Governmental Authority shall have commenced any action or proceeding to                enjoin the issuance and sale of the Debentures to the Purchasers pursuant to this                Agreement or to suspend or cease or stop trading of securities of BlackBerry, and                no Governmental Authority shall have given written notice to any party of its                intention to commence any such action or proceeding.   29.    Conditions of Closing for the Benefit of BlackBerry.          Each Purchaser acknowledges and agrees that BlackBerry’s obligation to issue and sell  the Debentures to the Purchasers is subject to the fulfilment of each of the following conditions,  which conditions are for the exclusive benefit of BlackBerry and may be waived, in whole or in  part, by BlackBerry in its sole discretion:          (a)    the representations, warranties and acknowledgements of each Purchaser set                forth in this Agreement shall be true and correct in all material respects as at the                Closing Date, with the same force and effect as if made as at the Closing Date                (except for representations, warranties and acknowledgements made as of a                specified date, the accuracy of which shall be determined as of that specified date,                and except in each case, for those representations, warranties and                acknowledgements that are subject to a materiality qualification, which must be                true and correct in all respects); and          (b)    all covenants of each Purchaser under this Agreement to be performed prior to                the Closing shall have been duly performed in all material respects.      36990-2073 30148883.13   

 

                                         - 33 -      30.   Conditions of Closing for the Benefit of the Purchasers.         BlackBerry acknowledges and agrees that each Purchaser’s obligation to purchase the  Debentures from BlackBerry is subject to the fulfilment of each of the following conditions, which  conditions are for the exclusive benefit of the Purchasers and may be waived, in whole or in part,  by the Purchasers in their sole discretion:          (a)    the representations and warranties of BlackBerry set forth in this Agreement shall                be true and correct in all material respects as at the Closing Date, with the same                force and effect as if made by BlackBerry as at the Closing Date (except for                representations and warranties made as of a specified date, the accuracy of which                shall be determined as of that specified date, and except in each case, for those                representations and warranties that are subject to a materiality or Material                Adverse Effect qualification, which must be true and correct in all respects);          (b)    all covenants of BlackBerry to be performed under this Agreement shall have                been duly performed in all material respects;          (c)    from and including the date hereof up to and including the Closing Date, there                shall not have occurred a Material Adverse Effect;          (d)    each Purchaser shall have received a legal opinion addressed to the Purchasers                in form and substance satisfactory to the Purchasers and their counsel, acting                reasonably, dated the Closing Date, from counsel to BlackBerry (who may rely,                as to matters of fact, on certificates of public officials and officers of BlackBerry)                with respect to the following matters:                (i)    that BlackBerry is a corporation existing under the laws of Ontario and has                      the corporate power to enter into and perform its obligations under this                      Agreement, and has the corporate power and capacity to own or hold its                      properties and to conduct the businesses carried on by it;                (ii)   as to the authorized share capital of BlackBerry;                (iii)  that the execution and delivery of and performance by BlackBerry of this                      Agreement has been authorized by all necessary corporate action on the                      part of BlackBerry;                (iv)   that this Agreement has been duly executed and delivered by BlackBerry,                      and constitutes a legal, valid and binding agreement of BlackBerry                      enforceable against it in accordance with its terms, subject to customary                      qualifications;                (v)    that neither the execution and delivery of this Agreement, the Indenture or                      the Debentures, nor the performance by BlackBerry of its obligations                      hereunder or thereunder, will conflict with or result in any breach of the                      constating documents or by-laws of BlackBerry;                (vi)   that the issuance of the Debentures has been authorized by all necessary                      corporate action on the part of BlackBerry, that the Debentures have been                      duly executed and delivered by BlackBerry and that subject to receipt of      36990-2073 30148883.13   

 

                                         - 34 -                          payment in full for them, the Debentures will be legal, valid and binding                      agreements of BlackBerry enforceable against it in accordance with their                      terms, subject to customary qualifications;                  (vii)  that the execution and delivery of and performance by BlackBerry of the                      Indenture has been authorized by all necessary corporate action on the                      part of BlackBerry;                (viii) that the Indenture has been duly executed and delivered by BlackBerry,                      and constitutes a legal, valid and binding agreement of BlackBerry                      enforceable against it in accordance with its terms, subject to customary                      qualifications;                (ix)   that the Underlying Common Shares have been validly authorized for                      issuance by BlackBerry and, upon the conversion of the Debentures in                      accordance with the terms and conditions of the Debentures, and when                      issued, will be validly issued and outstanding as fully paid Common Shares;                (x)    that the issuance and sale by BlackBerry of the Debentures to the                      Purchaser in accordance with this Agreement is exempt from the                      prospectus and registration requirements of applicable securities laws in                      Ontario and no documents are required to be filed by BlackBerry (other                      than customary private placement reports accompanied by requisite filing                      fees), proceedings taken or approvals, permits, consents or authorizations                      obtained under the applicable securities laws in Ontario to permit such                      issuance and sale;                (xi)   no filing, proceeding, approval, consent or authorization is required to be                      made, taken or obtained under the laws of Ontario to permit the issuance                      by BlackBerry of the Underlying Common Shares upon the conversion of                      the Debentures in accordance with the terms and conditions of the                      Debentures to the holders of the Debentures;                (xii)  the first trade of the Debentures in Ontario will not be a distribution or                      otherwise subject to the prospectus and registration requirements of                      applicable securities laws in Ontario if:                        (A)    BlackBerry is and has been a reporting issuer in a jurisdiction of                             Canada for the four months immediately preceding such first trade;                       (B)    at the time of the first trade, at least four months have elapsed from                             the date of distribution of the Debentures;                         (C)    the certificates representing the Debentures carry a legend, or an                             ownership statement issued under a direct registration system or                             other electronic book-entry system acceptable to the regulators                             bears a legend restriction notation, as required by Section 2.5(2)3(i)                             of National Instrument 45-102 - Resale of Securities (“NI 45-102”);                       (D)    the trade is not a “control distribution” as defined in NI 45-102;      36990-2073 30148883.13   

 

                                         - 35 -                          (E)   no unusual effort is made to prepare the market or to create a                            demand for the Debentures subject to such trade and no                            extraordinary commission or consideration is paid to a person or                            company in respect of the trade; and                       (F)   if the seller of the Debentures is an “insider” or “officer” of                            BlackBerry (as those terms are defined in applicable securities                            laws), the seller has no reasonable grounds to believe that                            BlackBerry is in default of any requirement of securities legislation;                            and                 (xiii) the first trade by a holder of Underlying Common Shares upon the                      conversion of the Debentures in accordance with the terms and conditions                      of the Debentures will not be a distribution or otherwise subject to the                      prospectus and registration requirements of applicable securities laws in                      Ontario, and no filing, proceeding, approval, consent or authorization will                      be required to be made, taken or obtained under the laws of Ontario to                      permit such trade or distribution, through investment dealers or brokers, if                      required, registered under the applicable legislation of Ontario who have                      complied with the relevant provisions of such legislation.   31.    Delivery and Payment.          The closing of the issuance of the Debentures (the “Closing”) will, subject to the  satisfaction or waiver of each of the conditions set forth in Sections 2, 3 and 4 of this Agreement,  to be completed remotely on September 1, 2020, or as soon thereafter as the other conditions of  Closing can be satisfied or have been waived (such date, the “Closing Date”), at 10:00 a.m.  (Toronto time) via electronic transmission of documents (such as by use of PDF) at the offices of  Torys LLP, 79 Wellington Street West, Toronto, Ontario, M5K 1N2; or at such other time and date  as may be agreed upon orally or in writing by the parties.   32.   Covenants   (4)   The Purchasers shall deliver or cause to be delivered to BlackBerry at or prior to Closing        by electronic means:          (a)    all documentation as may be required from the Purchasers by applicable                securities laws (including the rules and requirements of the TSX and NYSE, as                applicable) in connection with the purchase by the Purchasers of the Debentures;          (b)    wire transfers by or on behalf of the respective Purchasers in immediately                available United States funds to an account designated by BlackBerry in writing                at least one Business Day prior to Closing, in the aggregate amount of the                subscription price for the Debentures being purchased by such Purchasers, such                wire transfers to be made by the Purchasers; and          (c)    a certificate of each Purchaser, signed on behalf of such Purchaser, without                personal liability, by a senior officer of such Purchaser, addressed to BlackBerry                and dated the Closing Date certifying that (i) the representations, warranties and                acknowledgements of such Purchaser set forth in this Agreement which are                qualified by materiality are true and correct in all respects as at the Closing Date,      36990-2073 30148883.13   

 

                                         - 36 -                    with the same force and effect as if made by the Purchaser as at the Closing Date                (except to the extent that such representations, warranties and                acknowledgements expressly speak of an earlier date, in which event, such                representations, warranties and acknowledgements shall be true and correct as                of such earlier date), (ii) all other representations, warranties and                acknowledgements of such Purchaser set forth in this Agreement are true and                correct in all material respects as at the Closing Date, with the same force and                effect as if made by such Purchaser as at the Closing Date (except to the extent                that such representations, warranties and acknowledgements expressly speak of                an earlier date, in which event, such representations, warranties and                acknowledgements shall be true and correct in all material respects as of such                earlier date), and (iii) such Purchaser has performed in all material respects its                obligations under this Agreement required to be performed on or prior to the                Closing Date.   (5)   At or prior to Closing, BlackBerry shall:          (d)   deliver or cause to be delivered to the Purchasers:                (i)    one or more global certificates representing the Debentures registered in                      the name of “CDS & Co.” or “Cede & Co.”,  against satisfaction of the                      subscription price for the Debentures being purchased as contemplated in                      Section 6(1)(b) of this Agreement, with such Debentures to be issued in                      “book-entry only” form in accordance with instructions as to the respective                      Purchasers’ jurisdiction of residence as provided by the Purchasers;                 (ii)   a certificate of BlackBerry, signed on behalf of BlackBerry, without personal                      liability, by a senior officer of BlackBerry, addressed to each Purchaser and                      dated the Closing Date certifying that (i) the representations and warranties                      of BlackBerry set forth in this Agreement which are qualified by materiality                      or Material Adverse Effect are true and correct in all respects as at the                      Closing Date, with the same force and effect as if made by BlackBerry as                      at the Closing Date (except to the extent that such representations and                      warranties expressly speak of an earlier date, in which event, such                      representations and warranties shall be true and correct as of such earlier                      date), (ii) all other representations and warranties of BlackBerry set forth in                      this Agreement are true and correct in all material respects as at the                      Closing Date, with the same force and effect as if made by BlackBerry as                      at the Closing Date (except to the extent that such representations and                      warranties expressly speak of an earlier date, in which event, such                      representations and warranties shall be true and correct in all material                      respects as of such earlier date), (iii) BlackBerry has performed in all                      material respects its obligations under this Agreement required to be                      performed on or prior to the Closing Date, and (iv) since the date hereof,                      there has not occurred a Material Adverse Effect;                (iii)  certified copies of (i) the articles and by-laws of BlackBerry and each                      Guarantor, and (ii) all resolutions of the board of directors of BlackBerry      36990-2073 30148883.13   

 

                                         - 37 -                          approving the entering   into and completion of the transactions                      contemplated by this Agreement;                 (iv)   a certificate of Computershare Investor Services Inc. confirming the issued                      and outstanding Common Shares;                (v)    evidence satisfactory to the Purchasers of the approval of the listing and                      posting for trading on the TSX and NYSE  of the Underlying Common                      Shares subject only to the satisfaction by BlackBerry of customary listing                      conditions, which conditions shall not include a requirement of shareholder                      approval prior to the issuance of the Debentures;                (vi)   the Guarantees executed by the Guarantors;                (vii)  the opinion contemplated in Section 4(d) of this Agreement; and         (e)    execute and deliver the Indenture; and         (f)    pay, or cause to be paid, to HWIC an amount equal to all the reasonable and               documented legal fees and expenses incurred by HWIC  in connection with this               Agreement and the Transaction, including all reasonable fees, disbursements and               taxes of McCarthy Tétrault LLP and Shearman & Sterling LLP.   (6)    BlackBerry shall use commercially reasonable efforts to obtain TSX approval of the listing         of the Debentures by February 15, 2021.    33.    Outside Date.          Each Purchaser and BlackBerry agree that if Closing has not occurred on or prior to   September 9, 2020 (the  “Outside Date”), then any of the Purchasers or BlackBerry may   terminate this Agreement, except that the right to terminate this Agreement will not be available   to a party whose breach of this Agreement has been the cause of, or resulted in, the failure of   Closing to occur by such date. If this Agreement is properly terminated pursuant to the foregoing,   then there shall be no further liability of the parties hereunder. Nothing in this Section 7 will relieve   any party from liability for any breach of this Agreement.   34.    Mutual Covenant regarding Closing.          Subject to the terms and conditions of this Agreement, the Purchasers and BlackBerry  shall use their reasonable commercial efforts, on a cooperative basis, to take, or cause to be  taken, all actions and to do, or cause to be done, all things necessary, proper or advisable under  applicable laws to consummate the Transaction as soon as practicable, including:          (a)    BlackBerry using its reasonable commercial efforts to obtain and maintain all                approvals, clearances, consents, registrations, permits, authorizations, notices                and other confirmations required to be obtained from any domestic or foreign                federal, provincial, state, municipal or other governmental department, court,                tribunal, commission or commissioner, bureau, minister or ministry, board or                agency, or other regulatory authority, including any securities regulatory authority,                the NYSE and the TSX (each, a “Governmental Authority”) or other third party                including any person or entity exercising governmental powers that are      36990-2073 30148883.13   

 

                                         - 38 -                    necessary, proper or advisable to consummate the transactions contemplated by                this Agreement (the “Approvals”);          (b)    BlackBerry preparing and filing as promptly as practicable all necessary                documents, registrations, statements, petitions, filings and applications for the                Approvals; and          (c)    BlackBerry or the Purchasers, as the case may be, using reasonable commercial                efforts to oppose, lift or rescind any injunction or restraining or other order or                notice seeking to stop, or otherwise adversely affecting its ability to consummate,                the Transaction or imposing any material restrictions, limitations or conditions on                the parties or the Transaction.         The parties shall co-operate in the preparation of any application for the Approvals and  any other orders, clearances, consents, notices, rulings, exemptions, certificates, no-action letters  and approvals reasonably deemed by either the Purchasers or BlackBerry to be necessary to  discharge their respective obligations under this Agreement or otherwise advisable under  applicable laws in connection with the Transaction.         Subject to applicable laws, the parties shall cooperate with and keep each other fully  informed as to the status of and the processes and proceedings relating to obtaining the Approvals  and any other actions or activities pursuant to this Section 8, and shall promptly notify each other  of any material communication from any Governmental Authority in respect of the Transaction or  this Agreement, and shall not make any submissions, correspondence or filings, or participate in  any communications or meetings with any Governmental Authority in respect of any filings,  investigations or other inquiries or proceedings related to the Transaction or this Agreement  unless it consults with the other parties in advance and, to the extent not precluded by such  Governmental Authority, gives the other parties the opportunity to review drafts of, and provides  final copies of, any submissions, correspondence or filings, and to attend and participate in any  communications or meetings.    35.   Purchasers’ Acknowledgements.          Each Purchaser covenants to execute and deliver all documentation as may be required  to be executed and delivered by it pursuant to applicable securities laws in connection with the  Transaction. Each Purchaser acknowledges that:          (a)    BlackBerry is required to file a report of trade with all applicable securities                regulators containing personal information about each Purchaser. This report of                trade will include the full name, residential address and telephone number of each                Purchaser, the number and type of purchased securities, the Purchase Price, the                date of the Closing and the prospectus and registration exemption relied upon                under applicable securities laws to complete such purchase. In Ontario, this                information is collected indirectly by the Ontario Securities Commission under the                authority granted to it under, and for the purposes of the administration and                enforcement of, the securities legislation in Ontario. The Purchaser may contact                the Inquiries Officer at 20 Queen Street West, 22nd Floor, Toronto, Ontario, M5H                3S8 or by telephone at (416) 593-8314 for more information regarding the indirect                collection of such information by the Ontario Securities Commission. BlackBerry                may also be required pursuant to applicable securities laws to file this Agreement                on the System for Electronic Document Analysis and Retrieval (“SEDAR”). By     36990-2073 30148883.13   

 

                                         - 39 -                    completing this Agreement, the Purchaser authorizes the indirect collection of the                information described in this Section 9(a) by all applicable securities regulators                and consents to the disclosure of such information to the public through (i) the                filing of a report of trade with all applicable securities regulators and (ii) the filing                of this Agreement on SEDAR;          (b)    the Debentures and the Underlying Common Shares are subject to resale                restrictions under applicable Canadian and U.S. securities laws;          (c)    the certificates representing the Debentures and the Underlying Common Shares                (or alternatively the ownership statement or written notice provided to the                Purchaser if the Debentures and the Underlying Common Shares are issued                under a direct registration system or other electronic book-entry system) will bear                the restrictive legends as set forth in the Indenture;          (d)    the Debentures and the Underlying Common Shares have not been and will not                be registered under U.S. Securities Act, and may not be offered or sold in the                United States or to U.S. persons unless registered under the U.S. Securities Act                or an exemption from the registration requirements of the U.S. Securities Act is                available;           (e)    the Debentures are being offered and sold to the Purchaser on a “private                placement” basis;          (f)    it is not purchasing the Debentures as a result of any general solicitation or                general advertising, including advertisements, articles, notices or other                communications published in any newspaper, magazine or similar media or                broadcast over radio or television, or any seminar or meeting whose attendees                have been invited by general solicitation or general advertising;          (g)    no securities commission or similar regulatory authority has reviewed or passed                on the merits of the Debentures;          (h)    there is no government or other insurance covering the Debentures;          (i)    it has had access to such additional information, if any, concerning BlackBerry as                it has considered necessary in connection with its investment decision to acquire                the Debentures;          (j)    it has such knowledge and experience in financial and business matters as to be                capable of evaluating the merits and risks of its investment in the Debentures and                the Underlying Common Shares and is able to bear the economic risks of such                investment;          (k)    there are risks associated with the purchase of the Debentures; and          (l)    there are restrictions on a Purchaser’s ability to resell the Debentures and the                Underlying Common Shares, and it is the responsibility of the Purchaser to find                out what those restrictions are and to comply with them before selling the                Debentures or the Underlying Common Shares.      36990-2073 30148883.13   

 

                                         - 40 -      36.   Purchasers’ Representations and Warranties.          Each Purchaser hereby severally and not jointly makes the following representations and  warranties with respect to itself to BlackBerry, and acknowledges that BlackBerry is relying upon  such representations and warranties in connection with the issue and sale of the Debentures,  that:          (a)    Organization and Good Standing. As of the date hereof and as of the Closing                Date, it is a corporation, limited liability company or other entity duly incorporated,                established or organized and validly existing under the jurisdiction of its                organization.          (b)    Due Authorization. As of the date hereof and as of the Closing Date, (i) the                execution, delivery and performance by the Purchaser of this Agreement and the                consummation by the Purchaser of the transactions contemplated hereby are                within their respective corporate, trust or other governing powers and have been                duly authorized, and no other corporate, trust or other proceedings required by                the constating documents of the Purchaser are necessary to authorize the                execution, delivery and performance of this Agreement or the transactions                contemplated hereby; and (ii) this Agreement has been duly executed and                delivered by the Purchaser and when duly executed and delivered by each of the                other parties hereto, this Agreement will constitute a legal, valid and binding                agreement of the Purchaser enforceable against it in accordance with its terms,                except in each case as enforceability may be limited by applicable bankruptcy,                insolvency, reorganization, moratorium or similar laws affecting the enforcement                of creditors’ rights generally or by equitable principles relating to enforceability,                regardless of whether considered in a proceeding in equity or at law.          (c)    Governmental Authorization. As of the date hereof and as of the Closing Date,                the execution, delivery and performance by the Purchaser of this Agreement and                the consummation by the Purchaser of the transactions contemplated hereby,                require no action by or in respect of, or filing with or approval from, or consent or                authorization from, any Governmental Authority, other than (i) filings under                applicable securities laws; and (ii) any actions, filings or approvals the absence of                which would not reasonably be expected to materially impair the ability of it to                complete the Transaction on or prior to the Outside Date.          (d)    Non-Contravention. As of the date hereof and as of the Closing Date, the                execution, delivery and performance by the Purchaser of this Agreement and the                consummation by the Purchaser of the transactions contemplated hereby do not                and will not (i) contravene, conflict with, or result in any violation or breach of any                provision of (A) the articles of incorporation, by-laws or resolutions of the                shareholders or directors (or any committee thereof) of the Purchaser, or (B) in                the case where the Purchaser is not a corporation, its declaration of trust or other                constating document under which the Purchaser has been established or                organized, or any resolutions of the board, trustees or other body named in such                constating document as performing a similar function as a board of a corporation                or as trustees of a trust, or of a committee thereof, (ii) assuming compliance with                the matters referred to in paragraph (c) above, contravene, conflict with or result                in a violation or breach of any provision of any applicable law, or (iii) require any                consent or other action by any person under, or constitute, with or without notice     36990-2073 30148883.13   

 

                                         - 41 -                    or lapse of time or both, a breach of any material contract to which it is a party or                by which it or any of its properties or assets may be bound, with such exceptions,                in the case of each of clauses (ii) and (iii) above, as would not be reasonably                expected to adversely affect the ability of the Purchaser to consummate the                transactions contemplated hereby on or prior to the Outside Date.          (e)    Principal. The Purchaser is purchasing, or is deemed by Section 2.3(4) of NI 45-               106 to be purchasing, the Debentures as principal.          (f)    Offering Memorandum. It has not been provided with an offering memorandum                (as defined in any applicable Canadian securities laws) or any similar document                in connection with its subscription for the Debentures, and the decision to execute                this Agreement and to purchase the Debentures has not been based upon any                verbal or written representations as to fact or otherwise made by or on behalf of                BlackBerry, other than such written representations as are expressly contained in                this Agreement.          (g)    Investment Purposes. The Purchaser is purchasing the Debentures for                investment purposes only and not with a view to any resale, distribution or other                disposition of the Debentures or the Underlying Common Shares in violation of                applicable securities laws, and not in a transaction or series of transactions                involving a purchase and sale or a repurchase and resale in the course of or                incidental to a distribution.          (h)    Purchaser Status. Either (1) the Purchaser is not a person within the United                States or a “U.S. Person” (as such term is defined in Rule 902(k) of Regulation S                under the U.S. Securities Act), the Debentures were not offered to the Purchaser                in the United States and this Agreement has not been signed by the Purchaser in                the United States or (2) the Purchaser is a “qualified institutional buyer” within the                meaning of Rule 144A under the U.S. Securities Act.          (i)    No Joint Action. The Purchaser is acquiring the Debentures for its own account                and is not (a) acting together, within the meaning of the TSX Company Manual,                or (b) acting jointly or in concert, within the meaning of Canadian securities laws,                in each case, with any other person or entity in respect of its investment in                BlackBerry.   37.   Representations and Warranties of BlackBerry.         BlackBerry represents and warrants to each Purchaser, and acknowledges that each  Purchaser is relying upon such representations and warranties in purchasing the Debentures,  that:          (a)    Organization and Good Standing. As of the date hereof and as of the Closing                Date, each of BlackBerry and its subsidiaries has been duly created, incorporated,                amalgamated or organized and is validly existing and in good standing and up to                date in all corporate filings under the laws of its respective jurisdictions of                organization, is duly qualified to do business in each jurisdiction in which its                respective ownership or lease of property or the conduct of its respective                businesses requires such qualification, and has all power and authority necessary                to own or hold its respective properties and to conduct the businesses currently      36990-2073 30148883.13   

 

                                         - 42 -                    and customarily carried on by it, except where the failure to be so qualified or                have such power or authority would not, individually or in the aggregate, have or                reasonably be expected to have a Material Adverse Effect. As of the date hereof,                the subsidiaries listed on page 4 of BlackBerry’s Annual Report on Form 10-K                dated April 7, 2020 are the only subsidiaries of BlackBerry material to the                business, earnings, assets, condition (financial or otherwise), liabilities, results of                operations or business prospects of BlackBerry and its subsidiaries, taken as a                whole.          (b)    Capitalization. As of June 30, 2020, there were 555,573,072 Common Shares,                no Class A common shares and no preference shares issued and outstanding                and since June 30, 2020 to the date hereof, no Common Shares have been                issued or become issuable other than pursuant to BlackBerry’s equity incentive                plans or executive inducement equity awards. As of the date hereof and as of the                Closing Date, (i) BlackBerry’s authorized share capital consists of an unlimited                number of Common Shares, an unlimited number of Class A common shares and                an unlimited number of preference shares, issuable in series; (ii) all the                outstanding shares of capital stock or other equity interests of BlackBerry and of                each subsidiary of BlackBerry have been duly and validly authorized and issued                and are fully paid and non-assessable; (iii) all the outstanding shares of capital                stock or other equity interests of each subsidiary of BlackBerry (including each of                the subsidiaries of BlackBerry reflected in the BlackBerry Public Documents) are                owned directly or indirectly by BlackBerry, in each case, free and clear of any lien,                charge, encumbrance, security interest, restriction on voting or transfer (except                as may be set out in the constating documents of each subsidiary of BlackBerry                or liens, charges, or encumbrances, that have been publicly disclosed) or any                other claim of any third party, in each case, except (A) as publicly disclosed by                BlackBerry or (B) as would not result in a Material Adverse Effect; (iv) other than                the Existing Debentures, and other than the Debentures or in connection with the                Debentures there are no securities convertible into, or exchangeable or                exercisable for, or other rights to acquire from BlackBerry, Common Shares of                BlackBerry or other equity interests in BlackBerry, other than (A) as disclosed or                referred to the audited consolidated financial statements and the related notes                thereto of BlackBerry and its consolidated subsidiaries for the year ended                February 29, 2020 or the interim consolidated financial statements and the related                notes thereto of BlackBerry and its consolidated subsidiaries for the three months                ended May 31, 2020, (B) securities issued in the normal course after May 31,                2020 in connection with the issuance of securities by BlackBerry pursuant to its                equity incentive plans or executive inducement equity awards, and (C) as                contemplated by this Agreement; and (v) there are no contractual obligations of                BlackBerry or any subsidiary to repurchase, redeem or otherwise acquire any                outstanding securities or indebtedness of BlackBerry or any subsidiary, except in                the case of subsidiaries of BlackBerry, any such obligations entered into in the                ordinary course of business that would not individually or collectively result in a                Material Adverse Effect. For the purposes of this Agreement, a matter shall be                considered to be “publicly disclosed” only to the extent it is disclosed in one of the                BlackBerry Public Documents filed on SEDAR prior to the date hereof.          (c)    Guarantors. Each of the Guarantors are wholly-owned       subsidiaries of                BlackBerry.      36990-2073 30148883.13   

 

                                         - 43 -             (d)    Due Authorization. As of the date hereof and as of the Closing Date, the                execution, delivery and performance by BlackBerry of this Agreement and the                consummation by BlackBerry of the transactions contemplated hereby are within                the corporate powers of BlackBerry and have been duly authorized, and no other                corporate proceedings on the part of BlackBerry are necessary to authorize the                execution, delivery and performance of this Agreement, or the transactions                contemplated hereby. This Agreement has been duly executed and delivered by                BlackBerry and when duly executed and delivered in accordance with its terms                by each of the parties thereto, this Agreement will constitute a legal, valid and                binding agreement of BlackBerry enforceable against BlackBerry in accordance                with its terms, except as enforceability may be limited by applicable bankruptcy,                insolvency, fraudulent transfer, reorganization, moratorium or similar laws                affecting the enforcement of creditors’ rights generally or by equitable principles                relating to enforceability, regardless of whether considered in a proceeding in                equity or at law.          (e)    Power and Authority. BlackBerry has all requisite power and authority: (i) to                enter into the Indenture; (ii) to carry out all the terms and provisions of the                Indenture; and (iii) to issue and deliver the Debentures in accordance with the                provisions of this Agreement and the Underlying Common Shares in accordance                with the provisions of the Indenture. The Guarantors each have all requisite power                and authority: (i) to enter into the Guarantees and (ii) to carry out all the terms and                provisions of the Guarantees.          (f)    Authorization. When executed and delivered, the Indenture and the Guarantees                will constitute legal, valid and binding obligations of BlackBerry and the                Guarantors, respectively, enforceable in accordance with its terms, except as                enforceability may be limited by applicable bankruptcy, insolvency,                reorganization, moratorium or similar laws affecting the enforcement of creditors’                rights generally or by equitable principles relating to enforceability, regardless of                whether considered in a proceeding in equity or at law.          (g)    Authorization of Debentures. The issuance of the Debentures by BlackBerry to                the Purchasers in accordance with the terms of this Agreement has been                authorized by all necessary action of BlackBerry, and upon payment therefor in                accordance with this Agreement, the Debentures will be validly issued and                outstanding.          (h)    Authorization of Underlying Common Shares. The issuance of the Underlying                Common Shares in accordance with the terms of the Indenture has been                authorized by all necessary action of BlackBerry, and upon the conversion, and                when issued will be validly issued and outstanding as fully paid and non-               assessable Common Shares.          (i)    BlackBerry Securities. As of the date hereof and as of the Closing Date: (i) no                order, ruling or decision granted by a securities commission, court of competent                jurisdiction or regulatory or administrative body or other Governmental Authority                having jurisdiction is in effect, pending or (to the best of BlackBerry’s knowledge)                threatened that restricts any trades in any securities of BlackBerry including any                cease trade orders; (ii) the currently issued and outstanding Common Shares are                listed and posted for trading on the TSX and the NYSE, the currently issued and     36990-2073 30148883.13   

 

                                         - 44 -                    outstanding Existing Debentures are listed and posted for trading on the TSX, and                BlackBerry is in compliance in all material respects with all of the listing conditions                on such exchanges; and (iii) the Debentures to be sold pursuant to this Agreement                have been duly authorized for issuance and sale by all necessary action on the                part of BlackBerry and, when issued and delivered by BlackBerry against payment                of the consideration therefor pursuant to this Agreement will have been validly                issued and outstanding and will not have been issued in violation of or subject to                any pre-emptive rights or other contractual rights to purchase securities issued by                BlackBerry.          (j)    Governmental Authorization. As of the date hereof and as of the Closing Date,                the execution, delivery and performance by BlackBerry of this Agreement, the                Indenture and the Debentures or by the Guarantors of the Guarantees, and the                consummation by BlackBerry and the Guarantors of the transactions                contemplated hereby and thereby require no action by or in respect of, or filing                with or approval from, or consent or authorization from any Governmental                Authority, other than (i) filings under applicable securities laws (including filings                with the TSX and the NYSE); and (ii) any actions or filings the absence of which                would not reasonably be expected to materially impair the ability of BlackBerry to                complete the Transaction on or prior to the Outside Date.          (k)    Non-Contravention. As of the date hereof and as of the Closing Date, the                execution, delivery and performance by BlackBerry of this Agreement, the                Indenture and the Debentures and by the Guarantors of the Guarantees and the                consummation by BlackBerry and the Guarantors of the transactions                contemplated hereby and thereby do not and will not (i) contravene, conflict with,                or result in any violation or breach of any provision of the articles of amalgamation,                by-laws or resolutions of the shareholders or directors (or any committee thereof)                of BlackBerry or any of its subsidiaries; (ii) assuming compliance with the matters                referred to in paragraph (j) above, contravene, conflict with or result in a violation                or breach of any provision of any applicable law; or (iii) require any consent or                other action by any person under, constitute a default, or an event that, with or                without notice or lapse of time or both, would constitute a default, under, or cause                or permit the termination, cancellation, acceleration or other change of any right                or obligation or the loss of any benefit to which BlackBerry or any of its                subsidiaries is entitled under any provision of any material contract to which                BlackBerry or any of its subsidiaries is a party or by which it or any of its properties                or assets may be bound, with such exceptions, in the case of each of clauses (ii)                and (iii) above, as would not individually or in the aggregate, reasonably be                expected to have a Material Adverse Effect or adversely affect the ability of                BlackBerry to consummate the transactions contemplated hereby on or prior to                the Outside Date.          (l)    Compliance with Laws. BlackBerry and its subsidiaries are and have been in                compliance with, and conduct their businesses in conformity with, all applicable                laws, except where the failure to be in compliance or conformity would not result                in a Material Adverse Effect. BlackBerry is a reporting issuer under the securities                laws of each of the provinces of Canada (collectively the “Canadian                Jurisdictions”) that recognizes the concept of reporting issuer, is in compliance                in all material respects with the applicable securities legislation of the Canadian                Jurisdictions, and the respective rules, regulations and written and published     36990-2073 30148883.13   

 

                                         - 45 -                    policies thereunder, and is not on the list of defaulting reporting issuers                maintained by the  applicable securities regulatory authority in each such                Canadian Jurisdiction that maintains such a list. BlackBerry is subject to Section                13 or 15(d) of the United States Securities Exchange Act of 1934, as amended                (the “Exchange Act”) and has filed all reports required under the Exchange Act                in the last twelve month period.           (m)    Financial Statements. The audited consolidated financial statements and the                related notes thereto of BlackBerry and its consolidated subsidiaries for the years                ended February 29, 2020 and February 28, 2019 and  the interim consolidated                financial statements and the related notes thereto of BlackBerry and its                consolidated subsidiaries for the three months ended May 31, 2020    (the                “Financial Statements”) comply in all material respects with the applicable                requirements of the Canadian securities laws and present fairly the financial                position of BlackBerry and its subsidiaries as of the dates indicated and the results                of their operations and the changes in their cash flows for the periods specified,                and have been prepared in conformity with United States generally accepted                accounting principles, in each case applied on a consistent basis throughout the                periods covered thereby (except (i) as otherwise indicated in such financial                statements and notes thereto, or, in the case of audited statements, in the related                report of BlackBerry independent auditors, as the case may be, or (ii) in the case                of unaudited interim statements, are subject to nominal period-end adjustments                and may omit notes which are not required by applicable laws in the unaudited                statements). None of BlackBerry or its subsidiaries has any liabilities, obligations,                indebtedness or commitments, whether accrued, absolute, contingent or                otherwise, which are not disclosed or referred to in the Financial Statements,                other than liabilities, obligations, or indebtedness or commitments (i) incurred in                the normal course of business, (ii) which have been publicly disclosed by                BlackBerry, or (iii) which would not or would not reasonably be expected to have                a Material Adverse Effect.          (n)    No Material Adverse Change. Between February 29, 2020 and the date hereof,                (i) there has not been any material change in the share capital or long-term debt                of BlackBerry, or any dividend or distribution of any kind declared, set aside for                payment, paid or made by BlackBerry on any class of shares, or, individually or                in the aggregate, a Material Adverse Effect; (ii) neither BlackBerry nor any of its                subsidiaries has entered into any transaction or agreement that is material to                BlackBerry and its subsidiaries taken as a whole or incurred any liability or                obligation, direct or contingent, that is material to BlackBerry and its subsidiaries                taken as a whole; and (iii) neither BlackBerry nor any of its subsidiaries has                sustained any material loss or interference with its business from fire, explosion,                flood or other calamity, whether or not covered by insurance, or from any labor                disturbance or dispute or any action, order or decree of any court or arbitrator or                Governmental Authority, except in each of clauses (i) through (iii) above as                otherwise publicly disclosed by BlackBerry.          (o)    No Violation or Default. Other than as publicly disclosed by BlackBerry, neither                BlackBerry nor any of its subsidiaries is (i) in violation of its charter or by-laws or                similar organizational documents; (ii) in default of, and no event has occurred that,                with notice or lapse of time or both, would constitute such a default, in the due                performance or observance of any term, covenant or condition contained in any     36990-2073 30148883.13   

 

                                         - 46 -                    indenture, mortgage, deed of trust, loan agreement or other agreement or                instrument to which BlackBerry or any of its subsidiaries is a party or by which                BlackBerry or any of its subsidiaries is bound or to which any of the property or                assets of BlackBerry or any of its subsidiaries is subject; or (iii) in violation of any                laws, except, in the case of clauses (ii) and (iii) above, for any such default or                violation that would not, individually or in the aggregate, have a Material Adverse                Effect.          (p)    Legal Proceedings. Except as publicly disclosed by BlackBerry, there are no                legal, governmental or regulatory investigations, actions, suits or proceedings                pending to which BlackBerry or any of its subsidiaries is or may be a party or to                which any property of BlackBerry or any of its subsidiaries is or may be the subject                that, individually or in the aggregate, if determined adversely to BlackBerry or any                of its subsidiaries, would or would reasonably be expected to have a Material                Adverse Effect, and no such investigations, actions, suits or proceedings are                threatened or, to the knowledge of BlackBerry, contemplated by any                Governmental Authority or threatened by others.          (q)    Reports. BlackBerry has, in accordance with applicable laws, filed with securities                regulatory authorities, the TSX and the NYSE, as applicable, true and complete                copies of all forms, reports, schedules, statements, material change reports,                circulars, press releases, disclosures relating to options and other stock based                incentive plans, prospectuses, other offering documents and all other documents                required to be filed by it with securities regulatory authorities, the TSX or the                NYSE  as applicable since February 28, 2019 (such forms, reports, schedules,                statements and other documents, including any financial statements or other                documents, including any schedules included therein, are referred to herein as                the “BlackBerry Public Documents”). The BlackBerry Public Documents (i) at                the time filed did not; (ii) as of the date hereof (taken as a whole after giving effect                to all filings made prior to the date hereof), do not; and (iii) as of the Closing Date                (taken as a whole after giving effect to all filings made prior to the Closing Date)                will not, contain any untrue statement of a material fact or omit to state a material                fact required to be stated therein or necessary in order to make the statements                made therein, in light of the circumstances under which they were made, not                misleading except to the extent that such statements have been modified or                superseded by a later-filed company filing. BlackBerry has not filed any                confidential material change report with any of the securities regulatory                authorities, the TSX, the NYSE or any other self-regulatory authority that remains                confidential.          (r)    Title to Real and Personal Property. Except as publicly disclosed by BlackBerry,                BlackBerry and its subsidiaries have good and marketable, in the case of real                property, and valid, in the case of personal property, title in fee simple to, or have                valid rights to lease or otherwise use, all items of real and personal property that                are used or held by BlackBerry and its subsidiaries, in each case free and clear                of all liens, encumbrances, claims and defects and imperfections of title except                those that (i) do not materially interfere with the use made and proposed to be                made of such property by BlackBerry and its subsidiaries; (ii) would not or would                not reasonably be expected to have, individually or in the aggregate, a Material                Adverse Effect; or (iii) have been granted in connection with BlackBerry’s      36990-2073 30148883.13   

 

                                         - 47 -                    outstanding credit agreements and other applicable debt obligations, in each case                as publicly disclosed by BlackBerry.          (s)    Licenses and Permits. Except as publicly disclosed by BlackBerry, BlackBerry                and  its subsidiaries possess all licenses, certificates, permits and other                authorizations issued by, and have made all declarations and filings with, the                appropriate Governmental Authorities that are necessary for the ownership or                lease of their respective properties or the conduct of their respective businesses                except where the failure to possess or make the same would not, individually or                in the aggregate, have a Material Adverse Effect; and except as publicly disclosed                by BlackBerry or as would not have a Material Adverse Effect, neither BlackBerry                nor any of its subsidiaries has (to the best knowledge of BlackBerry) received any                written notice of any revocation or modification of any such license, certificate,                permit or authorization or has any reason to believe that any such license,                certificate, permit or authorization will not be renewed in the ordinary course.          (t)    Compliance with Environmental Laws. Except as publicly disclosed by                BlackBerry, BlackBerry and its subsidiaries (i) are in compliance with any and all                applicable laws relating to the protection of human health and safety, the                environment or hazardous or toxic substances or wastes, pollutants or                contaminants (collectively, “Environmental Laws”); (ii) have received and are in                compliance in all material respects with all permits, licenses or other approvals                required of them under applicable Environmental Laws to conduct their respective                businesses; and (iii) have not received written notice of any actual or potential                liability for the investigation or remediation of any disposal or release of hazardous                or toxic substances or wastes, pollutants or contaminants, except in any such                case for any such failure to comply with, or failure to receive required permits,                licenses or approvals, or liability as would not, individually or in the aggregate,                reasonably be expected to have a Material Adverse Effect.          (u)    Disclosure Controls. BlackBerry and its subsidiaries maintain an effective                system of “disclosure controls and procedures” (as defined in Rule 13a-15(e) of                the Exchange Act and National Instrument 52-109 - Certification of Disclosure in                Issuers’ Annual and Interim Filings (“NI 52-109”)) that are intended to provide                reasonable assurance that information required to be disclosed by BlackBerry in                its annual filings, interim filings or other reports filed or submitted under the                Exchange Act and Canadian securities laws is recorded, processed, summarized                and reported within the time periods specified in the United States Securities and                Exchange Commission’s and   Canadian securities authorities’ rules and forms,                including controls and procedures designed to ensure that such information is                accumulated and communicated to BlackBerry’s management as appropriate to                allow timely decisions regarding required disclosure. BlackBerry and its                subsidiaries have carried out evaluations of the effectiveness of their disclosure                controls and procedures as required by Rule 13a-15 of the Exchange Act and as                contemplated under NI 52-109.          (v)    Accounting Controls. BlackBerry and its subsidiaries maintain systems of                “internal control over financial reporting” (as defined in Rule 13a-15(f) of the                Exchange Act and NI 52-109) that comply with the requirements of the Exchange                Act and NI 52-109 and have been designed by, or under the supervision of, their                respective principal executive and principal financial officers, or persons     36990-2073 30148883.13   

 

                                         - 48 -                    performing similar functions, to provide reasonable assurance regarding the                reliability of financial reporting and the preparation of financial statements for                external purposes in accordance with United States generally accepted                accounting principles, including internal accounting controls sufficient to provide                reasonable assurance (i) that transactions are executed in accordance with                management’s general or specific authorizations; (ii) that transactions are                recorded as necessary to permit preparation of financial statements in conformity                with Canadian generally accepted accounting principles and to maintain asset                accountability; (iii) that access to assets is permitted only in accordance with                management’s general or specific authorization; (iv) that the recorded                accountability for assets is compared with the existing assets at reasonable                intervals and appropriate action is taken with respect to any differences; and (v)                regarding prevention or timely detection of unauthorized acquisition, use or                disposition of BlackBerry’s assets that could have a material effect on                BlackBerry’s annual financial statements or interim financial statements. Since                the date of the most recent balance sheet of BlackBerry publicly disclosed by                BlackBerry, BlackBerry’s auditors and the Audit Committee of the board of                directors of BlackBerry have not been advised of: (A) any significant deficiencies                in the design or operation of internal controls over financial reporting which are                reasonably likely to adversely affect BlackBerry’s ability to record, process,                summarize and report financial information; and (B) any fraud, whether or not                material, that involves management or other employees who have a significant                role in BlackBerry’s internal control over financial reporting. Except as publicly                disclosed by BlackBerry, there are no material weaknesses in BlackBerry’s                internal controls.          (w)    Certain Payments. Neither BlackBerry nor any of its subsidiaries nor, to the best                knowledge of BlackBerry, any director, officer, agent, employee or other person                associated with or acting on behalf of BlackBerry or any of its subsidiaries has (i)                used any corporate funds for any unlawful contribution, gift, entertainment or other                unlawful expense relating to political activity; (ii) made any direct or indirect                unlawful payment to any foreign or domestic government official or employee from                corporate funds; (iii) violated or is in violation of any provision of the Foreign                Corrupt Practices Act of 1977 or the Corruption of Foreign Public Officials Act                (Canada) or any other anti-corruption laws applicable to BlackBerry or any of its                subsidiaries; (iv) made any bribe, rebate, payoff, influence payment, kickback or                other unlawful payment, except in each case as would not be material to                BlackBerry and its subsidiaries, taken as a whole; (v) directly or indirectly,                obtained or induced or attempted to so obtain or induce the procurement of this                Agreement or any contract, consent, approval, right, interest, privilege or other                obligation or benefit related to this Agreement or the Transaction or your other                dealings with any of the Purchasers or their Connected Persons through any                violation of law or regulation; or (vi) have not given or agreed to give and shall not                give or agree to give to any person, either directly or indirectly, any placement                fee, introductory fee, arrangement fee, finder’s fee or any other fee,                compensation, monetary benefit or any other benefit, gift, commission,                gratification, bribe or kickback, whether described as a consultation fee or                otherwise, with the object of obtaining or inducing the procurement of the                Transaction or any contract, right, interest, privilege or other obligation or benefit                related to the Transaction, except for bona fide fees payable to arm’s length legal,                accounting or financial service providers. As used herein, “Connected Persons”     36990-2073 30148883.13   

 

                                         - 49 -                    means, with respect to a Purchaser: (A) its affiliates; (B) the advisers, agents,                representatives and consultants of it and its affiliates; and (C) the directors,                officers, partners and employees of it, its affiliates and of its and their advisers,                agents, representatives and consultants.          (x)    Compliance with Money Laundering Laws. The operations of BlackBerry and                its subsidiaries are and have been conducted at all times in compliance with                applicable financial recordkeeping and reporting requirements of the Currency                and Foreign Transactions Reporting Act of 1970, as amended, the Proceeds of                Crime (Money Laundering) Act (Canada), the money laundering statutes of all                applicable jurisdictions, the rules and regulations thereunder and any related or                similar rules, regulations or guidelines, issued, administered or enforced by any                governmental agency to which BlackBerry and its   subsidiaries are subject                (collectively, the “Money Laundering Laws”) and no action, suit or proceeding                by or before any Governmental Authority or body or any arbitrator involving                BlackBerry or any of its subsidiaries with respect to the Money Laundering Laws                is pending or, to the best knowledge of BlackBerry, threatened.          (y)    No Broker’s Fees. Neither BlackBerry nor any of its subsidiaries is a party to any                contract, agreement or understanding with any person that would give rise to a                valid claim against the Purchasers for a brokerage commission, finder’s fee or like                payment in connection with the issuance and sale of the Debentures.          (z)    Independent Accountants. Each of PricewaterhouseCoopers LLP, BlackBerry’s                current auditor, and Ernst & Young LLP, which has audited certain financial                statements of BlackBerry and its subsidiaries, is an independent registered public                accounting firm with respect to BlackBerry and its subsidiaries within the                applicable rules and regulations adopted by the Canadian securities regulators                and the Public Accounting Oversight Board (United States) and as required by                the Securities Act. There has not been any reportable event (within the meaning                of National Instrument 51-102 of the Canadian Securities Administrators) with                either of Ernst & Young LLP or PricewaterhouseCoopers LLP.          (aa)   Investment Company Act. BlackBerry is not and, after giving effect to the                offering and sale of the Debentures and the application of the proceeds thereof                as described herein, will not be required to be registered as an “investment                company” pursuant to the Investment Company Act of 1940, as amended, and                the rules and regulations of the United States Securities and Exchange                Commission thereunder.           (bb)   Taxes. Except as publicly disclosed by BlackBerry, BlackBerry and each                subsidiary has timely filed or caused to be filed all tax returns and reports required                to have been filed by it and has paid or caused to be paid all taxes required to                have been paid by it, except (i) taxes that are being contested in good faith by                appropriate proceedings and for which BlackBerry or such subsidiary has set                aside on the Financial Statements a reasonable reserve, or (ii) taxes that                commenced being contested in good faith by appropriate proceedings during the                period after the most recent period covered in the Financial Statements and in                which case BlackBerry or such subsidiary has set aside on its books a reasonable                reserve for such taxes. In Canada and each of its provinces and territories, there      36990-2073 30148883.13   

 

                                         - 50 -                    will be no stamp duty, stamp tax or similar indirect taxes upon issuance,                redemption or conversion of the Debentures.           (cc)   BlackBerry is not, and after giving effect to the offering and sale of the Debentures                and the application of the proceeds thereof as described herein will not be, an                “investment fund” as that term is used in paragraph (q) of the definition of                “accredited investor” in Section 1.1 of NI 45-106.          (dd)   Assuming the accuracy of the Purchasers’   representations and warranties                contained in Section 10, no registration under the U.S. Securities Act of 1933, as                amended, of the Debentures and no qualification of the Indenture under the Trust                Indenture Act of 1939, as amended, is required for the offer and sale of the                Debentures by BlackBerry to the Purchasers.   38.   Indemnification.          (a)    The representations, warranties and covenants of BlackBerry contained in this                Agreement are made by BlackBerry with the intent that they may be relied upon                by the Purchasers in entering into this Agreement, determining whether to                purchase the Debentures and consummating the transactions contemplated                hereby, and BlackBerry covenants and agrees to indemnify and save harmless                each Purchaser (and their respective affiliates and their respective shareholders,                officers, directors, employees and agents) from and against all (i) civil or                administrative penalties arising from violations or alleged violations of applicable                laws, (ii) losses, claims, damages, liabilities, costs and expenses, including all                amounts paid to settle actions (provided BlackBerry has previously consented to                such settlement) or satisfy judgements or awards, and (iii) reasonable legal fees                and expenses relating to the above, in each case caused by or arising directly or                indirectly by reason of any inaccuracy in or breach by BlackBerry of any                representation, warranty or covenant made by BlackBerry under this Agreement.          (b)    The representations, warranties and covenants of each Purchaser contained in                this Agreement are made by each Purchaser severally and not jointly with the                intent that they may be relied upon by BlackBerry in entering into this Agreement,                determining whether to issue the Debentures and consummating the transactions                contemplated hereby, and each Purchaser severally and not jointly covenants                and agrees to indemnify and save harmless BlackBerry (and its affiliates and their                respective shareholders, officers, directors, employees and agents) from and                against all (i) civil or administrative penalties arising from violations or alleged                violations of applicable laws, (ii) losses, claims, damages, liabilities, costs and                expenses, including all amounts paid to settle actions (provided the Purchaser                has previously consented to such settlement) or satisfy judgements or awards,                and (iii) reasonable legal fees and expenses relating to the above, in each case                caused by or arising directly or indirectly by reason of any inaccuracy in or breach                by such Purchaser of any representation, warranty or covenant made by the                Purchaser under this Agreement.   39.    Survival of Representations, Warranties and Covenants.          The Purchasers and BlackBerry agree that the representations and warranties made by  each of them in this Agreement, including pursuant to Sections 10 and 11 of this Agreement, and     36990-2073 30148883.13   

 

                                         - 51 -      in any certificate delivered pursuant hereto, shall survive until the end of the second anniversary  of the Closing Date; provided, however, that the representations and warranties set forth in  Sections 10(a), 10(b), 10(d), 11(a), 11(b), 11(c), 11(d) and 11(f) shall survive indefinitely.         The Purchasers and BlackBerry agree that unless required to be performed on or prior to  the Closing Date or unless otherwise expressly set forth herein, the covenants made pursuant  hereto shall survive indefinitely. For greater certainty, the Purchasers and BlackBerry each  acknowledge and agree that in the event of a breach or threatened breach of its covenants  hereunder, the harm suffered would not be compensable by monetary damages alone and,  accordingly, in addition to other available legal or equitable remedies, each non-breaching party  shall be entitled to apply for an injunction or specific performance with respect to such breach or  threatened breach, without proof of actual damages (and without the requirement of posting a  bond, undertaking or other security), and each of the Purchasers and BlackBerry agree not to  plead sufficiency of damages as a defence in such circumstances.   40.   Governing Law.         The Purchasers and BlackBerry agree that this Agreement shall be governed by and  interpreted and enforced in accordance with the laws of the Province of Ontario and the federal  laws of Canada applicable therein. Each of the Purchasers and BlackBerry irrevocably attorns  and submits to the non-exclusive jurisdiction of the Ontario courts situated in the City of Toronto,  and waives objection to the venue of any proceeding in such court or that such court provides an  inconvenient forum.   41.   Notices.         Any notice, direction or other communication given pursuant to this Agreement (each a  “Notice”) must be in writing, sent by personal delivery, courier, or email and addressed:          if to a Purchaser:   See Schedule A for notice information for each Purchaser           if to BlackBerry:    BlackBerry Limited                              2200 University Avenue East                              Waterloo, Ontario                              Canada  N2K 0A7                                                             Attention:   Randall Cook                              Email:       randall.cook@blackberry.com                                        with a copy to:      Torys LLP                              Suite 3000, 79 Wellington Street W.                              Toronto, Ontario M5K 1N2      36990-2073 30148883.13   

 

                                         - 52 -                                  Attention:   Glen Johnson                              Email:       grjohnson@torys.com                              Fax:         416.865.7380            Any Notice, if personally delivered or couriered, shall be deemed to have been validly and  effectively given and received on the date of such delivery to the recipient, if delivered before 5:00  p.m. on a Business Day in the place of delivery, or the Business Day in the place of delivery, if  not delivered on a Business Day or if sent after 5:00 p.m., and if sent by email, shall be deemed  to have been validly and effectively been given and received on the Business Day next following  the day it was transmitted. Any party may at any time change its address for service from time to  time by giving notice to the other parties in accordance with this Section 15.   42.    Assignment.          The Purchasers and BlackBerry agree that none of the Purchasers or BlackBerry may  assign or transfer this Agreement or any of the rights or obligations under it without the prior  written consent of the other parties. Notwithstanding the foregoing, any of the Purchasers shall  be entitled to assign its rights under this Agreement without the consent of BlackBerry to any  affiliates of such Purchaser that agree to be bound by all of the covenants of such Purchaser  contained herein and comply with the provisions of this Agreement and deliver to BlackBerry a  duly executed undertaking to such effect in form and substance satisfactory to BlackBerry, acting  reasonably, and provided that any such assignment shall not relieve such Purchaser of any of its  obligations hereunder and shall not provide subscription rights to such affiliates that are greater  in aggregate than those held by such Purchaser.   43.    Announcements.          Other than the press releases with respect to the Transaction issued by BlackBerry in  connection with the execution of the Consent Agreements and to be issued by BlackBerry  concurrent with the notice of redemption of the Existing Debentures, the Purchasers and  BlackBerry agree that during the period up to and including the Closing Date, no press release,  public statement or announcement or other public disclosure (a “Public Statement”) with respect  to this Agreement or the Transaction may be made except with the prior written consent and joint  approval of BlackBerry and the Purchasers or if required by law or a Governmental Authority, and  that where the Public Statement is required by law or a Governmental Authority, the person  required to make the Public Statement will use reasonable commercial efforts to obtain the  approval of the others as to the form, nature and extent of the disclosure.   44.    Entire Agreement.          The Purchasers and BlackBerry agree that this Agreement and the Consent Agreements,  contain, for good and valuable consideration, the entire agreement of the Purchasers and  BlackBerry relating to the subject matter hereof and there are no representations, covenants or  other agreements relating to the subject matter hereof except as stated or referred to herein. This  Agreement may not be amended or modified in any respect except by written instrument executed  by each of the Purchasers and BlackBerry.      36990-2073 30148883.13   

 

                                         - 53 -      45.   Expenses.         Subject to the provisions of Section 6(2)(c), the Purchasers and BlackBerry agree that all  costs and expenses (including the fees and disbursements of legal counsel and other professional  advisors) incurred in connection with this Agreement and the transactions contemplated herein  shall be paid by the party incurring such expenses.   46.   Enurement.         The Purchasers and BlackBerry agree that this Agreement is binding upon and enures to  the benefit of each of the Purchasers and BlackBerry and their respective successors and  assigns.   47.   Severability.         The Purchasers and BlackBerry agree that if any provision of this Agreement is  determined by a court of competent jurisdiction to be invalid, illegal or unenforceable in any  respect, such determination shall not impair or affect the validity, legality or enforceability of the  remaining provisions hereof, and each provision is hereby declared to be separate, severable and  distinct.   48.   Interpretation.         The Purchasers and BlackBerry agree that in this Agreement:          (a)    “including” means including without limitation;          (b)    words importing the singular number only shall include the plural and vice versa                and words importing any gender shall include all genders;          (c)    if a word or phrase is defined, its other grammatical forms have a corresponding                meaning;          (d)    the division of this Agreement into Sections and other subdivisions and the                insertion of headings are for convenient reference only and do not affect the                Agreement’s interpretation;          (e)    all amounts in this Agreement referred to by “$” or “U.S.$” mean United States                currency;          (f)    “Business Day” means any day other than a Saturday, Sunday or any day on                which banks are generally not open for business in the City of Toronto. In the                event that any action is required or permitted to be taken under this Agreement                on or by a date that is not a Business Day, such action may be taken on or by the                Business Day immediately following such date;          (g)    “Closing” and “Closing Date” have the meanings ascribed to those terms in                Section 5 hereof;          (h)    “Common Shares” means the common shares in the capital of BlackBerry;      36990-2073 30148883.13   

 

                                         - 54 -             (i)    “Consent Agreements”   means, collectively, the consent agreements entered                into between (i) BlackBerry and HWIC dated July 21, 2020; and (ii) BlackBerry                and [redacted] dated July 21, 2020;          (j)    “Guarantors”  means each of   BlackBerry Corporation, Cylance Inc., Good                Technology Software Inc., QNX Software Systems Limited and any other Person                (as defined in the Indenture) who from time to time guarantees the obligations of                BlackBerry under Specified Senior Indebtedness (as defined in the Indenture);          (k)    “Guarantees”  means the guarantees contemplated by the Indenture to be                executed and delivered by the Guarantors in substantially the form contemplated                by the Indenture;          (l)    “Indenture”  means the convertible debenture indenture providing for the                creation, issuance and governance of and in connection with the Debentures,                substantially in the form attached as Schedule B;          (m)    “Indenture Trustee” means BNY Trust Company of Canada, the trustee under                the Indenture;          (n)    “Material Adverse Effect”  means any fact, circumstance, change, event,                occurrence or effect that, individually or in the aggregate is, or would reasonably                be expected to be, materially adverse to the business, assets, condition (financial                or otherwise), liabilities or results of operations of BlackBerry and its subsidiaries                taken as a whole, provided that, none of the following will constitute or be taken                into account in determining whether a “Material Adverse Effect” has occurred or                could occur: (i) any change in United States generally accepted accounting                principles; (ii) any adoption, proposal, implementation or change in applicable law                or any interpretation thereof by any Governmental Authorities; (iii) any change in                global, national or regional political conditions (including the outbreak of war or                acts of terrorism) or in general economic, business, regulatory, political or market                conditions or in national or global financial or capital markets; (iv) any pandemic,                earthquake, hurricane, tornado or other natural disaster; and (v) any action taken                by the BlackBerry or any of its subsidiaries which is required pursuant to the                Agreement; provided, however, that with respect to clauses (i), (ii), (iii) and (iv) of                this definition, such matter does not have a materially disproportionate effect on                BlackBerry and its subsidiaries, taken as a whole, relative to other comparable                companies and entities operating in the industries in which BlackBerry and/or its                subsidiaries operate;          (o)    for purposes of this Agreement, it shall in each case be a question of fact as to                whether two persons are dealing “at arm’s length” in connection with securities                of BlackBerry, and without limitation: (i) a person will not be considered to be                dealing not at arm’s length with another person solely because it is under common                ownership with such person; (ii) persons who are affiliates of each other will be                presumed not to deal at arm’s length; (iii) persons who are acting jointly or in                concert with one another in connection with securities of BlackBerry are not                dealing at arm’s length; (iv) where one or more persons is controlling in fact the                actions of another person in connection with securities of BlackBerry, then such                persons are not dealing at arm’s length; and (v) where two or more persons are,                directly or indirectly, acting under the common direction of a single person in     36990-2073 30148883.13   

 

                                         - 55 -                    connection with securities of BlackBerry, then such persons are not dealing at                arm’s length;          (p)    the term “person” is to be broadly interpreted and includes an individual, a natural                person, a firm, a corporation, a partnership, a trust, an unincorporated                organization, the government of a country or any political subdivision thereof, or                any agency or department of any such government, and the executors,                administrators or other legal representatives of an individual in such capacity;          (q)    a person is deemed to be an “affiliate” of another person if one is a subsidiary of                the other, or if both are subsidiaries of the same person, or if each of them is                controlled by the same person;          (r)    a person is deemed to be a “subsidiary” of another person if it is controlled                directly or indirectly by that person, and includes a subsidiary of that subsidiary;                and          (s)    “control” means control in any manner that results in control in fact, whether                directly through the ownership of securities or indirectly through a trust, an                agreement or arrangement or otherwise.   49.    Further Assurances.          Each of the parties upon the request of the other, whether before or after Closing, shall  do, execute, acknowledge and deliver or cause to be done, executed, acknowledged and  delivered all such further acts, deeds, documents, assignments, transfers, conveyances, powers  of attorney and assurances as may reasonably be necessary   or desirable to complete the  transactions contemplated herein.   50.    Time of Essence.          The Purchasers and BlackBerry agree that time is of the essence in this Agreement.    51.    Counterparts.          The Purchasers and BlackBerry agree that this Agreement may be executed in any  number of counterparts, each of which shall be deemed to be an original and all of which taken  together shall be deemed to constitute one and the same instrument. Counterparts may be  executed either in original or electronic form and the parties may rely on delivery by electronic  delivery of an executed copy of this Agreement.   52.    Acceptance.          If the foregoing accurately reflects your understanding of our agreement, please sign in  the space provided below and return it to us by no later than 3:00 p.m. on August 31, 2020, failing  which it shall immediately become null and void.                                   [Signature pages follow]      36990-2073 30148883.13   

 

                                                  <PURCHASER>                                                                                                                                                               by:                                                          Name:                                                        Title:                                         36990-2073 30148883.13   

 

                                         - 57 -      Agreed as of this [] day of [], [202X]   BLACKBERRY LIMITED                          by:            Name:         Title:                     36990-2073 30148883.13EX-4.1

 Exhibit 4.1 

Certain information has been excluded from this agreement (indicated by “[***]”) because Taysha Gene Therapies, Inc. has determined
such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 
 AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 
 THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is
made as of the 2nd day of July, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), each of the investors listed on Schedule A hereto,
each of which is referred to in this Agreement as an “Investor”, each of the stockholders listed on Schedule B hereto, each of whom is referred to herein as a “Key Holder” and any Additional Purchaser (as
defined in the Purchase Agreement) that becomes a party to this Agreement in accordance with Section 6.9 hereof. 

RECITALS 

WHEREAS, the Key Holders and certain of the Investors (the “Existing Investors”) hold shares of the Company’s
Series A Preferred Stock and/or shares of Common Stock and possess registration rights, information rights, rights of first offer, and other rights pursuant to that certain Investors’ Rights Agreement dated as of March 4, 2020, by and
among the Company and such Existing Investors (the “Prior Agreement”); 
 WHEREAS, the Existing Investors and Key
Holders are holders of at least a majority of the Registrable Securities of the Company (as defined in the Prior Agreement), and desire to amend and restate the Prior Agreement in its entirety and to accept the rights created pursuant to this
Agreement in lieu of the rights granted to them under the Prior Agreement; and 
 WHEREAS, certain of the Investors are parties to
that certain Series B Preferred Stock Purchase Agreement of even date herewith by and among the Company and such Investors (the “Purchase Agreement”), under which certain of the Company’s and such Investors’ obligations
are conditioned upon the execution and delivery of this Agreement by such Investors and the Existing Investors and Key Holders holding at least a majority of the Registrable Securities, and the Company. 

NOW, THEREFORE, the Key Holders and the Existing Investors hereby agree that the Prior Agreement shall be amended and restated, and the
parties hereby agree as follows: 
 1.    Definitions. For purposes of this Agreement: 

1.1    “Affiliate” means (i) with respect to any specified Person, any other Person who, directly or
indirectly, controls, is controlled by, or is under common control with such Person, including without limitation any general partner, managing member, manager, officer or director of such Person or any venture capital fund or other investment fund
now or hereafter existing that is controlled by one or more general partners or managing members of, or shares the same management company or investment adviser with, such Person, and (ii) with respect to any specified Person that is a
partnership, limited partnership, corporation or limited liability company, any Person that is a partner, general partner, limited partner, shareholder or member thereof. For purposes of this definition, one or more Persons will be deemed to be
under common control if they have granted to one of such Persons (whether by agreement, granting of a power-of-attorney, or otherwise) the ability to exercise all
rights, receive all notices, and take any action under this Agreement. 

 1.2    “Board of Directors” means the board of
directors of the Company. 
 1.3    “Certificate of Incorporation” means the Company’s Amended and
Restated Certificate of Incorporation, as amended and/or restated from time to time. 
 1.4    “Common
Stock” means shares of the Company’s common stock, par value $0.00001 per share. 

1.5    “Competitor” means a Person engaged, directly or indirectly (including through any partnership,
limited liability company, corporation, joint venture or similar arrangement (whether now existing or formed hereafter)), in gene therapies for rare diseases, but shall not include (i) PBM, (ii) any Fidelity Investor or (iii) any financial
investment firm or collective investment vehicle that, together with its Affiliates, holds less than twenty percent (20%) of the outstanding equity of any Competitor and does not, nor do any of its Affiliates, have a right to designate any members
of the board of directors of any Competitor. Competitor specifically excludes the Board of Regents of the University of Texas System (the “Regents”). 

1.6    “Damages” means any loss, damage, claim or liability (joint or several) to which a party hereto
may become subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability (or any action in respect thereof) arises out of or is based upon: (i) any untrue statement or
alleged untrue statement of a material fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto; (ii) an omission or alleged
omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; or (iii) any violation or alleged violation by the indemnifying party (or any of its agents or
Affiliates) of the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law. 

1.7    “Derivative Securities” means any securities or rights convertible into, or exercisable or
exchangeable for (in each case, directly or indirectly), Common Stock, including options and warrants. 

1.8    “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and
regulations promulgated thereunder. 
 1.9    “Excluded Registration” means (i) a registration
relating to the sale or grant of securities to employees of the Company or a subsidiary pursuant to a stock option, stock purchase, equity incentive or similar plan; (ii) a registration relating to an SEC Rule 145 transaction; (iii) a
registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities; or (iv) a registration in which the only Common
Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered. 

1.10    “Fidelity” means Fidelity Management & Research Company and any successor or affiliated
registered investment advisor to the Fidelity Investors. 

  
 2 

 1.11    “Fidelity Investors” means the Investors that
are advisory or sub-advisory clients of Fidelity. 
 1.12    “FOIA
Party” means a Person that, in the determination of the Board of Directors, may be subject to, and thereby required to disclose non-public information furnished by or relating to the Company under,
the Freedom of Information Act, 5 U.S.C. 552 (“FOIA”), any state public records access law, any state or other jurisdiction’s laws similar in intent or effect to FOIA, or any other similar statutory or regulatory requirement.

 1.13    “Form S-1” means such form under the
Securities Act as in effect on the date hereof or any successor registration form under the Securities Act subsequently adopted by the SEC. 

1.14    “Form S-3” means such form under the Securities
Act as in effect on the date hereof or any registration form under the Securities Act subsequently adopted by the SEC that permits forward incorporation of substantial information by reference to other documents filed by the Company with the SEC.

 1.15    “GAAP” means generally accepted accounting principles in the United States as in effect from
time to time. 
 1.16    “Holder” means any holder of Registrable Securities who is a party to this
Agreement. 
 1.17    “Immediate Family Member” means a child, stepchild, grandchild, parent,
stepparent, grandparent, spouse, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law,
brother-in-law, or sister-in-law, including, adoptive relationships, of a
natural person referred to herein. 
 1.18    “Initiating Holders” means, collectively, Holders who
properly initiate a registration request under this Agreement. 
 1.19    “IPO” means the
Company’s first underwritten public offering of its Common Stock under the Securities Act. 
 1.20    “Key
Employee” means R.A. Session II. 
 1.21    “Key Holder Registrable Securities” means
(i) the 10,000,000 shares of Common Stock held by the Key Holders as of the date hereof, and (ii) any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a
dividend or other distribution with respect to, or in exchange for or in replacement of such shares. 

1.22    “Major Investor” means any Investor that, individually or together with such Investor’s
Affiliates, holds at least 666,666 shares of Registrable Securities (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification effected after the date hereof). 

  
 3 

 1.23    “New Securities” means, collectively, equity
securities of the Company, whether or not currently authorized, as well as rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable into or exercisable
for such equity securities. 
 1.24    “PBM” means PBM TGT Holdings, LLC and its Affiliates. 

1.25    “Person” means any individual, corporation, partnership, trust, limited liability company,
association or other entity. 
 1.26    “Preferred Stock” means, collectively, shares of the
Company’s Series A Preferred Stock and Series B Preferred Stock. 
 1.27    “Registrable
Securities” means (i) the Common Stock issuable or issued upon conversion of the Preferred Stock; (ii) any Common Stock, or any Common Stock issued or issuable (directly or indirectly) upon conversion
and/or exercise of any other securities of the Company, acquired by the Investors after the date hereof; (iii) the Key Holder Registrable Securities, provided, however, that such Key Holder Registrable
Securities shall not be deemed Registrable Securities and the Key Holders shall not be deemed Holders for the purposes of Sections 2.1 (and any other applicable Section with respect to registrations under
Section 2.1), 2.10, 3.1, 3.2, 4.1 (other than with respect to the Regents so long as the Regents are a Major Investor) and 6.6 (other than with respect to the Regents’ rights under
Section 6.6(c)); and (iv) any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in
replacement of, the shares referenced in clauses (i) and (ii) above; excluding in all cases, however, any Registrable Securities sold by a Person in a transaction in which the applicable rights under this Agreement are not
assigned pursuant to Section 6.1, and excluding for purposes of Section 2 any shares for which registration rights have terminated pursuant to Section 2.13 of this Agreement. 

1.28    “Registrable Securities then outstanding” means the number of shares determined by adding the
number of shares of outstanding Common Stock that are Registrable Securities and the number of shares of Common Stock issuable (directly or indirectly) pursuant to then exercisable and/or convertible securities that are Registrable
Securities. 
 1.29    “Restricted Securities” means the securities of the Company required to be
notated with the legend set forth in Section 2.12(b) hereof. 
 1.30    “SEC”
means the Securities and Exchange Commission. 
 1.31    “SEC Rule 144” means Rule 144 promulgated by
the SEC under the Securities Act. 
 1.32    “SEC Rule 145” means Rule 145 promulgated by the SEC under
the Securities Act. 
 1.33    “Securities Act” means the Securities Act of 1933, as amended, and the
rules and regulations promulgated thereunder. 

  
 4 

 1.34    “Selling Expenses” means all underwriting
discounts, selling commissions, and stock transfer taxes applicable to the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel borne and paid by
the Company as provided in Section 2.6. 
 1.35    “Series A Director” means
any director of the Company that the holders of record of the Series A Preferred Stock are entitled to elect, exclusively and as a separate class, pursuant to the Certificate of Incorporation. 

1.36    “Series A Preferred Stock” means shares of the Company’s Series A Preferred Stock, par value
$0.00001 per share. 
 1.37    “Series B Preferred Stock” means shares of the Company’s Series B
Preferred Stock, par value $0.00001 per share. 
 2.    Registration Rights. The Company covenants and agrees as
follows: 
 2.1    Demand Registration. 

(a)    Form S-1 Demand. If at any time after the earlier of (i) five
(5) years after the date of this Agreement or (ii) one hundred eighty (180) days after the effective date of the registration statement for the IPO, the Company receives a request from Holders of a majority of the Registrable Securities
then outstanding that the Company file a Form S-1 registration statement with respect to Registrable Securities, the anticipated aggregate offering price, net of Selling Expenses, of which exceeds
$10 million, then the Company shall (x) within ten (10) days after the date such request is given, give notice thereof (the “Demand Notice”) to all Holders other than the Initiating Holders; and (y) as soon as
practicable, and in any event within sixty (60) days after the date such request is given by the Initiating Holders, file a Form S-1 registration statement under the Securities Act covering all
Registrable Securities that the Initiating Holders requested to be registered and any additional Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to
the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Sections 2.1(c) and 2.3. 

(b)    Form S-3 Demand. If at any time when it is eligible to use a Form S-3 registration statement, the Company receives a request from Holders of at least a majority of the Registrable Securities then outstanding that the Company file a Form S-3
registration statement with respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering price, net of Selling Expenses, of at least $5 million, then the Company shall (i) within ten (10) days
after the date such request is given, give a Demand Notice to all Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within forty-five (45) days after the date such request is given by the
Initiating Holders, file a Form S-3 registration statement under the Securities Act covering all Registrable Securities requested to be included in such registration by any other Holders, as specified by
notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Sections 2.1(c) and 2.3. 

  
 5 

 (c)    Notwithstanding the foregoing obligations, if the Company
furnishes to Holders requesting a registration pursuant to this Section 2.1 a certificate signed by the Company’s chief executive officer stating that in the good faith judgment of the Board of Directors it would be
materially detrimental to the Company and its stockholders for such registration statement to either become effective or remain effective for as long as such registration statement otherwise would be required to remain effective, because such action
would (i) materially interfere with a significant acquisition, corporate reorganization, or other similar transaction involving the Company; (ii) require premature disclosure of material information that the Company has a bona fide
business purpose for preserving as confidential; or (iii) render the Company unable to comply with requirements under the Securities Act or Exchange Act, then the Company shall have the right to defer taking action with respect to such filing,
and any time periods with respect to filing or effectiveness thereof shall be tolled correspondingly, for a period of not more than one hundred twenty (120) days after the request of the Initiating Holders is given; provided,
however, that the Company may not invoke this right more than once in any twelve (12) month period; and provided further that the Company shall not register any securities for its own account or that of any other
stockholder during such one hundred twenty (120) day period other than an Excluded Registration. 
 (d)    The
Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Section 2.1(a) (i) during the period that is sixty (60) days before the Company’s good faith estimate of
the date of filing of, and ending on a date that is one hundred eighty (180) days after the effective date of, a Company-initiated registration, provided that the Company is actively employing in good faith commercially reasonable
efforts to cause such registration statement to become effective; (ii) after the Company has effected one (1) registration pursuant to Section 2.1(a); or (iii) if the Initiating Holders propose to dispose of shares of
Registrable Securities that may be immediately registered on Form S-3 pursuant to a request made pursuant to Section 2.1(b). The Company shall not be obligated to effect, or to take
any action to effect, any registration pursuant to Section 2.1(b) (i) during the period that is thirty (30) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is ninety
(90) days after the effective date of, a Company-initiated registration, provided that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; or
(ii) if the Company has effected two registrations pursuant to Section 2.1(b) within the twelve (12) month period immediately preceding the date of such request. A registration shall not be counted as “effected” for
purposes of this Section 2.1(d) until such time as the applicable registration statement has been declared effective by the SEC, unless the Initiating Holders withdraw their request for such registration, elect not to pay
the registration expenses therefor, and forfeit their right to one demand registration statement pursuant to Section 2.6, in which case such withdrawn registration statement shall be counted as “effected” for
purposes of this Section 2.1(d); provided, that if such withdrawal is during a period the Company has deferred taking action pursuant to Section 2.1(c), then the Initiating Holders may withdraw their
request for registration and such registration will not be counted as “effected” for purposes of this Section 2.1(d). 

2.2    Company Registration. If the Company proposes to register (including, for this purpose, a registration
effected by the Company for stockholders other than the Holders) any of its Common Stock under the Securities Act in connection with the public offering of such securities solely for cash (other than in an Excluded Registration), the Company shall,
at such time, 

  
 6 

 
promptly give each Holder notice of such registration. Upon the request of each Holder given within twenty (20) days after such notice is given by the Company, the Company shall, subject to
the provisions of Section 2.3, cause to be registered all of the Registrable Securities that each such Holder has requested to be included in such registration. The Company shall have the right to terminate or withdraw any
registration initiated by it under this Section 2.2 before the effective date of such registration, whether or not any Holder has elected to include Registrable Securities in such registration. The expenses (other than
Selling Expenses) of such withdrawn registration shall be borne by the Company in accordance with Section 2.6. 

2.3    Underwriting Requirements. 

(a)    If, pursuant to Section 2.1, the Initiating Holders intend to distribute the
Registrable Securities covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Section 2.1, and the Company shall include such information in the
Demand Notice. The underwriter(s) will be selected by the Board of Directors and shall be reasonably acceptable to a majority in interest of the Initiating Holders. In such event, the right of any Holder to include such Holder’s Registrable
Securities in such registration shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing
to distribute their securities through such underwriting shall (together with the Company as provided in Section 2.4(e)) enter into an underwriting agreement in customary form with the underwriter(s) selected for such
underwriting. Notwithstanding any other provision of this Section 2.3, if the managing underwriter(s) advise the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be
underwritten, then the Initiating Holders shall so advise all Holders of Registrable Securities that otherwise would be underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be
allocated among such Holders of Registrable Securities, including the Initiating Holders, in proportion (as nearly as practicable) to the number of Registrable Securities owned by each Holder or in such other proportion as shall mutually be agreed
to by all such selling Holders; provided, however, that the number of Registrable Securities held by the Holders to be included in such underwriting shall not be reduced unless Key Holder Registrable Securities and all other securities
are first entirely excluded from the underwriting. To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest one hundred
(100) shares. 
 (b)    In connection with any offering involving an underwriting of shares of the Company’s
capital stock pursuant to Section 2.2, the Company shall not be required to include any of the Holders’ Registrable Securities in such underwriting unless the Holders accept the terms of the underwriting as agreed upon
between the Company and its underwriters, and then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the Company. If the total number of securities, including Registrable
Securities, requested by stockholders to be included in such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their reasonable discretion determine is compatible with the success of the
offering, then the Company shall be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters and the Company in their sole discretion determine will not jeopardize the success
of the offering. If the underwriters determine that less than all of the 

  
 7 

 
Registrable Securities requested to be registered can be included in such offering, then the Registrable Securities that are included in such offering shall be allocated among the selling Holders
in proportion (as nearly as practicable to) the number of Registrable Securities owned by each selling Holder or in such other proportions as shall mutually be agreed to by all such selling Holders. To facilitate the allocation of shares in
accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest one hundred (100) shares. Notwithstanding the foregoing, in no event shall (i) the number of
Registrable Securities included in the offering be reduced unless all other securities (other than securities to be sold by the Company) are first entirely excluded from the offering, (ii) the number of Registrable Securities included in the
offering be reduced below thirty percent (30%) of the total number of securities included in such offering, unless such offering is the IPO, in which case the selling Holders may be excluded further if the underwriters make the determination
described above and no other stockholder’s securities are included in such offering, or (iii) notwithstanding (ii) above, any Registrable Securities which are not Key Holder Registrable Securities be excluded from such underwriting unless
all Key Holder Registrable Securities are first excluded from such offering. For purposes of the provision in this Section 2.3(b) concerning apportionment, for any selling Holder that is a partnership, limited liability
company, or corporation, the partners, members, retired partners, retired members, stockholders, and Affiliates of such Holder, or the estates and Immediate Family Members of any such partners, retired partners, members, and retired members and any
trusts for the benefit of any of the foregoing Persons, shall be deemed to be a single “selling Holder,” and any pro rata reduction with respect to such “selling Holder” shall be based upon the aggregate number of Registrable
Securities owned by all Persons included in such “selling Holder,” as defined in this sentence. 
 (c)    For
purposes of Section 2.1, a registration shall not be counted as “effected” if, as a result of an exercise of the underwriter’s cutback provisions in Section 2.3(a), fewer than fifty
percent (50%) of the total number of Registrable Securities that Holders have requested to be included in such registration statement are actually included. 

2.4    Obligations of the Company. Whenever required under this Section 2 to effect the
registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 

(a)    prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its
commercially reasonable efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement effective for a period
of up to one hundred twenty (120) days or, if earlier, until the distribution contemplated in the registration statement has been completed; provided, however, that (i) such one hundred twenty (120) day period shall be
extended for a period of time equal to the period the Holder refrains, at the request of an underwriter of Common Stock (or other securities) of the Company, from selling any securities included in such registration; 

(b)    prepare and file with the SEC such amendments and supplements to such registration statement, and the prospectus
used in connection with such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by such registration statement; 

  
 8 

 (c)    furnish to the selling Holders such numbers of copies of a
prospectus, including a preliminary prospectus, as required by the Securities Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities; 

(d)    use its commercially reasonable efforts to register and qualify the securities covered by such registration
statement under such other securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that the Company shall not be required to qualify to do
business or to file a general consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

(e)    in the event of any underwritten public offering, enter into and perform its obligations under an underwriting
agreement, in usual and customary form, with the underwriter(s) of such offering; 
 (f)    use its commercially
reasonable efforts to cause all such Registrable Securities covered by such registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities
issued by the Company are then listed; 
 (g)    provide a transfer agent and registrar for all Registrable Securities
registered pursuant to this Agreement and provide a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration; 

(h)    promptly make available for inspection by the selling Holders, any underwriter(s) participating in any disposition
pursuant to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders, all financial and other records, pertinent corporate documents, and properties of the
Company, and cause the Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any such seller, underwriter, attorney, accountant, or agent, in each case, as necessary or advisable
to verify the accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith; 

(i)    notify each selling Holder, promptly after the Company receives notice thereof, of the time when such registration
statement has been declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and 

(j)    after such registration statement becomes effective, notify each selling Holder of any request by the SEC that the
Company amend or supplement such registration statement or prospectus. 
 In addition, the Company shall ensure that, at all times after any registration
statement covering a public offering of securities of the Company under the Securities Act shall have become effective, its insider trading policy shall provide that the Company’s directors may implement a trading program under Rule 10b5-1 of the Exchange Act. 

  
 9 

 2.5    Furnish Information. It shall be a condition precedent to
the obligations of the Company to take any action pursuant to this Section 2 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself,
the Registrable Securities held by it, and the intended method of disposition of such securities as is reasonably required to effect the registration of such Holder’s Registrable Securities. 

2.6    Expenses of Registration. All expenses (other than Selling Expenses) incurred in connection with
registrations, filings, or qualifications pursuant to Section 2, including all registration, filing, and qualification fees; printers’ and accounting fees; fees and disbursements of counsel for the Company; and the
reasonable fees and disbursements, not to exceed $50,000, of one counsel for the selling Holders (“Selling Holder Counsel”), shall be borne and paid by the Company; provided, however, that the Company shall not
be required to pay for any expenses of any registration proceeding begun pursuant to Section 2.1 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable
Securities to be registered (in which case all selling Holders shall bear such expenses pro rata based upon the number of Registrable Securities that were to be included in the withdrawn registration), unless the Holders of a majority of the
Registrable Securities agree to forfeit their right to one registration pursuant to Sections 2.1(a) or 2.1(b), as the case may be; provided further that if, at the time of such withdrawal, the Holders shall have
learned of a material adverse change in the condition, business, or prospects of the Company from that known to the Holders at the time of their request and have withdrawn the request with reasonable promptness after learning of such information
then the Holders shall not be required to pay any of such expenses and shall not forfeit their right to one registration pursuant to Sections 2.1(a) or 2.1(b). All Selling Expenses relating to Registrable Securities registered pursuant
to this Section 2 shall be borne and paid by the Holders pro rata on the basis of the number of Registrable Securities registered on their behalf. 

2.7    Delay of Registration. No Holder shall have any right to obtain or seek an injunction restraining or
otherwise delaying any registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2. 

2.8    Indemnification. If any Registrable Securities are included in a registration statement under this
Section 2: 
 (a)    To the extent permitted by law, the Company will indemnify and hold
harmless each selling Holder, and the partners, members, officers, directors, and stockholders of each such Holder; legal counsel, accountants and investment advisers for each such Holder; any underwriter (as defined in the Securities Act) for each
such Holder; and each Person, if any, who controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other
aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that
the indemnity agreement contained in this Section 2.8(a) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Company, which consent shall
not be unreasonably withheld, nor shall the Company be liable for any Damages to the extent that they 

  
 10 

 
arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of any such Holder, underwriter, controlling Person,
or other aforementioned Person expressly for use in connection with such registration. 
 (b)    To the extent
permitted by law, each selling Holder, severally and not jointly, will indemnify and hold harmless the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company
within the meaning of the Securities Act, legal counsel and accountants for the Company, any underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of any such
underwriter or other Holder, against any Damages, in each case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of
such selling Holder expressly for use in connection with such registration; and each such selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with
investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Section 2.8(b) shall not apply
to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; and provided further that in no event shall the aggregate
amounts payable by any Holder by way of indemnity or contribution under Sections 2.8(b) and 2.8(d) exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of
fraud or willful misconduct by such Holder. 
 (c)    Promptly after receipt by an indemnified party under this
Section 2.8 of notice of the commencement of any action (including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof
is to be made against any indemnifying party under this Section 2.8, give the indemnifying party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the
extent the indemnifying party so desires, participate jointly with any other indemnifying party to which notice has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however,
that an indemnified party (together with all other indemnified parties that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if
representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such
action. The failure to give notice to the indemnifying party within a reasonable time of the commencement of any such action shall relieve such indemnifying party of any liability to the indemnified party under this
Section 2.8, only to the extent that such failure materially prejudices the indemnifying party’s ability to defend such action. The failure to give notice to the indemnifying party will not relieve it of any liability
that it may have to any indemnified party otherwise than under this Section 2.8. 
 (d)    To
provide for just and equitable contribution to joint liability under the Securities Act in any case in which either: (i) any party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this
Section 2.8 but it is judicially 

  
 11 

 
determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such
indemnification may not be enforced in such case, notwithstanding the fact that this Section 2.8 provides for indemnification in such case, or (ii) contribution under the Securities Act may be required on the part of
any party hereto for which indemnification is provided under this Section 2.8, then, and in each such case, such parties will contribute to the aggregate losses, claims, damages, liabilities, or expenses to which they may
be subject (after contribution from others) in such proportion as is appropriate to reflect the relative fault of each of the indemnifying party and the indemnified party in connection with the statements, omissions, or other actions that resulted
in such loss, claim, damage, liability, or expense, as well as to reflect any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things,
whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged omission of a material fact, relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent,
knowledge, access to information, and opportunity to correct or prevent such statement or omission; provided, however, that, in any such case (x) no Holder will be required to contribute any amount in excess of the public offering
price of all such Registrable Securities offered and sold by such Holder pursuant to such registration statement, and (y) no Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be
entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation; and provided further that in no event shall a Holder’s liability pursuant to this Section 2.8(d), when
combined with the amounts paid or payable by such Holder pursuant to Section 2.8(b), exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of
willful misconduct or fraud by such Holder. 
 (e)    Notwithstanding the foregoing, to the extent that any provisions
on indemnification and contribution contained in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, such provisions in the underwriting agreement shall control.

 (f)    Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten
public offering, the obligations of the Company and Holders under this Section 2.8 shall survive the completion of any offering of Registrable Securities in a registration under this Section 2, and
otherwise shall survive the termination of this Agreement. 
 2.9    Reports Under Exchange Act. With a view to
making available to the Holders the benefits of SEC Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form S-3, the Company shall: 
 (a)    make and keep available adequate current public
information, as those terms are understood and defined in SEC Rule 144, at all times after the effective date of the registration statement filed by the Company for the IPO; 

(b)    use commercially reasonable efforts to file with the SEC in a timely manner all reports and other documents
required of the Company under the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and 

  
 12 

 (c)    furnish to any Holder, so long as the Holder owns any
Registrable Securities, forthwith upon request (i) to the extent accurate, a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after ninety (90) days after the effective date
of the registration statement filed by the Company for the IPO), the Securities Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be
resold pursuant to Form S-3 (at any time after the Company so qualifies); and (ii) such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that
permits the selling of any such securities without registration (at any time after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form S-3 (at any time
after the Company so qualifies to use such form). 
 2.10    Limitations on Subsequent Registration Rights. From
and after the date of this Agreement, the Company shall not, without the prior written consent of the Holders of a majority of the Registrable Securities then outstanding, enter into any agreement with any holder or prospective holder of any
securities of the Company that would (i) provide to such holder or prospective holder the right to include securities in any registration on other than a subordinate basis after all Holders have had the opportunity to include in the
registration and offering all shares of Registrable Securities that they wish to so include; or (ii) allow such holder or prospective holder to initiate a demand for registration of any securities held by such holder or prospective holder;
provided that this limitation shall not apply to Registrable Securities acquired by any additional Investor that becomes a party to this Agreement in accordance with Section 6.9. 

2.11    “Market Stand-off” Agreement.
Each Holder hereby agrees that it will not, without the prior written consent of the managing underwriter, during the period commencing on the date of the final prospectus relating to the IPO, and ending on the date specified by the Company and the
managing underwriter (such period not to exceed one hundred eighty (180) days), (i) lend; offer; pledge; sell; contract to sell; sell any option or contract to purchase; purchase any option or contract to sell; grant any option, right, or
warrant to purchase; or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable (directly or indirectly) for Common Stock held immediately before
the effective date of the registration statement for the IPO or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of such securities, whether any
such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or other securities, in cash, or otherwise. The foregoing provisions of this Section 2.11 (A) shall
apply only to the IPO, (B) shall not apply to the sale of shares acquired in the IPO or in the open market on or after the IPO, (C) shall not apply to the sale of any shares to an underwriter pursuant to an underwriting agreement, or the
transfer of any shares to any trust for the direct or indirect benefit of the Holder or the immediate family of the Holder, provided that the trustee of the trust agrees to be bound in writing by the restrictions set forth herein, and
provided further that any such transfer shall not involve a disposition for value, and (D) shall be applicable to the Holders only if all officers and directors and all stockholders individually owning more than one percent (1%)
of the Company’s outstanding Common Stock (after giving effect to conversion into Common Stock of all outstanding Preferred Stock) are 

  
 13 

 
subject to the same restrictions. The underwriters in connection with such registration are intended third-party beneficiaries of this
Section 2.11 and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. Each Holder further agrees to execute such agreements as may be reasonably requested by the
underwriters in connection with such registration that are consistent with this Section 2.11 or that are necessary to give further effect thereto. In the event that the Company or the managing underwriter waives or
terminates any of the restrictions contained in this Section 2.11 or in a lock-up agreement with respect to the securities of any Holder, officer, director or greater than
one-percent stockholder of the Company (in any such case, the “Released Securities”), the restrictions contained in this Section 2.11 and in any
lock-up agreements executed by the Investors shall be waived or terminated, as applicable, to the same extent and with respect to the same percentage of securities of each Investor as the percentage of
Released Securities represent with respect to the securities held by the applicable Holder, officer, director or greater than one-percent stockholder. 

2.12    Restrictions on Transfer. 

(a)    The Preferred Stock and the Registrable Securities shall not be sold, pledged, or otherwise transferred, and the
Company shall not recognize and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except upon the conditions specified in this Agreement, which conditions are intended to ensure
compliance with the provisions of the Securities Act. A transferring Holder will cause any proposed purchaser, pledgee, or transferee of the Preferred Stock and the Registrable Securities held by such Holder to agree to take and hold such securities
subject to the provisions and upon the conditions specified in this Agreement. Notwithstanding the foregoing, the Company shall not require any transferee of shares pursuant to an effective registration statement or, following the IPO, SEC Rule 144
to be bound by the terms of this Agreement. 
 (b)    Each certificate, instrument, or book entry representing
(i) the Preferred Stock, (ii) the Registrable Securities, and (iii) any other securities issued in respect of the securities referenced in clauses (i) and (ii), upon any stock split, stock dividend, recapitalization, merger,
consolidation, or similar event, shall (unless otherwise permitted by the provisions of Section 2.12(c)) be notated with a legend substantially in the following form: 

THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. SUCH SHARES
MAY NOT BE SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT. 

THE SECURITIES REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER,
A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY. 

  
 14 

 The Holders consent to the Company making a notation in its records and giving instructions to any transfer
agent of the Restricted Securities in order to implement the restrictions on transfer set forth in this Section 2.12. 

(c)    The holder of such Restricted Securities, by acceptance of ownership thereof, agrees to comply in all respects
with the provisions of this Section 2. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration statement under the Securities Act covering the proposed
transaction or, following the IPO, the transfer is made pursuant to SEC Rule 144, the Holder thereof shall give notice to the Company of such Holder’s intention to effect such sale, pledge, or transfer. Each such notice shall describe the
manner and circumstances of the proposed sale, pledge, or transfer in sufficient detail and, if reasonably requested by the Company, shall be accompanied at such Holder’s expense by either (i) a written opinion of legal counsel who shall,
and whose legal opinion shall, be reasonably satisfactory to the Company, addressed to the Company, to the effect that the proposed transaction may be effected without registration under the Securities Act; (ii) a “no action” letter
from the SEC to the effect that the proposed sale, pledge, or transfer of such Restricted Securities without registration will not result in a recommendation by the staff of the SEC that action be taken with respect thereto; or (iii) any other
evidence reasonably satisfactory to counsel to the Company to the effect that the proposed sale, pledge, or transfer of the Restricted Securities may be effected without registration under the Securities Act, whereupon the Holder of such Restricted
Securities shall be entitled to sell, pledge, or transfer such Restricted Securities in accordance with the terms of the notice given by the Holder to the Company. The Company will not require such a legal opinion or “no action” letter
(x) in any transaction in compliance with SEC Rule 144; or (y) in any transaction in which such Holder distributes Restricted Securities to an Affiliate of such Holder for no consideration; provided that, other than in connection
with a transaction in compliance with SEC Rule 144 following the IPO, each transferee agrees in writing to be subject to the terms of this Section 2.12. Each certificate, instrument, or book entry representing the
Restricted Securities transferred as above provided shall be notated with, except if such transfer is made pursuant to SEC Rule 144 or pursuant to an effective registration statement, the appropriate restrictive legend set forth in
Section 2.12(b), except that such certificate instrument, or book entry shall not be notated with such restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend is not required in order
to establish compliance with any provisions of the Securities Act. 
 2.13    Termination of Registration Rights.
The right of any Holder to request registration or inclusion of Registrable Securities in any registration pursuant to Sections 2.1 or 2.2 shall terminate upon the earliest to occur of: 

(a)    the closing of a Deemed Liquidation Event, as such term is defined in the Certificate of Incorporation; 

(b)    such time after consummation of the IPO as Rule 144 or another similar exemption under the Securities Act is
available for the sale of all of such Holder’s shares without limitation during a three-month period without registration; and 

(c)    the third (3rd) anniversary of the IPO. 

  
 15 

 3.    Information Rights. 

3.1    Delivery of Financial Statements. The Company shall deliver to each Major Investor, provided that the
Board of Directors has not reasonably determined that such Major Investor is a Competitor of the Company: 
 (a)    as
soon as practicable, but in any event within one-hundred twenty (120) days after the end of each fiscal year of the Company (i) a balance sheet as of the end of such year, (ii) statements of
income and of cash flows for such year, and (iii) a statement of stockholders’ equity as of the end of such year, all such financial statements audited and certified by independent public accountants of regionally recognized standing
selected by the Company; 
 (b)    as soon as practicable, but in any event within
forty-five (45) days after the end of each of the first three (3) quarters of each fiscal year of the Company, unaudited statements of income and cash flows for such fiscal quarter, and an unaudited
balance sheet as of the end of such fiscal quarter, all prepared in accordance with GAAP (except that such financial statements may (i) be subject to normal year-end audit adjustments; and (ii) not
contain all notes thereto that may be required in accordance with GAAP); 
 (c)    as soon as practicable, but in any
event within forty-five (45) days after the end of each quarter of each fiscal year of the Company, a statement showing the number of shares of each class and series of capital stock and securities convertible into or exercisable for shares of
capital stock outstanding at the end of the period, the Common Stock issuable upon conversion or exercise of any outstanding securities convertible or exercisable for Common Stock and the exchange ratio or exercise price applicable thereto, and the
number of shares of issued stock options and stock options not yet issued but reserved for issuance, if any, all in sufficient detail as to permit the Holders to calculate their respective percentage equity ownership in the Company, and certified by
the controller of the Company as being true, complete, and correct; 
 (d)    as soon as practicable, but in any event
thirty (30) days before the end of each fiscal year, a budget and business plan for the next fiscal year (collectively, the “Budget”), approved by the Board of Directors and prepared on a monthly basis, including balance
sheets, income statements, and statements of cash flow for such months and, promptly after prepared, any other budgets or revised budgets prepared by the Company; and 

(e)    such other information relating to the financial condition, business, prospects, or corporate affairs of the
Company as any Major Investor may from time to time reasonably request; provided, however, that the Company shall not be obligated under this Section 3.1(d) to provide information (i) that the Company
reasonably determines in good faith to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in a form acceptable to the Company); or (ii) the disclosure of which would adversely affect the
attorney-client privilege between the Company and its counsel. 
 If, for any period, the Company has any subsidiary whose accounts are
consolidated with those of the Company, then in respect of such period the financial statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the Company and all such consolidated
subsidiaries. 

  
 16 

 Notwithstanding anything else in this Section 3.1 to the contrary,
the Company may cease providing the information set forth in this Section 3.1 during the period starting with the date sixty (60) days before the Company’s good-faith estimate of the date of filing of a
registration statement if it reasonably concludes it must do so to comply with the SEC rules applicable to such registration statement and related offering; provided that the Company’s covenants under this
Section 3.1 shall be reinstated at such time as the Company is no longer actively employing its commercially reasonable efforts to cause such registration statement to become effective. 

3.2    Inspection. The Company shall permit each Major Investor (provided that the Board of Directors has
not reasonably determined that such Major Investor is a Competitor of the Company), at such Major Investor’s expense, to visit and inspect the Company’s properties; examine its books of account and records; and discuss the Company’s
affairs, finances, and accounts with its officers, during normal business hours of the Company as may be reasonably requested by the Major Investor; provided, however, that the Company shall not be obligated pursuant to this
Section 3.2 to provide access to any information that it reasonably and in good faith considers to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in form
acceptable to the Company) or the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel. 

3.3    Termination of Information Rights. The covenants set forth in Section 3.1 and
Section 3.2 shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO, (ii) when the Company first becomes subject to the periodic reporting requirements of
Section 12(g) or 15(d) of the Exchange Act, or (iii) upon the closing of a Deemed Liquidation Event, as such term is defined in the Certificate of Incorporation, whichever event occurs first; provided, however, that in the
event the covenants set forth in Section 3.1 terminate upon a Deemed Liquidation Event, if the consideration received by the Investors in such Deemed Liquidation Event is not solely in the form of cash and/or publicly
traded securities, the Company will use commercially reasonable efforts to ensure that the Major Investors receive financial information from the acquiring company or other successor to the Company comparable to those set forth in
Section 3.1. 
 3.4    Confidentiality. Each Investor agrees that such Investor will
keep confidential and will not disclose, divulge, or use for any purpose (other than to monitor its investment in the Company) any confidential information obtained from the Company pursuant to the terms of this Agreement (including notice of the
Company’s intention to file a registration statement), unless such confidential information (a) is known or becomes known to the public in general (other than as a result of a breach of this Section 3.4 by such
Investor), (b) is or has been independently developed or conceived by such Investor without use of the Company’s confidential information, or (c) is or has been made known or disclosed to such Investor by a third party without a breach of
any obligation of confidentiality such third party may have to the Company; provided, however, that an Investor may disclose confidential information (i) to its attorneys, accountants, consultants, and other professionals to the
extent necessary to obtain their services in connection with monitoring its investment in the Company; (ii) to any prospective purchaser of any Registrable Securities from such Investor, if such prospective purchaser agrees to be bound by the
provisions of this Section 3.4; (iii) to any Affiliate, partner, member, stockholder, or wholly owned subsidiary of such Investor in the ordinary course of business, provided that such Investor informs such
Person that such information is confidential and directs such Person to maintain the 

  
 17 

 
confidentiality of such information; or (iv) as may otherwise be required by law, regulation, rule, court order or subpoena, provided that such Investor promptly notifies the Company
of such disclosure and takes reasonable steps to minimize the extent of any such required disclosure. 
 4.    Rights
to Future Stock Issuances. 
 4.1    Right of First Offer. Subject to the terms and conditions of this
Section 4.1 and applicable securities laws, if the Company proposes to offer or sell any New Securities, the Company shall first offer such New Securities to each Major Investor. A Major Investor shall be entitled to
apportion the right of first offer hereby granted to it in such proportions as it deems appropriate, among (i) itself, (ii) its Affiliates, and (iii) its beneficial interest holders, such as limited partners, members or any other
Person having “beneficial ownership,” as such term is defined in Rule 13d-3 promulgated under the Exchange Act, of such Major Investor; provided that each such Affiliate (x) is not
a Competitor or FOIA Party, unless such party’s purchase of New Securities is otherwise consented to by the Board of Directors, and (y) agrees to enter into this Agreement and each of the Amended and Restated Voting Agreement and Amended
and Restated Right of First Refusal and Co-Sale Agreement of even date herewith among the Company, the Investors and the other parties named therein, as an “Investor” under each such agreement
(provided that any FOIA Party shall not be entitled to any rights as a Major Investor under Sections 3.1, 3.2 and 4.1 hereof). 

(a)    The Company shall give notice (the “Offer Notice”) to each Major Investor, stating (i) its
bona fide intention to offer such New Securities, (ii) the number of such New Securities to be offered, and (iii) the price and terms, if any, upon which it proposes to offer such New Securities. 

(b)    By notification to the Company within twenty (20) days after the Offer Notice is given, each Major Investor
may elect to purchase or otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals the proportion that the Common Stock then held by such Major Investor (including all
shares of Common Stock then issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held by such Major Investor) bears to the total Common Stock of the Company
then outstanding (assuming full conversion and/or exercise, as applicable, of all Preferred Stock and any other Derivative Securities then outstanding). At the expiration of such twenty (20) day period, the Company shall promptly notify each
Major Investor that elects to purchase or acquire all the shares available to it (each, a “Fully Exercising Investor”) of any other Major Investor’s failure to do likewise. During the ten (10) day period commencing after
the Company has given such notice, each Fully Exercising Investor may, by giving notice to the Company, elect to purchase or acquire, in addition to the number of shares specified above, up to that portion of the New Securities for which Major
Investors were entitled to subscribe but that were not subscribed for by the Major Investors which is equal to the proportion that the Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable,
of Preferred Stock and any other Derivative Securities then held, by such Fully Exercising Investor bears to the Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred
Stock and any other Derivative Securities then held, by all Fully Exercising Investors who wish to purchase such unsubscribed shares. The closing of any sale pursuant to this Section 4.1(b) shall occur within the
later of ninety (90) days of the date that the Offer Notice is given and the date of initial sale of New Securities pursuant to Section 4.1(c). 

  
 18 

 (c)    If all New Securities referred to in the Offer Notice are not
elected to be purchased or acquired as provided in Section 4.1(b), the Company may, during the ninety (90) day period following the expiration of the periods provided in Section 4.1(b), offer
and sell the remaining unsubscribed portion of such New Securities to any Person or Persons at a price not less than, and upon terms no more favorable to the offeree than, those specified in the Offer Notice. If the Company does not enter into an
agreement for the sale of the New Securities within such period, or if such agreement is not consummated within thirty (30) days of the execution thereof, the right provided hereunder shall be deemed to be revived and such New Securities shall
not be offered unless first reoffered to the Major Investors in accordance with this Section 4.1. 

(d)    The right of first offer in this Section 4.1 shall not be applicable to
(i) Exempted Securities (as defined in the Certificate of Incorporation); (ii) shares of Common Stock issued in the IPO; and (iii) the issuance of shares of Series B Preferred Stock to Purchasers pursuant to
Section 1.3 of the Purchase Agreement. 
 (e)    Notwithstanding any provision hereof to the
contrary, in lieu of complying with the provisions of this Section 4.1, the Company may elect to give notice to the Major Investors within thirty (30) days after the issuance of New Securities. Such notice shall
describe the type, price, and terms of the New Securities. Each Major Investor shall have twenty (20) days from the date notice is given to elect to purchase up to the number of New Securities that would, if purchased by such Major Investor,
maintain such Major Investor’s percentage-ownership position, calculated as set forth in Section 4.1(b) before giving effect to the issuance of such New Securities. The closing of such sale shall occur within sixty
(60) days of the date notice is given to the Major Investors. 
 4.2    Termination. The covenants set forth
in Section 4.1 shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO, or (ii) upon the closing of a Deemed Liquidation Event, as such term is defined in the
Certificate of Incorporation, whichever event occurs first. 
 5.    Additional Covenants. 

5.1    Insurance. The Company shall use its commercially reasonable efforts to maintain, from financially sound and
reputable insurers Directors and Officers liability insurance and term “key-person” insurance on R.A. Session II, in an amount and on terms and conditions satisfactory to the Board of Directors,
until such time as the Board of Directors determines that such insurance should be discontinued. The key-person policy shall name the Company as loss payee, and neither policy shall be cancelable by the
Company without prior approval by the Board of Directors. Each Key Holder (other than the Regents) hereby covenants and agrees that, to the extent such Key Holder is named under such key-person policy, such
Key Holder will execute and deliver to the Company, as reasonably requested, a written notice and consent form with respect to such policy. 

  
 19 

 5.2    Employee Agreements. The Company will cause (i) each
Person now or hereafter employed by it or by any subsidiary (or engaged by the Company or any subsidiary as a consultant/independent contractor) with access to confidential information and/or trade secrets to enter into a nondisclosure and
proprietary rights assignment agreement; and (ii) each Key Employee to enter into a noncompetition and nonsolicitation agreement, substantially in the form approved by the Board of Directors with a term not to exceed one year. In addition, the
Company shall not amend, modify, terminate, waive, or otherwise alter, in whole or in part, any of the above-referenced agreements or any restricted stock agreement between the Company and any employee, without the consent of at least one of the
Series A Directors. 
 5.3    Employee Stock. Unless otherwise approved by the Board of Directors,
including a Series A Director, all future employees and consultants of the Company who purchase, receive options to purchase, or receive awards of shares of the Company’s capital stock after the date hereof shall be required to execute
restricted stock or option agreements, as applicable, providing for (i) vesting of shares over a four (4) year period, with the first twenty-five percent (25%) of such shares vesting following twelve (12) months of continued
employment or service, and the remaining shares vesting in equal monthly installments over the following thirty-six (36) months, and (ii) a market stand-off
provision substantially similar to that in Section 2.11. Without the prior approval by the Board of Directors, including a Series A Director, the Company shall not amend, modify, terminate, waive or otherwise alter, in whole or in part,
any stock purchase, stock restriction or option agreement with any existing employee or service provider if such amendment would cause it to be inconsistent with this Section 5.3. In addition, unless otherwise approved by
the Board of Directors, including a Series A Director, the Company shall retain (and not waive) a “right of first refusal” on employee transfers until the Company’s IPO and shall have the right to repurchase unvested shares at
cost upon termination of employment of a holder of restricted stock. 
 5.4    Matters Requiring Investor Director
Approval. So long as the holders of Series A Preferred Stock are entitled to elect any Series A Directors, the Company hereby covenants and agrees with each of the Investors that it shall not, without approval of the Board of Directors, which
approval must include the affirmative vote of at least one (1) of the Series A Directors: 
 (a)    make, or
permit any subsidiary to make, any loan or advance to, or own any stock or other securities of, any subsidiary or other corporation, partnership, or other entity unless it is wholly owned by the Company; 

(b)    make, or permit any subsidiary to make, any loan or advance to any Person, including, without limitation, any
employee or director of the Company or any subsidiary, except advances and similar expenditures in the ordinary course of business or under the terms of an employee stock or option plan approved by the Board of Directors; 

(c)    guarantee, directly or indirectly, or permit any subsidiary to guarantee, directly or indirectly, any indebtedness
except for trade accounts of the Company or any subsidiary arising in the ordinary course of business; 
 (d)    make
any investment inconsistent with any investment policy approved by the Board of Directors; 

  
 20 

 (e)    incur any aggregate indebtedness in excess of $100,000 that is
not already included in a budget approved by the Board of Directors, other than trade credit incurred in the ordinary course of business; 

(f)    otherwise enter into or be a party to any transaction with any director, officer, or employee of the Company or
any “associate” (as defined in Rule 12b-2 promulgated under the Exchange Act) of any such Person, including without limitation any “management bonus” or similar plan providing payments to
employees in connection with a Deemed Liquidation Event, as such term is defined in the Certificate of Incorporation, except for (i) transactions contemplated by this Agreement and the Purchase Agreement or (ii) transactions made in the
ordinary course of business and pursuant to reasonable requirements of the Company’s business and upon fair and reasonable terms that are approved by a majority of the Board of Directors; 

(g)    hire, terminate, or change the compensation of the executive officers, including approving any option grants or
stock awards to executive officers; 
 (h)    change the principal business of the Company, enter new lines of
business, or exit the current line of business; 
 (i)    sell, assign, license, pledge, or encumber material
technology or intellectual property, other than licenses granted in the ordinary course of business; or 
 (j)    enter
into any corporate strategic relationship involving the payment, contribution, or assignment by the Company or to the Company of money or assets greater than $100,000. 

5.5    Board Matters. Unless otherwise determined by the vote of a majority of the directors then in office, the
Board of Directors shall meet at least quarterly in accordance with an agreed-upon schedule. The Company shall reimburse the directors for all reasonable out-of-pocket
travel expenses incurred (consistent with the Company’s travel policy) in connection with attending meetings of the Board of Directors. Each Series A Director shall be entitled in such person’s discretion to be a member of any committee of
the Board of Directors. 
 5.6    Successor Indemnification. If the Company or any of its successors or assignees
consolidates with or merges into any other Person and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall be made so that the successors and assignees of the
Company assume the obligations of the Company with respect to indemnification of members of the Board of Directors as in effect immediately before such transaction, whether such obligations are contained in the Company’s Bylaws, the Certificate
of Incorporation, or elsewhere, as the case may be. 
 5.7    Indemnification Matters. The Company hereby
acknowledges that one (1) or more of the directors nominated to serve on the Board of Directors by the Investors (each an “Investor Director”) may have certain rights to indemnification, advancement of expenses and/or insurance
provided by one or more of the Investors and certain of their Affiliates (collectively, the “Investor Indemnitors”). The Company hereby agrees (a) that it is the indemnitor of first resort (i.e., its obligations to
any such Investor Director are primary and any obligation of the Investor 

  
 21 

 
Indemnitors to advance expenses or to provide indemnification for the same expenses or liabilities incurred by such Investor Director are secondary), (b) that it shall be required to advance the
full amount of expenses incurred by such Investor Director and shall be liable for the full amount of all expenses, judgments, penalties, fines and amounts paid in settlement by or on behalf of any such Investor Director to the extent legally
permitted and as required by the Company’s Certificate of Incorporation or Bylaws of the Company (or any agreement between the Company and such Investor Director), without regard to any rights such Investor Director may have against the
Investor Indemnitors, and, (c) that it irrevocably waives, relinquishes and releases the Investor Indemnitors from any and all claims against the Investor Indemnitors for contribution, subrogation or any other recovery of any kind in respect
thereof. The Company further agrees that no advancement or payment by the Investor Indemnitors on behalf of any such Investor Director with respect to any claim for which such Investor Director has sought indemnification from the Company shall
affect the foregoing and the Investor Indemnitors shall have a right of contribution and/or be subrogated to the extent of such advancement or payment to all of the rights of recovery of such Investor Director against the Company. The Investor
Directors and the Investor Indemnitors are intended third-party beneficiaries of this Section 5.7 and shall have the right, power and authority to enforce the provisions of this
Section 5.7 as though they were a party to this Agreement. 
 5.8    Right to Conduct
Activities. The Company hereby agrees and acknowledges that PBM TGT Holdings, LLC (together with its Affiliates) and each Fidelity Investor (together with its Affiliates) (collectively, the “Fund Investors”) are
professional investment organizations, and as such review the business plans and related proprietary information of many enterprises, some of which may compete directly or indirectly with the Company’s business (as currently conducted or as
currently propose to be conducted). The Company hereby agrees that, to the extent permitted under applicable law, the Fund Investors shall not be liable to the Company for any claim arising out of, or based upon, (i) the investment by any
Fund Investor in any entity competitive with the Company, or (ii) actions taken by any partner, officer, employee or other representative of a Fund Investor to assist any such competitive company, whether or not such action was taken as a
member of the board of directors of such competitive company or otherwise, and whether or not such action has a detrimental effect on the Company; provided, however, that the foregoing shall not relieve (x) any of the Investors from liability
associated with the unauthorized disclosure of the Company’s confidential information obtained pursuant to this Agreement, or (y) any director or officer of the Company from any liability associated with his or her fiduciary duties to the
Company. The Company acknowledges that the execution of this Agreement and the access to the Company’s confidential information shall in no way be construed to prohibit or restrict the Fund Investors, their investment advisers or their
investment advisers’ other investment advisory clients from maintaining, making or considering investments in such other enterprises, or from otherwise operating in the ordinary course of business, provided that such Fund Investor does not
disclose the Company’s confidential information in pursuit of such activities. 
 5.10    Termination of
Covenants. The covenants set forth in this Section 5, except for Sections 5.6, 5.7 and 5.8, shall terminate and be of no further force or effect (i) immediately before the consummation of the
IPO or (ii) upon a Deemed Liquidation Event, as such term is defined in the Certificate of Incorporation, whichever event occurs first. 

  
 22 

 6.    Miscellaneous. 

6.1    Successors and Assigns. The rights under this Agreement may be assigned (but only with all related
obligations) by a Holder to a transferee of Registrable Securities that (i) is an Affiliate of a Holder; (ii) is a Holder’s Immediate Family Member or trust for the benefit of an individual Holder or one or more of such Holder’s
Immediate Family Members or (iii) would hold, after giving effect to any transfer of shares of Registrable Securities thereto by such Holder, all of the Registrable Securities held by such Holder; provided, however, that
(x) the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee and the Registrable Securities with respect to which such rights are being transferred; and (y) such
transferee agrees in a written instrument delivered to the Company to be bound by and subject to the terms and conditions of this Agreement, including the provisions of Section 2.11. For the purposes of determining the number of shares
of Registrable Securities held by a transferee, the holdings of a transferee (1) that is an Affiliate or stockholder of a Holder; (2) who is a Holder’s Immediate Family Member; or (3) that is a trust for the benefit of an
individual Holder or such Holder’s Immediate Family Member shall be aggregated together and with those of the transferring Holder; provided further that all transferees who would not qualify individually for assignment of rights
shall, as a condition to the applicable transfer, establish a single attorney-in-fact for the purpose of exercising any rights, receiving notices, or taking any action
under this Agreement. The terms and conditions of this Agreement inure to the benefit of and are binding upon the respective successors and permitted assignees of the parties. Nothing in this Agreement, express or implied, is intended to confer upon
any party other than the parties hereto or their respective successors and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided herein. 

6.2    Governing Law. This Agreement shall be governed by the internal law of the State of Delaware, without regard
to conflict of law principles that would result in the application of any law other than the law of the State of Delaware, provided, however, that Texas substantive law (without regard to any choice of law doctrines) shall govern in all events the
Regents’ rights of sovereign immunity, any limitations on the extent of any indemnity provisions that purport to apply to the Regents, their governmental authority, and the treatment of information in the Regents’ possession under the
Texas Public Information Act. 
 6.3    Counterparts. This Agreement may be executed in two (2) or more
counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with
the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.  

6.4    Titles and Subtitles. The titles and subtitles used in this Agreement are for convenience only and are not
to be considered in construing or interpreting this Agreement. 
 6.5    Notices. 

(a)    All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be
deemed effectively given upon the earlier of actual 

  
 23 

 
receipt or (i) personal delivery to the party to be notified; (ii) when sent, if sent by electronic mail or facsimile during the recipient’s normal business hours, and if not sent
during normal business hours, then on the recipient’s next business day; (iii) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or (iv) one (1) business day after the
business day of deposit with a nationally recognized overnight courier, freight prepaid, specifying next-day delivery, with written verification of receipt. All communications shall be sent to the respective
parties at their addresses as set forth on Schedule A or Schedule B (as applicable) hereto, or to the principal office of the Company and to the attention of the Chief Executive Officer, in the case of the Company, or to such email
address, facsimile number, or address as subsequently modified by written notice given in accordance with this Section 6.5. If notice is given to the Company, a copy shall also be sent to Cooley LLP, 1299 Pennsylvania Ave,
NW, Suite 700, Washington, DC 20004, Attention: Brooke Nussbaum. 
 (b)    Consent to Electronic Notice. Each
Investor and Key Holder consents to the delivery of any stockholder notice pursuant to the Delaware General Corporation Law (the “DGCL”), as amended or superseded from time to time, by electronic transmission pursuant to Section 232
of the DGCL (or any successor thereto) at the electronic mail address or the facsimile number set forth below such Investor’s or Key Holder’s name on the Schedules hereto, as updated from time to time by notice to the Company, or as on the
books of the Company. To the extent that any notice given by means of electronic transmission is returned or undeliverable for any reason, the foregoing consent shall be deemed to have been revoked until a new or corrected electronic mail address
has been provided, and such attempted Electronic Notice shall be ineffective and deemed to not have been given. Each Investor and Key Holder agrees to promptly notify the Company of any change in such stockholder’s electronic mail address, and
that failure to do so shall not affect the foregoing. 
 6.6    Amendments and Waivers. Any term of this
Agreement may be amended, modified or terminated and the observance of any term of this Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company
and the holders of at least a majority of the Registrable Securities then outstanding; provided that the Company may in its sole discretion waive compliance with Section 2.12(c) (and the Company’s failure to object promptly
in writing after notification of a proposed assignment allegedly in violation of Section 2.12(c) shall be deemed to be a waiver); and provided further that any provision hereof may be waived by any waiving party on such
party’s own behalf, without the consent of any other party. Notwithstanding the foregoing, (a) this Agreement may not be amended, modified or terminated and the observance of any term hereof may not be waived with respect to any Investor
without the written consent of such Investor, unless such amendment, modification, termination, or waiver applies to all Investors in the same fashion (it being agreed that a waiver of the provisions of Section 4 with
respect to a particular transaction shall be deemed to apply to all Investors in the same fashion if such waiver does so by its terms, notwithstanding the fact that certain Investors may nonetheless, by agreement with the Company, purchase
securities in such transaction; provided, however, that where following such a waiver any Major Investor, by agreement with the Company, purchases securities in such transaction, such waiver shall not be effective as to any other Major Investor who
did not waive such provision unless such Major Investor is also permitted to participate in such offering on a pro rata basis (based on the level of participation of the Major Investor purchasing the largest portion of such Major Investor’s pro
rata share), in accordance with the other provisions set forth in Section 4, but in no event in 

  
 24 

 
excess of the number of New Securities that such Major Investor would have been entitled to purchase in the absence of such waiver), (b) Sections 3.1 and 3.2,
Section 4 and any other section of this Agreement applicable to the Major Investors (including this clause (b) of this Section 6.6) may not be amended, modified, terminated or waived without
the written consent of the holders of at least a majority of the Registrable Securities then outstanding and held by the Major Investors, (c) the provisions in this Agreement that relate to the acknowledgements, rights and privileges unique to
the Regents shall not be amended without the prior written consent of the Regents, (d) Sections 2.11, 3.1 and 3.3, and any provision in this Agreement that relates to the acknowledgements, rights and privileges unique to
the Fidelity Investors, shall not be amended in a manner adverse to the Fidelity Investors without the prior written consent of the Fidelity Investors holding a majority of the Registerable Securities held by all Fidelity Investors and
(e) Sections 2.11, 3.1 and 3.3, and any provision in this Agreement that relates to the acknowledgements, rights and privileges unique to PBM, shall not be amended in a manner adverse to PBM without the prior written
consent of PBM. Further, this Agreement may not be amended, modified or terminated, and no provision hereof may be waived, in each case, in any way which would adversely affect the rights of the Key Holders hereunder in a manner disproportionate to
any adverse effect such amendment, modification, termination or waiver would have on the rights of the Investors hereunder, without also the written consent of the holders of at least a majority of the Registrable Securities held by the Key Holders.
Notwithstanding the foregoing, Schedule A hereto may be amended by the Company from time to time to add transferees of any Registrable Securities in compliance with the terms of this Agreement without the consent of the other parties; and
Schedule A hereto may also be amended by the Company after the date of this Agreement without the consent of the other parties to add information regarding any additional Investor who becomes a party to this Agreement in accordance with
Section 6.9. The Company shall give prompt notice of any amendment, modification or termination hereof or waiver hereunder to any party hereto that did not consent in writing to such amendment, modification, termination, or
waiver. Any amendment, modification, termination, or waiver effected in accordance with this Section 6.6 shall be binding on all parties hereto, regardless of whether any such party has consented thereto. No waivers of or
exceptions to any term, condition, or provision of this Agreement, in any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such term, condition, or provision. 

6.7    Severability. In case any one or more of the provisions contained in this Agreement is for any reason held
to be invalid, illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid, illegal, or unenforceable provision shall be reformed and construed so
that it will be valid, legal, and enforceable to the maximum extent permitted by law. 
 6.8    Aggregation of
Stock. All shares of Registrable Securities held or acquired by Affiliates shall be aggregated together for the purpose of determining the availability of any rights under this Agreement and such Affiliated persons may apportion such rights as
among themselves in any manner they deem appropriate. 
 6.9    Additional Investors. Notwithstanding anything to
the contrary contained herein, if the Company issues additional shares of the Company’s Series B Preferred Stock after the date hereof, whether pursuant to the Purchase Agreement or otherwise, any purchaser of such shares of Series B Preferred
Stock may become a party to this Agreement by executing and 

  
 25 

 
delivering an additional counterpart signature page to this Agreement, and thereafter shall be deemed an “Investor” for all purposes hereunder. No action or consent by the Investors
shall be required for such joinder to this Agreement by such additional Investor, so long as such additional Investor has agreed in writing to be bound by all of the obligations as an “Investor” hereunder. 

6.10    Entire Agreement. This Agreement (including any Schedules and Exhibits hereto) constitutes the full and
entire understanding and agreement among the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties is expressly canceled. Upon the effectiveness
of this Agreement, the Prior Agreement shall be deemed amended and restated in its entirety by this Agreement and shall be of no further force or effect. 

6.11    Dispute Resolution. The parties (a) hereby irrevocably and unconditionally submit to the jurisdiction
of the state courts of the State of Delaware and to the jurisdiction of the United States District Court for the District of Delaware for the purpose of any suit, action or other proceeding arising out of or based upon this Agreement, (b) agree
not to commence any suit, action or other proceeding arising out of or based upon this Agreement except in the state courts of the State of Delaware or the United States District Court for the District of Delaware, and (c) hereby waive, and
agree not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, to the extent permitted by law, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property
is exempt or immune from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be
enforced in or by such court. 
 WAIVER OF JURY TRIAL: EACH PARTY (OTHER THAN THE REGENTS) HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR
CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT, THE OTHER TRANSACTION DOCUMENTS, THE SECURITIES OR THE SUBJECT MATTER HEREOF OR THEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING
OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION, INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND
STATUTORY CLAIMS. THIS SECTION HAS BEEN FULLY DISCUSSED BY EACH OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH
ITS LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. 
 The prevailing
party shall be entitled to reasonable attorney’s fees, costs, and necessary disbursements in addition to any other relief to which such party may be entitled; provided, however, that to the extent the
non-prevailing party is the Regents, the prevailing party may make no recovery pursuant to this Section 6.11 from the Regents; and provided further, that the Regents may make no
recovery pursuant to this Section 6.11. Each of the parties to this Agreement (other than the Regents) consents to personal jurisdiction for any equitable action sought in the U.S. District Court for the District of
Delaware or any court of the State of Delaware having subject matter jurisdiction. 

  
 26 

 6.12    Delays or Omissions. No delay or omission to exercise any
right, power, or remedy accruing to any party under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such nonbreaching or nondefaulting party, nor shall it be
construed to be a waiver of or acquiescence to any such breach or default, or to any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore
or thereafter occurring. All remedies, whether under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative. 

6.13    Acknowledgment. The Company, the Key Holders and the Investors each acknowledge that the Regents are an
agency of the State of Texas and under the constitution and the laws of the State of Texas possess certain rights and privileges, are subject to certain limitations and restrictions, and only have such authority as is granted to them under the
constitution and laws of the State of Texas. Notwithstanding any provision hereof, nothing in this Agreement is intended to be, nor will it be construed to be, a waiver of the sovereign immunity of the State of Texas or a prospective waiver or
restriction of any of the rights, remedies, claims, and privileges of the State of Texas. Moreover, notwithstanding the generality or specificity of any provision hereof, the provisions of this Agreement as they pertain to the Regents are
enforceable only to the extent authorized by the constitution and laws of the State of Texas; accordingly, to the extent any provision hereof conflicts with the constitution or laws of the State of Texas or exceeds the right, power or authority of
the Regents to agree to such provision, then that provision will not be enforceable against the Regents or the State of Texas. 
 [Signature
Page(s) to Follow] 

  
 27 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	TAYSHA GENE THERAPIES, INC.
		
	By:	 	 /s/ R.A. Session II

	Name:	 	R.A. Session II
	Title:	 	President

  

			
	KEY HOLDERS:
		
	Signature:	 	 /s/ R.A. Session II

	Name: 	 	R.A. Session II

  

SIGNATURE PAGE TO INVESTORS’ RIGHTS AGREEMENT

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	KEY HOLDERS:
		
	Signature:	 	 /s/ Dan Janiak

	Name: 	 	Dan Janiak

  

SIGNATURE PAGE TO INVESTORS’ RIGHTS AGREEMENT

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTORS:
	
	PBM TGT Holdings, LLC
	
	By: PBM Capital Group, LLC, its manager
		
	By: 	 	 /s/ Paul B. Manning

	Name:	 	Paul B. Manning
	Title: 	 	CEO

  

SIGNATURE PAGE TO INVESTORS’ RIGHTS AGREEMENT

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTORS:
	
	Nolan Capital, LLC
		
	By: 	 	 /s/ Sean Nolan

	Name:	 	Sean Nolan
	Title: 	 	President

  

SIGNATURE PAGE TO INVESTORS’ RIGHTS AGREEMENT

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTORS:
	
	Fidelity Mt. Vernon Street Trust: Fidelity Series Growth Company Fund
		
	By:	 	 /s/ Chris Maher

	Name:	 	Chris Maher
	Title:	 	Authorized Signatory
	
	Fidelity Mt. Vernon Street Trust: Fidelity Growth Company Fund
		
	By:	 	 /s/ Chris Maher

	Name:	 	Chris Maher
	Title:	 	Authorized Signatory
	
	Fidelity Growth Company Commingled Pool
	
	By: Fidelity Management Trust Company, as Trustee
		
	By:	 	 /s/ Chris Maher

	Name:	 	Chris Maher
	Title:	 	Authorized Signatory

  

SIGNATURE PAGE TO INVESTORS’ RIGHTS AGREEMENT

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTORS:
	
	Fidelity Mt. Vernon Street Trust: Fidelity Growth Company K6 Fund
		
	By:	 	 /s/ Chris Maher

	Name:	 	Chris Maher
	Title:	 	Authorized Signatory
	
	Fidelity Select Portfolios: Biotechnology Portfolio
		
	By:	 	 /s/ Chris Maher

	Name:	 	Chris Maher
	Title:	 	Authorized Signatory
	
	Fidelity Advisor Series VII: Fidelity Advisor Biotechnology Fund
		
	By:	 	 /s/ Chris Maher

	Name:	 	Chris Maher
	Title:	 	Authorized Signatory

  

SIGNATURE PAGE TO INVESTORS’ RIGHTS AGREEMENT

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTORS:
	
	Sands Capital Life Sciences Pulse Fund, LLC
		
	By:	 	 /s/ Jonathan Goodman

	Name:	 	Jonathan Goodman
	Title:	 	General Counsel

  

SIGNATURE PAGE TO INVESTORS’ RIGHTS AGREEMENT

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTORS:
	
	Octagon Investments Master Fund LP
	
	By: Octagon Capital Advisors LP, its Investment Manager
		
	By:	 	 /s/ Ting Jia

	Name:	 	Ting Jia
	Title:	 	Managing Member

  

SIGNATURE PAGE TO INVESTORS’ RIGHTS AGREEMENT

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTORS:
	
	VENROCK HEALTHCARE CAPITAL PARTNERS III, L.P.
	
	By: VHCP Management III, LLC, its general partner
	By: VR Advisor, LLC, its manager
		
	By:	 	 /s/ Nimish
Shah                    

	Name:	 	Nimish Shah
	Title:	 	Authorized Signatory
	
	VHCP CO-INVESTMENT HOLDINGS III, LLC
	
	By: VHCP Management III, LLC, its manager
	By: VR Advisor, LLC, its manager
		
	By:	 	 /s/ Nimish Shah

	Name:	 	Nimish Shah
	Title:	 	Authorized Signatory

  

SIGNATURE PAGE TO INVESTORS’ RIGHTS AGREEMENT

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTORS:
	
	GC&H Investments, LLC
		
	By:	 	 /s/ Jim
Kindler                    

	Name:	 	Jim Kindler
	Title:	 	Manager

  

SIGNATURE PAGE TO INVESTORS’ RIGHTS AGREEMENT

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTORS:
	
	Perceptive Life Sciences Master Fund LTD
		
	By:	 	 /s/ James H.
Mannix                    

	Name:	 	James H. Mannix
	Title:	 	Chief Operating Officer

  

SIGNATURE PAGE TO INVESTORS’ RIGHTS AGREEMENT

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTORS:
	
	GV 2019, L.P.
	By: GV 2019 GP, L.P., its General Partner
	By: GV 2019 GP, L.L.C., its General Partner
		
	By:	 	 /s/ Daphne M.
Chang                                        

	Name:	 	Daphne M. Chang
	Title:	 	Authorized Signatory

  

SIGNATURE PAGE TO INVESTORS’ RIGHTS AGREEMENT

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTORS:
		
	By:	 	 /s/ Doug
Jennings                                        

	Name:	 	Doug Jennings

  

SIGNATURE PAGE TO INVESTORS’ RIGHTS AGREEMENT

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTORS:
		
	By:	 	 /s/ Ryan
Walker                                        

	Name:	 	Ryan Walker

  

SIGNATURE PAGE TO INVESTORS’ RIGHTS AGREEMENT

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTORS:
		
	By:	 	 /s/ Suku
Nagendran                                        

	Name:	 	Sukumar Nagendran

  

SIGNATURE PAGE TO INVESTORS’ RIGHTS AGREEMENT

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTORS:
		
	By: 	 	 /s/ Suyash Prasad

	Name:	 	Suyash Prasad

  

SIGNATURE PAGE TO INVESTORS’ RIGHTS AGREEMENT

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTORS:
		
	By: 	 	 /s/ Lauren Murdza

	Name:	 	Lauren Murdza

  

SIGNATURE PAGE TO INVESTORS’ RIGHTS AGREEMENT

 SCHEDULE A 

INVESTORS 
  

	
	Name and Address
	
	PBM TGT Holdings, LLC
	
	Nolan Capital, LLC
	
	Fidelity Mt. Vernon Street Trust: Fidelity Series Growth Company Fund
	
	Fidelity Mt. Vernon Street Trust: Fidelity Growth Company Fund
	
	Fidelity Growth Company Commingled Pool
	
	Fidelity Mt. Vernon Street Trust : Fidelity Growth Company K6 Fund
	
	Fidelity Select Portfolios: Biotechnology Portfolio
	
	Fidelity Advisor Series VII: Fidelity Advisor Biotechnology Fund
	
	Sands Capital Life Sciences Pulse Fund, LLC
	
	Octagon Investments Master Fund LP
	
	Venrock Healthcare Capital Partners III, L.P.
	
	VHCP Co-Investment Holdings III, LLC
	
	GC&H Investments, LLC
	
	Perceptive Life Sciences Master Fund LTD
	
	GV 2019, L.P.
	
	Doug Jennings
	
	Ryan Walker
	
	Sukumar Nagendran
	
	Suyash Prasad
	
	Lauren Murdza
	
	Chardan Healthcare Investments, LLC

	
	
	Bios Fund II NT, LP
	
	Bios Fund II QP, LP
	
	Bios Fund II, LP
	
	Bios Fund III NT, LP
	
	Bios Fund III QP, LP
	
	Bios Fund III, LP
	
	Invus Public Equities, LP
	
	 Casdin Partners Master Fund, L.P.
  

PBM Capital Group, LLC

	
	Franklin Strategic Series – Franklin Biotechnology Discovery Fund
	
	Franklin Templeton Investment Funds – Franklin Biotechnology Discover Fund
	
	ArrowMark Life Science Fund, LP
	
	Meridian Small Cap Growth Fund
	
	BlackRock Health Sciences Opportunities Portfolio, a Series of BlackRock Funds
	
	BLACKROCK HEALTH SCIENCES TRUST
	
	BlackRock Global Funds – World Healthscience Fund
	
	BLACKROCK HEALTH SCIENCES MASTER UNIT TRUST
	
	BLACKROCK HEALTH SCIENCES TRUST II
	
	BLACKROCK HEALTH SCIENCES MASTER UNIT TRUST
	
	BLACKROCK HEALTH SCIENCES TRUST II
	
	Anthony Lamb
	
	Emily Ware
	
	Ralph Shifflett
	
	Joshua Moerman
	
	Lee Williams
	
	Russell Polsky
	
	Mark Blaze
	
	Candace Taylor
	
	Christa Cosner
	
	Gregory MacDonald

	
	
	David Zawitz
	
	David Glover
	
	David Halloran
	
	Debra Walker
	
	Diana Smalls
	
	Elizabeth Kodi
	
	Gary Massengill
	
	Jessica DeGraff
	
	Joseph Pedersen
	
	Melissa Woodruff
	
	Patrick Nolan
	
	Shannon Chen
	
	Stephanie Culley
	
	Sung You
	
	Casey Steffan
	
	Christopher Henry
	
	Jodi Mills
	
	Joseph Wrege
	
	Joshua Batman
	
	Juan Rodriguez
	
	Kevin Miller
	
	Matthew Powell
	
	Cynthia Moravec
	
	Jeffrey Kopocis
	
	Joan Oehmke
	
	Kristen Heckel
	
	Luisa Assink
	
	Phillip Edwards
	
	Roger Varner
	
	Ronald Buchanan

	
	
	Teresa Hastings
	
	Travis Coyner
	
	Wendie Charles
	
	Peter Reines
	
	Thaddeus J. Spinks, VMD
	
	Jennifer Reynolds
	
	Al Novak
	
	Carr Family LLC
	
	Brendan Clancy
	
	Peter Taylor
	
	Jonathan Leach
	
	Tom Selinger
	
	Chuck Koeniger
	
	Richard Gilliam
	
	Ray Caterino Jr.
	
	Benj Garrett
	
	Linda Ricca
	
	Joe Hall
	
	Sean Stalfort
	
	Jay Stalfort
	
	John P. Williamson, Jr.
	
	Steven Goldman
	
	John A Stalfort III 2018 Irrevocable Trust
	
	Jayson Rieger
	
	Dry Pond Partners, LLC
	
	The Don and Jenna Mosman Revocable Living Trust, dated September 21, 2018
	
	Joseph Pedersen
	
	Melissa Woodruff
	
	Gary Massengill
	
	Christa Cosner
	
	Sung You
	
	David Glover
	
	BKB Growth Investments, LLC

 SCHEDULE B 

KEY HOLDERS 
 R.A. Session II 

The Board of Regents of the University of Texas System 
 Dan
Janiak 

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Anthony Lamb

	Name: Anthony Lamb

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Emily Ware

	Name: Emily Ware

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Ralph Shifflett

	Name: Ralph Shifflett

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Joshua Moerman

	Name: Joshua Moerman

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Lee Williams

	Name: Lee Williams

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Russell Polsky

	Name: Russell Polsky

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Mark Blaze

	Name: Mark Blaze

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Candace Taylor

	Name: Candace Taylor

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Christa Cosner

	Name: Christa Cosner

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Gregory MacDonald

	Name: Gregory MacDonald

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ David Zawitz

	Name: David Zawitz

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ David Glover

	Name: David Glover

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ David Halloran

	Name: David Halloran

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Debra Walker

	Name: Debra Walker

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Diana Smalls

	Name: Diana Smalls

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Elizabeth Kodi

	Name: Elizabeth Kodi

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Gary Massengill

	Name: Gary Massengill

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Jessica DeGraff

	Name: Jessica DeGraff

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Joseph Pedersen

	Name: Joseph Pedersen

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Melissa Woodruff

	Name: Melissa Woodruff

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Patrick Nolan

	Name: Patrick Nolan

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Shannon Chen

	Name: Shannon Chen

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Stephanie Culley

	Name: Stephanie Culley

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Sung You

	Name: Sung You

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Casey Steffan

	Name: Casey Steffan

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Christopher Henry

	Name: Christopher Henry

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Jodi Mills

	Name: Jodi Mills

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Joseph Wrege

	Name: Joseph Wrege

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Joshua Batman

	Name: Joshua Batman

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Juan Rodriguez

	Name: Juan Rodriguez

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Kevin Miller

	Name: Kevin Miller

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Matthew Powell

	Name: Matthew Powell

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Cynthia Moravec

	 Name: Cynthia Moravec

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Jeffrey Kopocis

	 Name: Jeffrey Kopocis

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Joan Oehmke

	 Name: Joan Oehmke

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Kristen Heckel

	 Name: Kristen Heckel

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Luisa Assink

	 Name: Luisa Assink

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Phillip Edwards

	Name: Phillip Edwards

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Roger Varner

	Name: Roger Varner

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Ronald Buchanan

	 Name: Ronald Buchanan

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Teresa Hastings

	Name: Teresa Hastings

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Travis Coyner

	 Name: Travis Coyner

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Wendie Charles

	 Name: Wendie Charles

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Peter Reines

	 Name: Peter Reines

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Thaddeus J. Spinks, VMD

	 Name: Thaddeus J. Spinks, VMD

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Jennifer Reynolds

	 Name: Jennifer Reynolds

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Al Novak

	Name: Al Novak

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

Carr Family LLC 
  

	
	 /s/ John Carr

	Name: John Carr
	Title: Manager

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Brendan Clancy

	Name: Brendan Clancy

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Peter Taylor

	Name: Peter Taylor

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Jonathan H Leach VMD

	Name: Jonathan H Leach VMD

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Tom Selinger

	Name: Tom Selinger

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Chuck Koeniger

	Name: Chuck Koeniger

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Richard Gilliam

	Name: Richard Gilliam

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Ray Caterino Jr.

	Name: Ray Caterino Jr.

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Benj Garrett

	Name: Benj Garrett

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Linda Ricca

	Name: Linda Ricca

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Joe Hall

	Name: Joe Hall

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Sean Stalfort

	Name: Sean Stalfort

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Jay Stalfort

	Name: Jay Stalfort

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ John P. Williamson, Jr.

	Name: John P. Williamson, Jr.

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Steven Goldman

	Name: Steven Goldman

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

John A Stalfort III 2018 Irrevocable Trust 
  

	
	 /s/ Gineane H Stalfort

	Name: Gineane H Stalfort
	 Title: Trustee

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Jayson Rieger

	Name: Jayson Rieger

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

Dry Pond Partners, LLC 
  

			
	 /s/ Scott C. Sullivan

	Name:	 	Scott C. Sullivan
	Title	 	Manager
	
	 /s/ Bruce B. Cameron, IV

	Name:	 	Bruce B. Cameron, IV
	Title:	 	Manager

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Don Mosman

	Name: Don Mosman

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Joseph Pedersen

	Name: Joseph Pedersen

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Melissa Woodruff

	Name: Melissa Woodruff

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Gary Massengill

	Name: Gary Massengill

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Christa Cosner

	Name: Christa Cosner

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ Sung You

	Name: Sung You

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

 

	
	 /s/ David Glover

	Name: David Glover

 JOINDER AGREEMENT TO THE 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is executing and delivering this Joinder Agreement, which shall serve as a counterpart signature page pursuant to the terms
and conditions of the Amended and Restated Investors’ Rights Agreement, dated as of July 2, 2020, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), and the other parties thereto, and as may
be hereafter amended from time to time (the “Agreement”). 
 The undersigned is joining the Agreement as an
“Investor” thereunder, and agrees that the undersigned shall be and have all rights and obligations of an “Investor” as such term is defined in the Agreement, including, without limitation, Section 2.12 thereof. 

By executing and delivering this Joinder Agreement to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to
comply with the provisions of the Agreement as an Investor thereunder, and recognizes that the undersigned will receive the benefits of the Agreement as an Investor thereunder from and after the date hereof. 

Accordingly, the undersigned has executed and delivered this Joinder Agreement to be effective as of August 24, 2020. 

BKB Growth Investments, LLC 
  

			
	 /s/ Paul B. Manning

	Name:	 	Paul B. Manning
	Title:	 	Manager
	
	 /s/ Bradford Manning

	Name:	 	Bradford Manning
	Title:	 	Manager

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00313-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00313-of-00352.parquet"}]]